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Chondrosarcoma of bone is a malignant hyaline cartilage forming tumour 
(Figure 1.1). The term chondrosarcoma describes a heterogeneous group 
of leasions with diverse morphologic features and clinical behaviour. Apart 
from conventional central and peripheral chondrosarcoma constituting the 
largest subgroup (~85%) this encompasses rare subtypes such as clear cell 
chondrosarcoma (~1%), mesenchymal chondrosarcoma (~2%), juxtacortical 
chondrosarcoma (~2%) and dedifferentiated chondrosarcoma (~10%) as 
well1. In this thesis the use of the term chondrosarcoma is confined to 
conventional chondrosarcoma. 
Characteristics
The incidence of conventional chondrosarcoma is about 1:50 0001. The 
incidence in males and females is almost equal, and the mean age of 
diagnosis is 30 to 60 years. Chondrosarcomas are mostly found in bones 
that elongate by endochondral ossification with the most common sites 
being the pelvis followed by the proximal femur, proximal humerus, distal 
femur and ribs. When comparing histologically the different cartilaginous 
tumours to the growth plate, parallels between normal and neoplastic 
chondrocyte growth and differentiation become evident. Resting (primitive, 
mesenchymal stem-cell like) chondrocytes are found in mesenchymal 
chondrosarcoma2, while clear cell chondrosarcoma consists mainly of 
hypertrophic chondrocytes3. Osteochondroma, a benign cartilaginous 
tumour at the surface of bone, recapitulates all differentiation levels of the 
growth plate4. In contrast, enchondroma, a benign cartilaginous tumour 
in the medullar cavity of bone, and conventional peripheral and central 
chondrosarcoma mostly contain proliferating chondrocytes, lying in small 
lacunae5,6. The more rarely occurring dedifferentiated chondrosarcoma is 
thought to arise from conventional chondrosarcoma in which tumour cells 
transdifferentiate towards a more spindle-cell phenotype7. In addition, the 
rare subtype juxtacortical chondrosarcoma is recognised, which also contains 
proliferating chondrocytes6. This specific diagnostic term is used as a result 
of its typical clinicoradiological presentation and its in general relatively 
favourable prognosis as compared to conventional chondrosarcoma.
There is a clinical as well as a morphological spectrum of cartilaginous 
tumours. Central chondrosarcoma is the most common subtype 
(>85%) of conventional chondrosarcoma8. Malignant transformation of 
an enchondroma to a central chondrosarcoma is estimated to be < 1%. 
However, since in 40% of central chondrosarcomas remnants of a pre-
existing enchondroma are found, there is considerable debate whether 
these tumours are secondary to enchondroma or arise mostly de novo8. The 
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Figure 1.1 Central chondrosarcoma. (A) Gross specimen of central chondrosarcoma of distal 
femur. (B) Microscopic image of grade II chondrosarcoma (Hematoxylin and Eosin staining). 
Moderate cellularity Tumour cells are lying in a chondroid matrix, with moderate cellularity. 
Pre-existing lamellar bone (top). 
Chapter 1
frequency of malignant transformation is significantly higher (15-30%) in 
patients with multiple enchondromas in the context of the extremely rare 
non-hereditary disorder Ollier disease9. Conventional chondrosarcoma at 
the surface of bone (secondary peripheral chondrosarcoma) per definition 
develops within a pre-existing osteochondroma6. Secondary peripheral 
chondrosarcomas constitute up to 15% of conventional chondrosarcomas 
in referral centers8. Multiple osteochondromas (MO), previously known as 
hereditary multiple exostoses (HME), is an autosomal dominant disorder 
and malignant transformation occurs in 1-3% of the cases of MO10-13. In 
addition, chondrosarcomas may biologically progress: up to 13% of recurrent 
chondrosarcomas exhibit a higher grade of malignancy than the original 
neoplasm, with an adverse prognosis14,15. 
Diagnosis
Benign cartilaginous tumours are asymptomatic, and are often found by 
incidence at radiology made for other reasons8. In contrast, malignant 
tumours almost always produce symptoms such as local swelling and pain. 
The distinction between enchondroma or osteochondroma and low-grade 
conventional chondrosarcoma is difficult, both at the radiological level (in case 
of central chondrosarcoma) and the histological level (for both subtypes)16,17. 
Diagnosis should be made in a multidisciplinary setting, based on clinical, 
radiological and histological aspects. Dynamic MRI has been proven to 
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be informative in distinguishing benign from malignant cartilaginous 
tumours18. Histologically, the distinction between enchondroma and low-
grade conventional central chondrosarcoma is mainly based on growth 
patterns and cytomorphological features16,19,20. Encasement (new shells of 
reactive bone, formed at the periphery of cartilage nodules), is a feature 
of benign tumours, while entrapment (permeation of tumour around 
pre-existing lamellar bone), points to a faster growing process and thus 
malignancy16. 
Histologically, chondrosarcomas are divided in three grades of malignancy 
based primarily on cellularity, nuclear size and chromasia, mitoses and the 
composition of the matrix14 (Figure 1.2). Grade I tumours are moderately 
cellular and nuclei are uniformly sized and hyperchromatic. Grade II 
tumours are more cellular and nuclei are atypically shaped, hyperchromatic 
and larger, and mitoses can be found. At the end of the spectrum, grade III 
tumours are hypercellular, with nuclear pleomorphism, and mitoses can be 
frequent. In addition, the extracellular matrix of grade III tumours becomes 
more mucoid/myxoid compared to the abundant chondroid matrix seen in 
grade I tumours and their vascularity is increased. Differences in 5 year 
survival and the occurrence of metastases show the clinical importance 
of histological grading14. While grade I and II tumours rarely metastasise 
(respectively 0 and 10%), grade III tumours do so in 71% of the cases. 5 Year 
survival is lowest in patients with grade III tumours (29%) compared to 64% 
in grade II tumours and 83% in grade I chondrosarcomas14,15. 
Figure 1.2 Histological spectrum of central cartilaginous tumours.  Enchondroma is hy-
pocellular and a large amount of cartilaginous matrix is present. Foci of calcification (left) are 
common. Cellularity in grade I chondrosarcoma is also low, cytonuclear atypia is limited and 
a large amount of hyaline extracellular matrix is present. In addition, binucleated cells are 
seen, while mitosis are absent. Grade II chondrosarcoma shows increased cellularity and a 
diminished amount of matrix which becomes more mucomyxoid. Cytonuclear atypia is found 
more often and mitosis may be present. High cellularity and abundant cutonuclear atypia are 
found in grade III chondrosarcoma. Note that progression to a higher grade occurs only in 




A correct diagnosis is essential for therapeutic decision making21. Surgery 
is the only option for curative treatment since chondrosarcomas are highly 
resistant to conventional chemotherapy and radiotherapy. Therefore, 
development of targeted therapy for chondrosarcoma would mean a major 
advance in chondrosarcoma therapy. Studies regarding the mechanism 
underlying resistance are sparse22. While for benign leasions a wait-and-see 
policy is justified, malignant tumours require more aggressive treatment. 
Grade I chondrosarcomas are prone to local recurrence but almost never 
metastasize14. Therefore, there is a trend in sarcoma centers to treat them 
by curettage with margin improvement by phenol23 or cryosurgery24. In 
contrast, high-grade tumours are usually treated by often mutilating wide 
en bloc resection or even amputation, since these often metastasize, being 
lethal in the majority of patients. 
Genetics
Although histologically similar, central and peripheral chondrosarcoma have 
been shown to be genetically, and thereby molecularly, different entities. 
In Multiple Osteochondromas germline mutations have been identified in 
the EXT tumour suppressor genes, located on chromosomes 8q24 (EXT1) 
and 11p11-12 (EXT2)25-28. These EXT genes encode glycosyltransferases 
involved in heparan sulphate biosynthesis29. In MO, germline mutations in 
EXT1 or EXT2 with loss of the remaining wild-type allele is found. Recently, 
in solitary osteochondromas somatic homozygous deletions of EXT1 have 
been demonstrated30. In both hereditary and solitary osteochondromas 
mRNA expression of EXT1 or EXT2 is decreased31. This probably results 
in intracellular accumulation of heparan sulphate proteoglycans (HSPGs), 
since the Syndecan2 and the CD44v3 core proteins were shown to aberrantly 
localize in the Golgi apparatus in solitary and hereditary osteochondroma 
and peripheral chondrosarcoma31. The EXT1 homologue in Drosophila (tout 
velu, ttv) is required for IHH diffusion to its receptor that signals to PTHLH 
and thereby controls chondrocyte proliferation32. In contrast to the growth 
plate, in osteochondroma IHH signalling has become cell autonomous, 
probably overcoming the diffusion problems caused by defective HSPGs due 
to EXT inactivation. 
Additional genetic alterations are thought to be required for malignant 
transformation of osteochondroma towards low-grade secondary peripheral 
chondrosarcoma. These additional alterations presumably cause 
chromosomal instability, since peripheral chondrosarcomas are shown to 
be aneuploid with DNA indices ranging from 0.56 to 2.0133. At the protein 
level, progression from osteochondroma towards low-grade peripheral 
chondrosarcoma is characterised by a re-activation of PTHLH signalling34. 
Its downstream target, BCL-2, can be used as a diagnostic marker in those 
cases in which it is hard to distinguish between benign and malignant 
Chapter 1
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cases, with osteochondromas being negative in 95% (specificity) and 
chondrosarcomas scoring positive in 57% (sensitivity)35. This re-activation 
of PTHLH is hypothesised to be caused by increased TGF-beta signalling, 
since IHH signalling has been shown to be downregulated in peripheral 
chondrosarcoma36. 
Despite the increasing number of genetical studies including peripheral 
and central chondrosarcomas as separate subgroups, no specific genetic 
aberrations for the more common central chondrosarcoma have been 
identified as yet. Mutations in EXT1 and EXT2 have not been reported, 
and reports on IHH signalling on proliferation in central chondrosarcoma 
are still inconclusive. A positive relation between histological grade and 
the degree of karyotypic complexity and aneuploidy was found33. Near-
diploidy and limited loss of heterozygosity are typical of low-grade central 
chondrosarcomas rather than of peripheral chondrosarcomas pointing to 
an oncogenic mechanism with few alterations, sufficient for oncogenesis33. 
Multiple studies report alterations at chromosomal bands 9p21 and 12q13-
1537-41. Genetic loss at the 9p21 locus as found by cytogenetics, loss of 
heterozygosity analysis and comparative genomic hybridisation suggest an 
important role for the CDKN2A/INK4a locus. Loss of protein expression 
of the tumour suppressor gene p16, encoded by this locus, was found to 
be associated with increased histological grade in central chondrosarcoma, 
and thereby to be important for tumour progression42. 
Rearrangements in the 12q13-14 region have been frequently reported 
in sarcomas. Several genes in this region have been indicated to be of 
importance for tumourigenesis, such as SAS (sarcoma amplified sequence), 
CDK4 (cyclin dependent kinase 4) and GLI (glioma associated oncogene 
homologue). Also two other often implicated genes in sarcomas, HMGA2 (high 
mobility group AT-hook 2) and MDM2 (murine double minute 2), are located 
just outside the 12q13-14 region. Moreover, the progression from low-grade 
to high-grade central chondrosarcoma is characterised by p53 alterations33. 
Despite the large number of studies involving central chondrosarcomas, the 
exact underlying molecular mechanism is still largely unknown.
General introduction
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1.2 Clinical problems in chondrosarcoma management
In this thesis three clinical problems are addressed:
1. The difficult histological distinction between benign and low-grade 
malignant cartilaginous tumours
2. The lack of prognostic markers superior to subjective histological grading
3. Chemo- and radiotherapy resistance of chondrosarcoma 
1.2.1 Histological distinction between benign and low-grade malignant 
cartilaginous tumours
The distinction between enchondroma and low-grade chondrosarcoma 
is considered one of the most difficult subjects in surgical pathology. 
Currently, diagnostic parameters are lacking, both at the histological16,19,20 
and radiological43-45 level. However, the distinction is important since 
enchondromas are normally expectatively followed. Surgical treatment of 
enchondromas is only applied in case of recurrent fracture, unacceptable 
swelling or functional loss. In these cases intraleasional surgery is applied, 
also known as curettage, in which the tumour is removed without aiming 
for tumour free margins. The benefit of this surgical technique is that the 
environment of the tumour, the bone, and thereby its function, is unaffected.
In contrast, low-grade chondrosarcomas are more prone to recur after 
intraleasional surgery. In addition, they demonstrate a more aggressive 
behaviour in 13% of the local recurrences14,15. Therefore, in case of low-grade 
chondrosarcoma, intraleasional surgery is combined with local application 
of phenol23 or cryosurgery to improve surgical margins21,24.
Figure 1.3 Organisation of the 
human growth plate.Hema-
toxylin and Eosin staining of the 
epiphyseal growth plate is shown. 
The resting zone contains stem-
cell like chondrocytes. These cells 
start proliferating upon a yet un-
known stimulus, thereby initiat-
ing longitudinal growth of the 
bone. The cells in the lower part 
of the resting zone enter the pro-
liferative zone and ensemble on 
orderly, longitudinal collumns. 
These chondrocytes stop prolifer-
ating at a certain timepoint and 
differentiate into hypertrophic 
chondrocytes in the transition 
zone. Finally, the hypertrophic 
chondrocytes undergo apoptosis, 
allowing ingrowth of vessels and 
invasion of osteoblasts depositing 
bone. This leaves a scaffold for 
new bone formation.  
Chapter 1
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Enchondroma and low-grade chondrosarcoma are part of a continuous 
spectrum (Figure 1.2) that, due to the lack of molecular parameters, is rather 
artificially separated and subjected to a large interobserver variability17. It 
would be of great help to make use of objective histological parameters, to 
identify those tumours that are prone to local recurrence and need a more 
aggressive therapy.
1.2.2 Lack of prognostic markers
At the opposite end of the spectrum of cartilaginous tumours, a similar 
diagnostic problem occurs. Chondrosarcomas are divided in three 
histological grades, according to the criteria proposed by Evans in 1977 
(Figure 1.2). The 10 years survival of chondrosarcoma patients decreases 
gradually along the spectrum. Whereas 83% of the patients with a grade I 
chondrosarcoma are still alive after 10 years, this is 64% in case of grade 
II chondrosarcoma and only 29% for grade III chondrosarcoma. Whereas 
grade I chondrosarcoma almost never metastasise to distant organs, 
grade II chondrosarcoma metastasises in 10% of the cases and grade III 
chondrosarcoma in 71%14,15.
This division of malignant tumours in three histological grades is based on 
the cellularity, nuclear atypia, the muco-myxoid changes and the increased 
vascularisation of the tumours (Table 1.1). However, also here a great 
interobserver variability is experienced and the need for objective parameters 
is high. Although many studies have been attempting to unravel molecular 
events underlying chondrosarcoma development and progression, no better 
predictors of outcome than histological grade have been found so far. The 
criteria presently used are summarised in table 1.1. 
1.2.3 Challenges in chondrosarcoma treatment
Chondrosarcomas are notorious for their resistance to conventional chemo- 
and radiotherapy, leaving surgery the only treatment option. Therefore, 
there is nothing with curative intention to offer to patients with tumours 
at inoperable locations or metastatic disease. Little is known about the 
mechanisms of resistance of chondrosarcoma. It has been speculated that 
the expression of P-glycoprotein22,46,47 is the culprit for chemotherapeutic 
resistance of chondrosarcoma. P-glycoprotein is the product of multiple drug 
resistance gene (MDR-1)48. P-glycoprotein is an ATP driven membranous 
pump, which removes a wide spectrum of cytotoxic drugs from tumour 
cells. Many studies have demonstrated chemotherapeutic resistance, an 
increased metastasis rate and poorer prognosis in tumours expressing 
P-glycoprotein, a.o. in osteosarcoma49. 
Secondly, cytostatic drugs are most effective in destroying cells which are 
fast dividing. Chondrosarcomas have a slow growth rate, as compared 
to other solid tumours, which suggests that chemotherapeutic agents 
might not be working efficiently on the tumour cells. The third problem 
General introduction
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in attacking chondrosarcoma tumour cells may be the accessibility of the 
cells. Low-grade chondrosarcoma cells are surrounded by a firm, avascular 
cartilaginous matrix. One can imagine that this matrix protects the cells 
against chemotherapy. In this respect, systemic treatment of high-grade 
chondrosarcoma would be facilitated by their high vascularity, through 
which the drugs can be delivered to the tumour cells. Another mechanism 
through which the resistance of chondrosarcoma might be explained is the 
overexpression of anti-apoptotic protein BCL2, which inhibits the apoptotic 
machinery. This could also be an explanation for radiotherapy resistance of 
chondrosarcoma. In addition, for radiotherapy to be effective the formation 
of free radicals is essential. Cartilage however, is known to be highly hypoxic, 
which prevents the formation of free radicals50. 
Treatment attempts using conventional treatment modalities
Treatment of conventional chondrosarcoma with conventional chemo- and 
Chapter 1
Enchondroma




Entrapment of pre-existing bone by permeative cartilage
Exclusive presence or marked preponderance of small, densely-staining nuclei
Intercellular background varies from chondroid to myxoid (with transitional areas being 
present in many tumours)
Calcification and bone formation are frequent, though not exclusive
Multiple nuclei within one lacuna are often frequent
Small number of larger, pleomorphic nuclei in isolated areas is not considered to indicate a 
higher grade as long as cellularity and mitotic activity are absent
Grade II
Significant proportion of the nuclei are at least of moderate size
Increased cellularity
Paler-staining nuclei with visible nuclear detail
Intercellular background is myxoid rather than chondroid
Finding of mitosis, but <2 per 10 high power fields
Grade III
Pleiomorphic/anaplastic nuclei
Cellularity may be so dense that the appearance is that of a spindle cell sarcoma with no 
appreciable chondroid or myxoid matrix
Increased vascularity
Presence of 2 or more mitoses per 10 high power fields
Table 1.1 Histological criteria within the cartilaginous tumour spectrum Criteria are 
site, syndrome and age dependent
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radiotherapy has not led to satisfactory results, until now. However, some 
small studies had good results with combining two conventional drugs, or 
treatment modalities (listed in table 1.2). In 1999 a large retrospective study 
on 227 chondrosarcomas was published, which showed that adjunctive 
chemotherapy and/or radiation therapy after an intralaesional resection, 
for recurrent disease, or for distant metastasis did not appear to alter the 
outcome51. 
New treatment attempts in radiotherapy
Proton beam therapy has been used to increase the dose delivered to the 
tumour52,53. Preclinical and clinical studies are listed in table 1.2 and 1.3, 
respectively. Currently, a phase II trial is performed using proton beam 
therapy for skull base chondrosarcoma (Table 1.3). With this technique 
tumour cells can be attacked in near proximity of the brain, while the dosis 
to adjacent critical normal structures is minimised. The results of this study 
are expected in 2011 (http://clinicalresearch.nih.gov/). 
Sensitisation for conventional treatment modalities
An important approach in overcoming resistance is to sensitise the 
chondrosarcoma cells to become more vulnerable to conventional chemo- or 
radiation therapy. One example is the inhibition of BCL2, which is expressed 
in peripheral and high-grade central chondrosarcomas and is controlling 
chondrocyte proliferation34,35. Overexpression of BCL-2 inhibits apoptosis 
and thereby could make the tumour cells insensitive to radiation- (and 
chemo) therapy. Restoration of the apoptotic pathway would then make the 
tumours vulnerable to therapy. Improvement in radiotherapy sensitivity of 
chondrosarcoma was found by silencing anti-apoptotic BCL-2, BCL-X and 
XIAP54 (Table 1.4). 
Also by restoration of p16, the inhibitor of the CDK4-Cyclin D1 complex, 
chondrosarcoma cells could be sensitised to radiation in vitro. This is 
discussed more in detail in chapter 4 of this thesis55. Parch et al. used 
the telomerase activity inhibitor BIBR1532 to sensitise telomerase positive 
chondrosarcoma cells to paclitaxel, a conventional chemotherapeutic agent56. 
Telomeres are non-coding repetitive sequences that typically constitute the 
end of linear chromosomes. They protect the coding regions of the genome 
from degradation, but become shorter every cell division. Cancer cells are 
able to overcome their limited life span by activating telomerase. Martin et al. 
found telomerase activity in 7 out of 16 chondrosarcomas and hypothesised 
that this telomerase activity, together with the loss of cell cycle regulation, 
caused aggressiveness of chondrosarcoma cells in vitro57. However, our 
research group previously showed the absence of telomerase activity in 46 
patient samples (9/10 enchondroma and 37 chondrosarcomas); only in one 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Another strategy to sensitise cells to conventional chemo- or radiotherapy, 
which is successfully applied in many carcinoma types, is hyperthermia. 
The whole body, or part of the body, is heated to 42 to 44 degrees, which 
makes the cancer cells more vulnerable to therapeutics. One study using 
hyperthermia has been described, including 1 chondrosarcoma (Table 1.2).
Targets for alternative treatment options 
Many molecular events in chondrosarcoma progression have been ilucidated 
in the last years, which generated potential targets for therapy alternative 
or in addition to conventional chemo- and radiotherapy (reviewed in59). 
The most important being the finding of increased expression of PTHLH in 
high grade central chondrosarcomas suggesting a role for BCL2 inhibitors 
and metalloproteinases and cathepsin B suggesting a potential role for 
cathepsin inhibitors. Another target for chondrosarcoma therapy might be 
estrogen signalling, as estrogen receptors are found in chondrosarcoma by 
immunohistochemistry60. In addition, aromatase, the enzyme that mediates 
the formation of estrogen, is active in chondrosarcoma 60. Therefore the use 
of anti-estrogen treatment, which has been established in breast cancer, 
might have a place in the treatment of chondrosarcoma. Antiangiogenic 
therapy combined with chemotherapy was shown to induce apoptosis in a 
xenograft chondrosarcoma model61. Also attemps using HDAC inhibitors, 
monoclonal antibodies to PTHLH and PPAR agonists looked promising 
(Table 1.4)
Apomab is a fully human monoclonal antibody directed against human 
death receptor 5 (DR5; TRAIL-R2) with potential proapoptotic and 
antineoplastic activities. Mimicking the natural ligand TRAIL (tumour 
necrosis factor-related apoptosis inducing ligand), apomab binds to DR5, 
which may directly activate the extrinsic apoptosis pathway62. DR5 is 
expressed in a broad range of cancers (reviewed in63). However, the clinical 
trial on Apomab in which ao. chondrosarcomas were enrolled, has recently 
been closed for chondrosarcomas since no effect was found (Table 1.3). 
Perifosine is an orally active alkyl-phosphocholine compound with potential 
antineoplastic activity. Instead of targeting the DNA, like the conventional 
chemotherapeutic agents, perifosine targets cellular membranes and 
modulates membrane permeability and mitogenic signal transduction, 
resulting in cell differentiation and inhibition of cell growth64. Dasatinib and 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.3 Finding alternatives to conventional anti-cancer therapy in 
chondrosarcoma: aim and outline of the thesis
Before addressing the approaches to new therapeutic treatment of 
chondrosarcoma that are presented in this thesis, the sometimes problematic 
distinction between benign and low-grade malignant cartilaginous tumours 
was assessed, within the Eurobonet consortium, an European Commission 
granted network of excellence to study the biology and pathology of bone 
tumours. In Chapter 2, the interobserver variability in the histological 
grading of cartilaginous tumours, between 18 specialised pathologists is 
investigated. Subsequently, a second set of 57 cartilaginous tumours, were 
studied to find an optimal set of parameters to differentiate enchondroma 
from low-grade chondrosarcoma. A algorithm based on five parameters 
is proposed that may improve reliability of the diagnosis of cartilagious 
tumours.
Four different approaches to new therapeutic treatment of chondrosarcoma 
are presented in this thesis.
1.3.1 Normal growth regulators (Morphogens/HSPGs) in analogy to 
peripheral tumours 
Based on knowledge we have on genetic aberrations in the EXT genes in 
peripheral chondrosarcomas and Multiple Osteochondromas we investigated 
the role of these genes and their downstream Indian Hedgehog pathway in 
central chondrosarcomas. 
Central cartilaginous tumours mostly arise in bones that elongate via 
endochondral ossification. The growth plate plays a pivotal role during 
this process. Therefore, studying the signalling pathways implicated in the 
normal growth process might elucidate the development of cartilaginous 
tumours. The growth plate is a cartilaginous structure entrapped between 
the epiphysis and metaphysis at the end of the bone. It functions as a scaffold 
and is replaced by bone in a coordinated fashion65,66. Different morphological 
zones of chondrocytes at different stages can be distinguished (Figure 1.3)67. 
The resting zone is located in the part of the growth plate most proximal to the 
epiphysis. Upon a yet unknown stimulus, the resting chondrocytes enter the 
proliferative zone. The flat proliferating chondrocytes assemble in orderly, 
longitudinal columns and start producing extracellular matrix proteins (e.g. 
collagen type II). Eventually these chondrocytes loose their proliferative 
capacity and start to differentiate into hyperthrophic chondrocytes. These 
hypertrophic chondrocytes become larger and obtain a more rounded 
appearance. Now, also a different type of collagen is produced, collagen type 
X. Finally, the extracellular matrix around the hypertrophic chondrocytes 
is calcified and the chondrocytes will undergo apoptosis (programmed cell 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the area to form trabecular bone65. 
Heparan sulphate proteoglycans (HSPGs) are extracellular matrix proteins 
which are important for signal transduction in the growth plate. HSPGs are 
crucial for the gradient formation by which long distance diffusion of Indian 
hedgehog (IHH), decapentaplegic and wingless signal to their receptors as 
demonstrated in Drosphila Melanogaster32,68-70. The human homologues for 
these morphogens are Indian and sonic hedgehog, TGFβ/BMP and WNT, 
respectively71. Indian Hedgehog (IHH) orchestrates chondrocyte proliferation 
and differentiation in the human growth plate. IHH signals to its receptor 
patched (PTCH), which subsequently releases its inhibition on intracellular 
smoothened (SMO), resulting in the translocation of GLI transcription factors 
to the nucleus (Figure 1.4). Here, PTHLH is transcribed together with PTCH 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.4 Hedgehog signalling. Left: In the absence of the ligand, hedgehog (HH), signalling 
is inactive. The transmembrane receptor Patched (PTCH) inhibits another transmembrane 
protein Smoothened (SMO). This prevents the transcription factor GLI to enter the nucle-
us through interactions with cytoplasmic proteins, including Fused and Supressor of fused 
(Sufu). Right: HH signalling is initiated upon binding of the ligand, e.g. Indian Hedgehog, to 
PTCH. This results in the release of SMO by PTCH, thereby activating a cascade that leads 
to the translocation of GLI to the nucleus. There it activates transcription of targets genes, 
amongst which are also PTCH and GLI itself. Active HH signalling leads to activation of PTHLH 
in the human growth plate and thereby controls longitudinal growth of the bones. Adapted 
from Pasca di Magliano et al. 2003;Nat Rev Cancer:903-11.
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signalling inhibits chondrocyte differentiation and consequently controls 
longitudinal growth73,74.
HSPGs are formed in the golgi apparatus of the chondrocytes. Elongation 
of the heparan sulphate side chains that are linked to the proteoglycan 
protein cores occurs by the hetero-oligomeric EXT1/EXT2 complex, a type II 
transmembrane glycoprotein. This complex is formed by the protein products 
of EXT1 and EXT2 genes. While it is evident that inactivation of the EXT genes 
is the driving force for the development of benign peripheral cartilaginous 
tumours26-28,30,59, in the far more common central chondrosarcomas the role 
of EXT and its downstream targets has not been systematically studied so 
far. Since the ultimate goal of the PTHLH pathway is controlling chondrocyte 
proliferation, interfering with this pathway might inhibit chondrosarcoma 
growth. As described previously, some promising results were found by using 
IHH blocking agents as triparanol and cyclopamine75. In Chapter 3 EXT1 
and EXT2 are evaluated in central chondrosarcoma at the DNA (mutational 
screening, arrayCGH) and mRNA level. Localisation of HSPGs (CD44v3 
and SDC2) in the chondrosarcoma tumour cells was studied. Morphogens 
signalling WNT (β-catenin) and TGFB (PAI-1 and phosphorylated Smad2) 
were studied by immunohistochemistry, while IHH signalling was studied 
by qPCR. The possible role of cyclopamine in chondrosarcoma treatment 
was studied in vitro.
1.3.2 Cell cycle regulation 
The second hypothesis driven approach was based on (the loss of) cell cycle 
regulation in chondrosarcoma. 2q13 amplifications and 9p21 deletions 
suggest an important role for cell cycle regulators in the progression of 
chondrosarcoma. Chapter 4 describes the investigation of the pRb and 
p53 pathways in chondrosarcomas and their potential targets for therapy 
of high grade chondrosarcomas. The role of CDKN2A/p16 and CDK4 in 
chondrosarcoma cell survival and proliferation is investigated in vitro using 
lentiviral constructs overexpressing CDKN2A/p16 and inhibiting CDK4. 
CDK4 controls progression through the cell cycle by forming a complex with 
CyclinD1, which regulates the transit of the cell through the G1 restriction 
point. CDKN2A/p16 is the inhibitor of this CDK4-CyclinD1 complex. The 
CDKN2A/p16 tumour suppressor gene, located in this region, was shown 
to be important for chondrosarcoma progression, since inactivation was 
restricted to high-grade chondrosarcoma37,42. Defects in the cell cycle 
pathway are found at high rates in almost all types of human cancer76,77. 
In breast cancer cells, CDK inhibitors were effective in treating tumours 
that overexpress the CDK4-cyclin D1 complex or that have lost CDKN2A/
p16 function78. Therefore we hypothesise that the inhibition of CDK4 and 
the re-expression of p16 might be of therapeutic value in chondrosarcoma. 
Subsequently, in this chapter the expression of CDK4, MDM2, and c-MYC 
at the mRNA and protein level in a large series of central chondrosarcomas 
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was investigated as potential progression markers, to look for prognostic 
markers. 
1.3.3 Kinome profiling
In chapter 5 an array approach is used to search for new treatment 
options for chondrosarcoma. Large scale kinase analysis, also referred to as 
kinomics, was applied using the Pepchip. Kinases, alternatively known as 
a phosphotransferases, are enzymes that phosphorylate tyrosine/serine or 
threonine residues on other proteins. Phosphorylation means the addition of 
one extra phosphate group causing the donor protein to be either activated 
or inactivated (Figure 1.5). The opposite action is executed by phosphatases, 
which remove a phosphate group from a protein (dephosphorylation).
Many enzymes and receptors are switched “on” or “off” by phosphorylation 
and dephosphorylation, by kinases and phospatases (Figure 1.5). Thereby 
kinases play a major role in signalling cascades that determine cell cycle 
entry, cell survival and differentiation fate. Kinases are excellent targets 
for anti-cancer therapy because of their switch function; their regulation 
is reversible, rapid (merely in seconds) and does not require new protein 
synthesis (reviewed in79). Thereby kinases have a large advantage over 
conventional chemotherapeutics that work less targeted and thereby cause 
much more damage in the patient. Up to 518 different kinases have been 
identified in humans. 
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Figure 1.5 Kinases are able to tranfer a phosphate group to a donor protein (phosphoryla-
tion). This protein is thereby either activated or inactivated. Phosphatases exert the opposite; 
they remove a phosphate group from a protein (dephosphorylation). These actions provide a 
molecular switch and are important in many cellular processes, i.e. transcriptional activation, 
stimulation of cell division and apoptosis. 
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Until now, little is known about the use of kinase inhibitors in chondrosarcoma 
treatment. Klenke et al. showed that SU6668, which inhibits tyrosine kinases 
Flk-1/KDR, PDGFRbeta and FGFR1, is able to repress chondrosarcoma 
growth via antiangiogenesis in an in vivo model using severe combined 
immunodeficient (SCID) mice80 (Table 1.4). Another study reported the 
prolonged cell survival of chondrosarcoma cell line JJ012 upon activation 
of AKT by Tenascin-C, an extracellular matrix protein81. This suggests an 
important role for the AKT-kinase in chondrosarcoma survival.
Since our results pointed to susceptibility of chondrosarcoma cell lines to 
dasatinib and imatinib, both drugs were tested in vitro. 
1.3.4 COX-2 inhibition 
Based on the finding of COX-2 protein expression in central and peripheral 
cartilage forming tumours we hypothesised a potential role for the use of 
selective COX-2 inhibitors, which was the subject of our studies described 
in chapter 6. 
Both COX enzyme isoforms, COX-1 and COX-2, are responsible for the 
production of prostaglandins, tromboxane and leukotriens82. Whereas COX-
1 is constitutively expressed under physiologic conditions, COX-2 is induced 
by cytokines, growth factors and free radicals, which render this molecule a 
suitable target for (anti-cancer) therapy. A protective effect of non-steroidal 
anti-inflammatory drugs (NSAIDs) has been suggested against development 
and growth of colorectal cancer. Celecoxib and rofecoxib, both selective 
COX-2 inhibitors, were shown to reduce the number and size of colorectal 
polyps in the adjuvant treatment of Familiar Adenomatous Polyposis (FAP) 
patients83,84. NSAIDs interfere with the cyclooxygenase pathway by blocking 
the attachment site for arachidonic acid (AA) on the COX enzyme (Figure 
1.6). 
Tumour specific COX-2 positivity has been extensively described for various 
malignancies; i.e. colorectal carcinoma with 80% positive tumours85 and 
breast cancer (reviewed in86). Endo et al. reported high COX-2 expression 
in a substantial amount of chondrosarcoma (16/72), which was associated 
with histological grade and poor prognosis87. Another study showed 13/24 
chondrosarcomas to express COX-2 by western blot analysis, whereas 8 
enchondromas were negative88. In chapter 6 COX-2 mRNA levels are 
evaluated in a large series of chondrosarcoma patients. The effects of COX-2 
inhibition at COX-2 protein expression, PGLE2 levels and cell proliferation in 
4 high-grade chondrosarcoma cell lines was investigated in vitro. Moreover, 
a chondrosarcoma xenograft model of immunoincompetent nude mice was 
used to study the effects of (prophylactic) treatment with the specific COX-2 
inhibitor celecoxib.
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State of the art as described in this introduction and aims of the thesis are 
summarised in figure 1.7 for peripheral cartilaginous tumours and in figure 
1.8 for central cartilaginous tumours. 
The results of all chapters will be summarised in chapter 7, together with 
implications for further research.
General introduction
Figure 1.6 COX-1 is consitutively expressed in different cell types and is considered to be 
mainly associated with the production of prostaglandins (PGD2, PGE2, PGF2), tromboxane 
(TXA) and leukotriens under normal physiologic conditions. In contrast COX-2 is induced by 
cytokines, growth factors and free radicals and is expressed in inflammatory cells. 
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Figure 1.7 State of the art and implications for potential therapeutic strategies in periph-
eral chondrosarcoma. A multistep model of the progression of osteochondroma towards sec-
ondary peripheral chondrosarcoma is shown. Results from previous studies are summarised. 
Arrow shows a candidate for potential therapeutic strategy. 
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Figure 1.8 State of the art and implications for potential therapeutic strategies in cen-
tral chondrosarcoma. A multistep model of the progression of central chondrosarcoma is 
shown. Results from relevant previous studies are summarised. Arrows indicate possibilities 
for targeted treatment. Strategies investigated in this thesis are represented in capsules. MMP: 
matrix metalloproteinase, OXPHOS: oxidative phosphorylation. 
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Abstract 
The distinction between benign and malignant cartilaginous tumours of 
bone is one of the most difficult subjects in surgical pathology. The grading 
of chondrosarcoma also seems to vary considerably among pathologists. 
However, clinical management differs. The purpose of this study was 1) 
to investigate interobserver variability in histological diagnosis and grading 
of central cartilaginous tumours and 2) to assess the diagnostic value of 
defined histological parameters in differentiating enchondroma and central 
grade I chondrosarcoma. The interobserver variability was assessed using 
a set of 16 cases evaluated by 18 specialised pathologists. Subsequently, 
20 enchondromas and 37 central grade I chondrosarcomas diagnosed in a 
multidisciplinary team with full clinical, radiological and pathological data 
available with 10 years of follow-up were collected. Cytological and tissue-
architectural features were assessed to find an optimal set of parameters 
to differentiate enchondroma from central grade I chondrosarcoma. We 
demonstrate considerable variation in the histological assessment of 
cartilaginous tumours (weighted kappa = 0.78). The distinction between 
enchondroma and grade I chondrosarcoma was shown to be the most 
disconcordant (kappa coefficient = 0.54), and also the differentiation 
between grade I and grade II chondrosarcoma was subjected to variation 
(kappa coefficient = 0.80). The application of a combination of 5 parameters 
(high cellularity, presence of host bone entrapment, open chromatin, mucoid 
matrix quality and age above 45 years) allowed optimal differentiation 
between enchondromas and central grade I chondrosarcomas. With a 
classification tree based on 2 parameters (mucoid matrix degeneration 
more then 20% and/or host bone entrapment present), 54 of the 57 (94.7%) 
cases were assessed correctly (sensitivity 95% and specificity 95%). Our 
study confirms the low reliability of the diagnosis and grading of central 
chondrosarcoma. However these classifications guide therapeutic decision 
making in daily practice. Therefore we propose a classification model that, 
combined with a tailored radiological assessment, may improve reliability of 




Cartilaginous tumours are the most common primary tumours of bone1,2. 
Enchondroma and its malignant counterpart central chondrosarcoma 
account for 10% (range 3% -17%) and 13% (range 8% -17%) of bone 
tumours, respectively3-5. The incidence of chondrosarcoma is 1:50,000, 
with a nearly equal age distribution between males and females. Central 
and peripheral chondrosarcomas are recognised, the latter developing 
secondary to a pre-existent osteochondroma. Although central and 
peripheral chondrosarcomas are similar at the cytomorphological level, 
these two types of chondrosarcomas have been shown to arise through 
distinct genetic pathways6. On the molecular level, expression of certain 
molecules i.e. BCL-2 and PTHLH have been found to be indicators of 
malignant progression in peripheral chondrosarcomas7,8. For the differential 
diagnosis central chondrosarcoma versus enchondroma these parameters 
are lacking, stressing the need of better defining parameters at the light 
microscopical level. 
Surgical treatment is the only curative treatment for patients with 
chondrosarcoma9, since these tumours do not respond well to radiotherapy 
and/or chemotherapy10. En-bloc resection is the only curative treatment4,9,11, 
frequently leading to considerable morbidity and demanding reconstruction. 
However following recent trends, grade I chondrosarcoma may be treated 
by curettage, eventually followed by vigorous local adjuvant therapy i.e. 
cryosurgery or phenolisation12,13. However, little follow-up data is available 
as yet to advocate it as a proven save alternative. For enchondromas a 
wait-and-see approach or intraleasional treatment is permissible4,9,11. As a 
result, the preoperative differentiation between enchondromas and central 
grade I chondrosarcomas remains important.
The preoperative assessment of these leasions is based upon clinico-
radiological and histopathological evaluation of a biopsy specimen. 
Clinical symptoms and radiographic features are of help in differentiating 
between enchondroma and central grade I chondrosarcoma, but both lack 
specificity11,14,15. Previous studies have shown that conventional radiology 
is not reliable in differentiating benign from low-grade malignant tumours 
in this differential diagnosis, amongst others hampered by the absence of 
objective and reproducible criteria11. However, studies by means of dynamic 
contrast enhanced MR-imaging have improved the sensitivity in this specific 
differential diagnosis16,17. 
Several histopathological features are used to differentiate central grade 
I chondrosarcoma from enchondroma, but this differentiation remains a 
diagnostic challenge, often requiring expert opinion. 
In the present study, reliability and reproducibility of current 
histopathological methods were assessed between 18 expert pathologists. 
The level of agreement was assessed by the evaluation of 16 slides 
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accompanied by conventional radiology, magnetic resonance images or 
computed tomography scans. Subsequently, we evaluated the diagnostic 
value of individual morphologic criteria in differentiating enchondroma from 
central grade I chondrosarcomas and investigated their diagnostic power 
using a set of 57 cases, of which 10 years of follow up was available.
Materials and Methods
Cases to study interobserver variability
To investigate the interobserver variability between expert pathologists, 
16 central cartilaginous tumours were selected (Table 2.1). There was 
consensus in advance that grading would be performed according to the 
criteria originally described by Evans et al18. Patient age and location of 
the tumour were provided, together with pre-operative radiographs, 
magnetic resonance images or computed tomography scans. One tumour 
occurred in the context of enchondromatosis (Ollier disease). All specimens 
were handled according to the ethical guidelines described in “Code for 
Slide number Age Location
1 48 Proximal femur
2 22 Distal femur (tumour related to Ollier disease)
3 40 Femur
4 54 Proximal humerus
5 44 Humerus
6 39 Tibia
7 37 Proximal humerus
8 22 Proximal humerus
9 62 Proximal femur
10 29 Proximal phalanx, dig 3
11 40 Proximal tibia
12 39 Medial femur condyl
13 37 Femur
14 68 Rib
15 54 Proximal fibula
16 58 Distal femur




Proper Secondary Use of Human Tissue in The Netherlands” of the Dutch 
Federations of Medical Scientific Societies. Eighteen musculoskeletal 
pathologists participated in the study. Sixteen of the pathologists were 
involved in EuroBoNeT, an European Commission granted Network of 
Excellence for studying the pathology and genetics of bone tumours and 
two were USA expert pathologists.
Cases to study histological criteria
Seventy-four sequential patients admitted to the Leiden University Medical 
Center between 1984 and 1990 with either enchondroma or central grade I 
chondrosarcoma were retrieved from our database. This database consists of 
radiological documentation, histological slides as well as at least 10 years of 
detailed follow-up including adequate radiological follow-up documentation. 
Fifteen out of 74 patients were excluded, because their tumour was localised 
in the phalanges. Phalangeal chondrosarcomas have been shown to have 
a protracted clinical course with almost no metastases despite ominous 
histology19. Clinical details are given in table 2.2. Two cases were excluded 
because there was too little histological material available to make a reliable 
diagnosis. This leaves 57 patients, with a mean and median age of 46 years 
(range: 2-88 years). 
Histopathology
The criteria used were those noted to be of diagnostic value in the 
literature14,15,18,20. The histological criteria used and the scoring system 
are documented in table 2.3 and illustrated in figure 2.1. The histological 
slides of the biopsies of all 57 patients were subsequently scored by two 
investigators (D.E. and P.C.W.H.). Localisation of the tumour, age of the 
patient and clinical symptoms (swelling, pain or fracture) were provided. 
As a gold standard for a benign diagnosis (enchondroma) following biopsy, a 
clinico-radiological follow up of at least 10 years was a prerequisite and the 
diagnosis was obtained in consensus after review by a panel of clinicians, 
radiologists and pathologists, established in the Netherlands Committee on 
Bone Tumours. For grade I chondrosarcomas the diagnosis obtained from 




Intra class correlations were calculated to assess agreement between the 
18 pathologists. These intra class correlations are equivalent to weighted 
kappa coefficients with quadratic weights and we refer to them in the text as 
weighted kappa’s. Kappa coefficients measure the percentage of agreement 
among observers adjusted for the degree of agreement that would be 
expected by chance alone.
Interobserver variability in chondrosarcoma
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Figure 2.1 Light-micrographs displaying the morphologic parameters shown to be of di-
agnostic value (A) Presence of host bone entrapment, magnification 20x. (B) Open chromatin, 
magnification 63x. (C) High cellularity, magnification 40x. (D) Mucoid matrix quality, magni-
fication 10x.
Histological criteria
Cross tables were made and sensitivity, specificity and positive predictive 
values for enchondroma or low-grade chondrosarcoma were computed for 
different diagnostic parameters. The Chi-square test was used to compare 
percentages between the two groups. A p-value less than or equal to 0.05 
was determined as significant. Classification trees21 and forward stepwise 
logistic regression with likelihood ratio test (LR) were used to select the 
optimal combination of cytological and histological criteria to differentiate 
enchondroma from central grade I chondrosarcoma. Logistic regression 
was also used to assess the value of the matrix quality in differentiating 
enchondroma from central grade I chondrosarcoma.
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Results 
Assessment of interobserver variability 
The most discordant results were found in the distinction between 
enchondroma and grade I chondrosarcoma (kappa coefficient = 0.54). 
Results for all cases are shown in figure 2.2. The weighted kappa for the 
total dataset was 0.78. From the ten cases that were considered to be benign 
by one or more pathologists only one showed complete consensus (case 10). 
Light-micrograph and radiograph corresponding to slide 4, a tumour with 
considerable interobserver variability, is shown in figure 2.3. Furthermore, 
the distinction between enchodroma and grade I, versus grade II and III 
resulted in a kappa coefficient of 0.80. Particularly the cases 1, 6 and 9 
show a lot of variation (figure 2.2). Distinction between grade II and grade 
III chondrosarcoma seems to be less problematic, according to figure 2.2. 
Assessment of histological criteria to distinguish enchondroma vs grade I 
chondrosarcoma
Clinical details of the 57 cases are documented in table 2.2. Spontaneous pain 
alone proved to be of some diagnostic value in this differential diagnosis (35% 
of the enchondromas versus 62% of the central grade I chondrosarcomas, 
p-value=0.05). Also the presence of a combination of clinical symptoms 
(Spontaneous pain, presence of a mass, fracture) pointed to malignancy, 
although the p-value did not reach significance (p-value=0.08).
Interobserver variability in chondrosarcoma
Figure 2.2 Diagnoses of the 18 pathologists are given per slide. Slides are arranged from 
merely benign interpretation (left) to malignant interpretation (right).
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Slight differences in the anatomical localisation of enchondromas and 
central grade I chondrosarcomas were observed in our patient selection 
(Table 2.2). This difference however did not reach statistical significance. 
Age frequencies for patients below 45 year versus above 45 year are given. 
A cut-off value of 45 years was chosen because it was found to distinguish best 
between the groups in our data set (details not shown). Table 2.3 shows the 
frequencies of several cytopathological and architectural parameters, used 
to differentiate between central grade I chondrosarcoma and enchondroma. 
The parameters with the most discriminating strength were host bone 
entrapment as shown in figure 2.1A (positive predicting value (PPV)=97.0%), 
marked nuclear pleomorphism (Figure 2.1B) (PPV=88.2%), high cellularity 
(Figure 2.1C) (PPV=89.8%) and irregular distribution of cells (PPV=85.4%) 
The p-value of these individual parameters was less than 0.001.
Table 2.4 shows the differences in matrix quality between enchondromas and 
grade I chondrosarcomas. All 22 tumours with mucoid matrix degeneration 
Enchondromas (n=20) Chondrosarcomas (n=37) P-value PPV(%)(CCS I)




































































































Table 2.2 Clinical details, localisation and age at presentation of the 57 patients to 
study histological criteria. *Statistically significant
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Table 2.3 Cytological and architectural parameters scored on biopsy specimens of the 




Figure 2.3: Light-micrograph, 
magnification 10x (A) and radio-
graph (B) corresponding to slide 
4, which was interpreted as a 
benign leasion by seven of the 
pathologists and as a malignant 
grade I chondrosarcoma by nine 
pathologists.
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Matrix quality
Enchondromas (n=20) Chondrosarcomas (n=37) P-value
No. % No. %
Chondroid < 80% 0 0 16 43,2 0.000*=> 80% 20 100 21 56,8
Mucoid < 20% 20 100 15 40,6 0.000*=> 20% 0 0 22 59,4
Myxoid < 20% 20 100 25 67,6 0.002*=> 20% 0 0 12 32,4
Table 2.4. Morphologic matrix quality of enchondromas and chondrosarcomas. 
*Statistically significant in X2-test: linear by linear association
greater than or equal to 20% were central grade I chondrosarcoma. The 
same was true for all 16 tumours with a matrix quality which consisted 
of less than 80% of chondroid structure and all 12 tumours with myxoid 
structure greater than or equal to 20%. Multiple logistic regression was 
used to asses the value of the matrix quality in differentiating enchondroma 
from central grade I chondrosarcoma. An increase of chondroid structure 
by 10% decreases the “chance” (odds) for chondrosarcomas by a factor of 
0.8 (p=0.008). An increase in mucoid or myxoid structure of the matrix 
enhanced the “chance” (odds) of malignancy by a factor 7.18 (p=0.004) and 
2.12 (p=0.315) respectively.
Multiple stepwise logistic regression method (LR), using both patient 
characteristics, the variables of table 2.3 and the matrix quality variables 
as possible predictors, showed that the most predictive combination of 
parameters for central grade I chondrosarcoma was high cellularity, presence 
of host bone entrapment, open chromatin, mucoid matrix degeneration and 
age above 45 years. These parameters together gave a perfect prediction in our 
series. Using classification trees, a simple classification rule was obtained in 
which 54 of the 57 (94.7%) cases were assessed correctly. If mucoid matrix 
degeneration greater than or equal to 20% and/or host bone entrapment 
was present, the tumour was statistically considered malignant. With this 
classification rule, 2 tumours were assessed incorrectly as enchondromas 
and 1 as a chondrosarcoma (sensitivity 95%, specificity 95%).
Table 2.5 shows the consensus diagnosis made after at least 10 years of 
clinico-radiological follow-up and used as gold standard compared to the 
diagnosis made on the biopsy assessed by the investigators in this study, 
using only the histological slides at the start of the follow-up period. 
Reviewing and scoring the biopsies without having access to radiological 












Enchondromas 18 4 22
Chondrosarcomas 2 33 35
Total 20 37 57
Table 2.5. Histopathological assessment compared with the consensus diagnosis after 
ten years of follow-up. *This diagnosis was made only aware of the localisation of the tumour, 
the age of the patient and some clinical symptoms (like swelling, pain or fracture).
Discussion 
The distinction between benign and malignant central cartilaginous 
tumours of bone is regarded to be one of the most difficult subjects in 
surgical pathology. In addition, the grading of these neoplasms also seems to 
differ considerably among pathologists. Our study, assessing interobserver 
variability among 18 specialised bone tumour pathologists, confirmed 
that the diagnosis and histological grading of cartilaginous tumours is 
challenging. This is in concordance with the results of the American SLICED 
(Skeletal Leasions Interobserver Correlation among Expert Diagnosticians) 
study group22. We demonstrated that the largest variability was found in the 
distinction between enchondroma and grade I chondrosarcoma. 
This distinction is important to guide surgical management. While an 
wait-and-see approach or intraleasional treatment is permissible for 
enchondromas4,9,11, grade I tumours should be treated more aggressively using 
curettage with vigorous adjuvant therapy (cryosurgery or phenolisation)12,13 
or by en-bloc resection. 
Histopathological features to distinguish benign from malignant 
cartilaginous tumours were advocated in the past9,15,18,20, although the 
diagnostic value of individual morphologic criteria or how they are handled 
in clinical practice by different pathologists have never been investigated 
statistically. We therefore collected a second set of 57 central cartilaginous 
tumours to assess the value of histomorphological criteria and clinical 
parameters to investigate the diagnostic power of an optimal combination 
of these in predicting a correct diagnosis. The diagnosis of these tumours 
was substantiated by a multidisciplinary assessment in the Netherlands 
Committee on Bone Tumours and by 10 years follow-up.
Clinical symptoms are believed to be helpful in the evaluation of a patient 
presenting with a cartilaginous tumour. In this study, 35% of patients with 
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enchondromas and 62% of the patients with central grade I chondrosarcoma 
presented with spontaneous pain. This difference is significant, although 
presentation without pain does not exclude malignancy and should not 
delay additional analysis. Anatomical tumour localisation was not found 
to be of diagnostic value in the differential diagnosis in our selection. This 
was skewed by the exclusion of cases with phalangeal localisation in the 
group of cases to study histological criteria, because of their specific clinico-
pathologic features19.
Our study demonstrates that the 4 most important histological parameters 
are host bone entrapment (PPV=97.0%), high cellularity (PPV=89.75%), 
marked nuclear pleomorphism (PPV=88.2%) and irregular distribution of 
cells (PPV=85.4%) (p< 0.001). The differential diagnosis can be assessed with 
a great degree of accuracy if the biopsy specimen contains a combination 
of presence of host bone entrapment, open chromatin, mucoid matrix 
degeneration and the patient’s age is above 45 years. 
A prerequisite for this diagnostic power is the necessity that all of these 
parameters can be assessed in a biopsy, which depends on quality and 
quantity of the biopsy specimen. The present series contained both open 
and closed biopsies. Previous studies showed that reliable results could be 
obtained by either open or closed (Trocart) biopsy in experienced hands23. 
Sampling errors however could give false predicting results when interpreted 
without detailed knowledge of the radiological presentation. 
Using the simple classification rule proposed in this paper (mucoid matrix 
degeneration and/or host bone entrapment present), 3 of the 57 tumours 
were assessed incorrectly. To improve this, a more complex algorithm 
is needed: classify all tumours as malignant if host bone entrapment is 
present, unless the cellularity in the slide is low, the patient age is below 45 
years and the mucoid matrix degeneration is less than 20%. With this more 
complicated classification rule only one tumour was assessed incorrectly as 
an enchondroma. 
Without using the proposed algorithm we were able to correctly distinguish 
between enchondromas and chondrosarcomas in 90% (18/20) and 89% 
(33/35) of the cases, respectively (Table 2.5) using 13 cytological and 
morphologic features. However, this study shows that a combination of 5 
(or at a minimum of 3) of these features improved this distinction.
Histological grading is currently the only predictor of clinical outcome to guide 
therapeutic strategy, since there are no biomarkers available so far, despite 
extensive literature24. Our study amongst 18 bone tumour pathologists also 
showed that histological grading of chondrosarcoma is subjected to a large 
interobserver variability. Therefore we would advocate using follow-up data 
instead of histological grading as a measurement for outcome in molecular 
studies searching for prognostic parameters of chondrosarcoma. 
In institutes using intraleasional surgery with adjuvant therapy for grade I 
chondrosarcoma, the distinction with grade II chondrosarcoma is essential 
Interobserver variability in chondrosarcoma
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to determine whether en-bloc resection is indicated. 
In conclusion; we showed considerable interobserver variability, even 
amongst expert bone tumour pathologists, in the histological diagnosis of 
enchondroma and low grade chondrosarcoma. In daily practice, the primary 
differential diagnosis will be made based upon radiology. Localisation in 
the axial skeleton and size greater than 5 cm have been shown to be a 
reliable predictor for malignancy11. Even using dynamic contrast enhanced 
MR-imaging and an experienced bone tumour radiologist an absolute 
distinction between malignant and benign cannot be made on radiological 
grounds alone11,25,26. Therefore, when the radiological assessment of a 
benign versus a low- grade malignant central cartilaginous tumour remains 
uncertain, a biopsy needs to be performed and assessed by an experienced 
pathologist, addressing the question of malignancy using a combination of 
histopathological criteria (high cellularity, presence of host bone entrapment, 
open chromatin, mucoid matrix quality and age above 45 years). This 
combined multidisciplinary approach using defined criteria could optimise 
the diagnostic pathway leading to optimal therapeutic management.
Acknowledgements
The authors like to thank the specialised panellists that participated in the 
interobserver variability study: T. Aigner, N. Athanasou, F. Bertoni, 
B. Bjerkehagen, T. Bohling, H. Bürger, S. Daugaard, E. de Alava, 
H. Domanski, R. Forsyth, L. Kindblom, A.Llombart Bosch, P. Mainil-Varlet, 
J .Meis-Kindblom, R.Sciot, C. Inwards, A. Rosenberg. The continuous support 
of the Netherlands Committee on Bone Tumours is highly acknowledged. 
References
 1. Bertoni F, Bacchini P, Hogendoorn PCW. Chondrosarcoma. In: Fletcher CDM, 
Unni KK, Mertens F, editors. World Health Organisation classification of 
tumours. Pathology and genetics of tumours of soft tissue and bone.Lyon: 
IARC Press; 2002. p. 247-51.
 2. Bovée JVMG, Cleton-Jansen AM, Taminiau AHM, Hogendoorn PCW. Emerging 
pathways in the development of chondrosarcoma of bone and the implications 
for targeted treatment. Lancet Oncol 2005;6:599-607.
 3. Taconis WK. Clear cell chondrosarcoma: report of three cases and review of 
the literature. Diagn Imag Clin Med 1986;55:219-27.
 4. Unni KK. Chondrosarcoma (Primary, Secondary, Dedifferentiated, and Clear 
Cell). In: Unni KK, editor. Dahlin’s bone tumours. General aspects and data 
on 11,087 cases. 5 ed. Philadelphia: Lippincot-Raven Publishers; 1996. p. 71-
108.
 5. Mulder JD, Schütte HE, Kroon HM, Taconis WK. Radiologic atlas of bone 
tumours. 2 ed. Amsterdam: Elsevier; 1993.
 6. Bovée JVMG, Cleton-Jansen AM, Kuipers-Dijkshoorn N, Van den Broek LJCM, 
Taminiau AHM, Cornelisse CJ, et al. Loss of heterozygosity and DNA ploidy 
point to a diverging genetic mechanism in the origin of peripheral and central 
chondrosarcoma. Genes Chrom Cancer 1999;26:237-46.
 7. Bovée JVMG, Van den Broek LJCM, Cleton-Jansen AM, Hogendoorn PCW. 
45
Up-regulation of PTHrP and Bcl-2 expression characterizes the progression 
of osteochondroma towards peripheral chondrosarcoma and is a late event in 
central chondrosarcoma. Lab Invest 2000;80:1925-33.
 8. Hameetman L, Kok P, Eilers PHC, Cleton-Jansen AM, Hogendoorn PCW, Bovée 
JVMG. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis 
of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 
2005;446:430-7.
 9. Mirra JM. Intramedullary cartilage- and chondroid-producing tumours. In: 
Mirra JM, Picci P, Gold RH, editors. Bone tumours. Clinical, radiologic, and 
pathologic correlations. 1 ed. Philadelphia: Lea & Febiger; 1989. p. 439-690.
 10. Eriksson AI, Schiller A, Mankin HJ. The management of chondrosarcoma of 
bone. Clin Orthop 1980;44-66.
 11. Geirnaerdt MJA, Hermans J, Bloem JL, Kroon HM, Pope TL, Taminiau AHM, 
et al. Usefullness of radiography in differentiating  enchondroma from central 
grade I chondrosarcoma. A J R 1997;169:1097-104.
 12. Leerapun T, Hugate RR, Inwards CY, Scully SP, Sim FH. Surgical management 
of conventional grade I chondrosarcoma of long bones. Clinical Orthopaedics 
and Related Research 2007;166-72.
 13. Veth R, Schreuder B, van Beem H, Pruszczynski M, de Rooy J. Cryosurgery 
in aggressive, benign, and low-grade malignant bone tumours. Lancet Oncol 
2005;6:25-34.
 14. Sanerkin NG. The diagnosis and grading of chondrosarcoma of bone: a 
combined cytologic and histologic approach. Cancer 1980;45:582-94.
 15. Schiller AL. Diagnosis of borderline cartilage leasions of bone. Semin Diagn 
Pathol 1985;2:42-62.
 16. Geirnaerdt MJA, Bloem JL, Eulderink F, Hogendoorn PCW, Taminiau AHM. 
Cartilaginous tumours: correlation of gadolineum-enhanced MR Imaging and 
histopathologic findings. Radiology 1993;186:813-7.
 17. Geirnaerdt MJ, Hogendoorn PCW, Bloem JL, Taminiau AHM, Van der Woude 
HJ. Cartilaginous tumours: fast contrast-enhanced MR imaging. Radiology 
2000;214:539-46.
 18. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma 
of bone. A clinicopathologic analysis with emphasis on histologic grading. 
Cancer 1977;40:818-31.
 19. Bovée JVMG, Van der Heul RO, Taminiau AHM, Hogendoorn PCW. 
Chondrosarcoma of the Phalanx: a locally aggressive leasion with minimal 
metastatic potential. A report of 35 cases and a review of the literature. Cancer 
1999;86:1724-32.
 20. Mirra JM, Gold R, Downs J, Eckardt JJ. A new histologic approach to 
the differentiation of enchondroma and chondrosarcoma of the bones. A 
clinicopathologic analysis of 51 cases. Clin Orthop 1985;214-37.
 21. Breiman L, Friedman LH, Olshen RA, Stone CJ. Classification and regression 
trees. Monterey, CA: Wadsworth and Brooks/Cole; 1984.
 22. Reliability of Histopathologic and Radiologic Grading of Cartilaginous 
Neoplasms in Long Bones. J Bone Joint Surg Am 2007;89-A:2113-23.
 23. Van der Bijl AE, Taminiau AHM, Beerman H, Hogendoorn PCW. Accuracy 
of the Jamhidi trocar biopsy in the diagnosis of bone tumours. Clin Orthop 
1997;334:233-43.
 24. Rozeman LB, Hogendoorn PCW, Bovée JVMG. Diagnosis and prognosis of 
chondrosarcoma of bone. Expert Rev Mol Diagn 2002;2:461-72.
 25. Hudson TM, Manaster BJ, Springfield DS, Spanier SS, Enneking WF, Hawkins 
JrIF. Radiology of medullary chondrosarcoma: preoperative treatment 
Interobserver variability in chondrosarcoma
46
planning. Skeletal Radiol 1983;10:69-78.
 26. Dietlein M, Féaux de Lacroix W, Neufang KFR, Steinbrich W, Schmidt J. 
Zur Problematik der Dignitätsbeurteilung von Knorpeltumouren langer 
Rohrenknochen aus radiologischer und pathologischer Sicht. Rontgen Blatt 
1990;174:180.
Chapter 2
3. Aberrant Heparan Sulphate Proteoglycan 
localisation, despite normal Exostosin, in 
central chondrosarcoma 
Yvonne M. Schrage, Liesbeth Hameetman, Karoly Szuhai, 
Anne-Marie Cleton-Jansen, Antonie H.M. Taminiau, 
Pancras C.W. Hogendoorn, Judith V.M.G. Bovée. 
Am J Pathol 2009;174:979-88
48
Abstract
EXT1 and EXT2 are involved in the formation of (multiple) osteochondromas, 
which can progress to secondary peripheral chondrosarcomas. Primary 
central chondrosarcoma occurs in the medullar cavity of bone and is the 
most common subtype. The role of EXT and its downstream targets in 
central chondrosarcomas is unknown. 
The EXT1/EXT2 protein complex is involved in heparan sulphate 
proteoglycan (HSPG) biosynthesis, important for signal transduction of 
Indian Hedgehog (IHH), WNT and transforming growth factor beta (TGFB). 
EXT1 and EXT2 were evaluated in central chondrosarcoma at the DNA 
(mutational screening, arrayCGH) and mRNA level. Immunohistochemistry 
was used to asses HSPGs (CD44v3 and SDC2), WNT (β-catenin) and TGFB 
(PAI-1 and phosphorylated Smad2) signalling, while IHH signalling was 
studied by qPCR and in vitro. 
EXT1 and EXT2 mRNA levels are normal in central chondrosarcoma. 
Genomic alterations are absent in these regions and in 30 other HSPG 
related genes. HSPGs are aberrantly located; CD44v3 in the Golgi and 
SDC2 in cytoplasm and nucleus, which was not caused by mutation. 
WNT signalling was negatively- and TGFB was positively correlated with 
increasing histological grade (p=0,038 and p=0,002). IHH signalling was 
active, and inhibition decreased cell viability in one of six cell cultures.  Our 
data suggest that, despite normal EXT in central chondrosarcomas, HSPGs 





The tumour suppressor genes EXT1 and EXT2 are known for their 
involvement in peripheral cartilaginous tumours. They cause the hereditary 
syndrome Multiple Osteochondromas (MO)(OMIM #133700), previously 
known as Hereditary Multiple Exostoses1-3. In MO patients, benign cartilage 
capped bony outgrowths (osteochondromas) develop at the surface of bones 
formed by endochondral ossification. Histologically, they bear a strong 
resemblance to the normal growth plate. 1-5% of osteochondromas progress 
to (secondary) peripheral chondrosarcoma. 
While secondary peripheral chondrosarcoma is a rare chondrosarcoma 
subtype (less than 15% in tertiary referral centers), primary conventional 
central chondrosarcoma arising in the medullar cavity of bone is far more 
common (>80% of conventional chondrosarcoma)4,5. Enchondromas are 
benign cartilage tumours occurring in the center of the bone 4. Enchondromas 
occur mostly as solitary leasions, although they may occur as multiple 
leasions in the context of non-hereditary enchondromatosis (Ollier disease) 
(OMIM #166000)6. 
The protein products of EXT1 and EXT2, Exostosin 1 and Exostosin 2, are 
type II transmembrane glycoproteins that form a hetero-oligomeric complex, 
located in the Golgi membrane. This complex is responsible for elongation 
of heparan sulphate side chains that are linked to the proteoglycan protein 
cores, consequently forming heparan sulphate proteoglycans (HSPGs)7,8.
HSPGs are involved in sequestering growth factors, anchorage to the 
extracellular matrix and in several growth signalling pathways9. Various 
HSPGs have been described e.g. syndecan (SDCs), perlecan and glypican 
families and CD44 isoforms containing HS bearing variable exon 3 (v3)9,10. 
In Drosophila Melanogaster, HSPGs were shown to be essential for gradient 
formation of the morphogens hedgehog, decapentaplegic and wingless11. The 
human homologues for these morphogens are Indian and Sonic hedgehog, 
TGFB / BMP and WNT, respectively12. Indian Hedgehog (IHH) orchestrates 
chondrocyte proliferation and differentiation in the human growth plate. 
IHH signals to its receptor patched (PTCH), which subsequently releases its 
inhibition on intracellular smoothened (SMO), resulting in the translocation 
of GLI transcription factors to the nucleus. Here, PTHLH is transcribed 
together with PTCH and GLI, guaranteeing the preservation of this signalling 
cascade13. PTHLH signalling inhibits chondrocyte differentiation and 
consequently controls longitudinal growth14,15.
While it is evident that inactivation of the EXT genes is the driving force for 
the development of benign peripheral cartilaginous tumours1-3,16,17, in the far 
more common central chondrosarcomas the role of EXT and its downstream 
targets has not been systematically studied so far. 
We therefore investigated EXT and its downstream targets in central 
EXT and HSPG in central chondrosarcoma
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chondrosarcoma. Results are compared to its rare peripheral counterpart 
for which EXT involvement is quite well characterised1-3. We studied EXT at 
the DNA and mRNA level and investigated the expression of HSPGs using 
immunohistochemistry. Activity of IHH, TGFB and WNT signalling, which 
require HSPGs for proper signalling, was also studied in a large series of 
central chondrosarcomas including six chondrosarcoma cell cultures. 
Material and methods
Patient material
Enchondromas and conventional central chondrosarcomas were selected 
based on accepted clinicopathological18 and radiological19 criteria. 
Peripheral, juxtacortical, mesenchymal, dedifferentiated and clear-cell 
chondrosarcomas were excluded. In total, specimens of 110 patients were 
used for this study, including both formalin fixed paraffin embedded (n=95) 
and fresh frozen (n=34) tissue. Both paraffin and frozen series included 
enchondromatosis (Ollier disease) related tumours. Details are outlined in 
table 3.1. Histological grading was performed according to Evans et al20. All 
specimens were handled according to the ethical guidelines as described in 
“Code for Proper Secondary Use of Human Tissue in The Netherlands” of the 
Dutch Federation of Medical Scientific Societies.
 Enchondroma Chondrosarcoma
 FFPE fresh frozen FFPE fresh frozen
Total number of 
tumours 33 7* 62 27
Grade I  -  - 27 11
Grade II  -  - 25 7
Grade III  -  - 10 9
    
Male:Female 20:13 3:4 32:30 17:10
Enchondromatosis 6 5 6 7










Median follow up 
months (range) 65 (6-170)  87 (5-247)  
Table 3.1 Clinicopathological data of the 110 patients. FFPE: formalin fixed paraffin 
embedded. *All fresh frozen enchondromas were located in the phalanx.
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Quantitative real time reverse transcriptase PCR (q-RT-PCR)
q-RT-PCR was used to study the expression level of EXT1 and EXT2 and 
the activity of IHH signalling. Of 34 cases fresh frozen tumour tissue was 
available for RNA isolation, performed as described previously21. Four growth 
plate samples, acquired from resections or biopsies for orthopedic clinical 
conditions not related to cartilaginous tumours, were used as controls. 
Results were compared to those of 28 peripheral tumours described 
previously16. Primers for EXT1, EXT2, PTCH, GLI1 and GLI2 were described 
previously22. Four control genes (CYPA, CPSF6, SRPR and HNRPH1) were 
selected to normalise the expression data, because of their invariable 
expression in chondrosarcoma23. Data of the cell cultures were normalised 
against HPRT and GAPDH. As a reference for normalisation and statistical 
analysis a calibration curve of a mixture consisting of 15 highly diverse cell 
lines24 was included. Normalisation was performed using GENORM25.
Genomic analysis:
Mutation analysis EXT1/2 and SDC2
Two tumours with decreased EXT1 expression (L803 and L1689) were 
subjected to direct sequencing of  the coding sequences of EXT1 and EXT2 
and multiplex ligation-dependent probe amplification assay designed 
for EXT1 and EXT2 as described26,27. DNA was isolated from fresh frozen 
tumour tissue. DNA isolated from another set of seven tumours (four with 
nuclear and three with cytoplasmic SDC2 expression at IHC) and their 
corresponding normal lymphocytes were screened for mutations by direct 
sequencing analysis of the 5 exons of the coding region of the SDC2 gene. 
Primer sequences are listed in table 3.2.
EXT and HSPG in central chondrosarcoma


















Table 3.2 Primer sequences SDC2 mutation analysis
52
 Array comparative genomic hybridisation (CGH) 
L803 and L1689 were also analysed by array CGH using a high resolution 
8q array containing a tiling bacterial artificial choromosome (BAC) clone 
set as described16. In addition, the seven tumours that were subjected to 
mutational screening for SDC2 were hybridised to a custom made HD-
Agilent oligonucleotide array containing 4x44000 immobilised 60mer 
oligonucleotides. Genomic intervals containing 35 genomic regions of 37 
genes selected on their function in cartilage biosynthesis (Supplementary 
table 3.1) were subjected to Agilent’s eArray web tool (http://earray.chem.
agilent.com/earray/) to generate oligonucleotide (60mer) microarray probe 
sequences. For each gene of interest probes were selected both for exonic 
and intronic areas with a spacing at 500-1000 base intervals, additional 
probes sequences were selected 5000 bps before and after targeted genes to 
include potential control elements, such as promoter regions. A total 37040 
oligonucleotide probes were selected in genomic regions, additional probes 
till 44000 were added as internal control selected as a default from the array 
design options. Slides were printed and produced by Agilent Technologies 
using standard company protocols available as custom service. Array 
probes, layout, and access to purchase this microarray from Agilent array 
can be obtained from the responsible author (KS). 
Test and reference samples were labeled, hybridised, washed, scanned 
and analysed following standard protocols provided by Agilent (Agilent 
Technologies, Amstelveen, The Netherlands). 
Immunohistochemistry
For 95 tumours formalin-fixed, paraffin-embedded material was available 
(Table 3.1). All were stained for PAI-1 and a subset of 19 tumours for 
phosphorylated Smad2 to evaluate TGFB signalling28,29. In addition all 
were stained for β-catenin, to evaluate canonical WNT signalling30, HSPG 
expression (SDC2 and CD44v3) was evaluated in a subset of 30 tumours. 
Subsets were representative for the total group of patients. Details of 
primary antibodies are described in table 3.3. PAI1, phosphorylated Smad2 
and β-catenin immunohistochemistry was scored semi-quantitatively as 
described previously31, by two observers (YMS, JVMG) independently. Both 
were blinded towards clinicopathological data. In brief, scores were given 
for β-catenin, PAI1 and phosphorylated Smad2 intensity (1 = weak, 2 = 
moderate, 3 = strong) and for percentage of positive cells (1 = 0-24%, 2 = 
25-49%, 3 = 50-74% and 4 = 75%-100% positive cells in the total tumour 
section). To avoid tumours with single positive cells being regarded as 
positive, cut off levels for statistical analysis were applied corresponding to 
general staining pattern (sum of score β-catenin ≥ 2 and PAI1 ≥ 3). SDC2 
and CD44v3 were evaluated based on presence or absence and localisation 
of staining as described 23. Specificity of the SDC2 antibody for membranous 
staining was tested using a tissue microarray (TMA) containing 79 soft tissue 
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tumours of 28 different entities, as was described previously32.
Immunoblotting
To confirm the nuclear localisation of SDC2 as shown by 
immunohistochemistry two fresh central chondrosarcoma samples were 
digested overnight in dissociation medium containing 0.1% collagenase 
(Sigma, Zwijndrecht, The Netherlands) and 0.1% dispase (Life Technologies, 
Breda, The Netherlands) 100 IU/mL. Cell fractionation was performed using 
2 different lysis buffers. To extract cytoplasmic proteins a buffer containing 
10 mM HEPES pH7,9, 10 mM KCl, 0,1 mM EGTA, 0,1 mM EDTA, 1 mM 
DTT, 0,5 mM PMSF, 2 μg/ml Leupeptin, 1 μg/ml Pepstatin A and 2 μg/ml 
Aprotinin was used, followed by the addition of 10% NP-40. Subsequently, 
the extraction of nuclear proteins was performed by vigorously rocking the 
sample for 15 minutes in the presence of a buffer containing 20 mM HEPES 
pH7,9, 400mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 
2 μg/ml Leupeptin, 1 μg/ml Pepstatin A and 2 μg/ml Aprotinin. Protein 
concentrations were measured using a DC Protein Assay (Biorad, Hercules, 
CA, USA). 10 mg of each sample was run on SDS-PAGE. Proteins were 
electrophoretically transferred onto polyvinylidene difluoride membranes 
(Immobilon-P, Millipore). Membranes were pre-incubated with 15% Skinned 
milk in Tris-buffered saline/Tween. After incubation with first and secondary 






control Staining [AB] AR*
CD44v3 Labvision Mono Tonsil Membrane, cytoplasm 1:400 C
58K Golgi protein Abcam Ltd Poly Tonsil Perinuclear 1:100 C
Syndecan-2 
(10H4) G. David


















Mono Mamma-carcinoma Cytoplasm 1:350 N
PS2 P. ten Dijke29 Poly Prostate Nuclear 1:2000 C
Table 3.3 Antibodies used for IHC, WB and IF. [AB]; antibody concentration, AR; antigen 
retrieval, C; citrate, N; none. *Antigen retrieval was performed using citrate buffer at 98°C for 
20 minutes.
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antibodies (Table 3.3), the membranes were developed with ECLTM Western 
blotting detection reagent (Amersham Biosciences, Buckinghamshire, 
UK) and visualised by exposure to X-ray films (Hyperfilm ECL, Amersham 
Biosciences, Buckinghamsire, UK).
Confocal microscopy and immunofluorescence
To confirm localisation of CD44v3 in the Golgi apparatus, two central 
chondrosarcomas (with peri-nuclear CD44v3 expression) were selected 
for fluorescent double staining using CD44v3 and the 58K Golgi protein 
antibodies as described previously22.
Hedgehog activity in vitro
Chondrosarcoma cell lines CH287933, C384234, OUMS2735 and SW1353 
(American Type Culture Collection, Manassas, VA (ATCC)), central 
chondrosarcoma primary cultures L784 and L869 and cyclopamine 
responsive pancreatic carcinoma cell line PANC1 (ATCC)36 were used to 
analyse HH signalling. Chondrosarcoma cell lines were cultured in RPMI1640 
and PANC1 in DMEM (both Gibco, Invitrogen Life-Technologies, Scotland, 
UK)) supplemented with 10% heat-inactivated fetal calf serum (Gibco) at 
37ºC in a humidified incubator with 95% air and 5% CO2. Cartilaginous 
phenotype was confirmed by RT-PCR, showing mRNA expression of collagens 
I, 2B, 3, and 10; Aggrecan; and SOX937.
For RNA analysis, 2,5 * 105 cells were seeded in a 6-wells plate. After 24 
hours the medium was replaced with serum starved medium (0,05% FCS) 
containing either 10 μM cyclopamine (Toronto Research Chemicals, North 
York, Ontario, CA) or DMSO 0,1%. Cells were harvested after 24 hours 
and RNA was isolated using Trizol and microspin column (Qiagen, Hilden, 
Germany). Cell viability was assessed by WST-1 colorimetric assay (Roche 
Diagnostics GmbH, Penzberg, Germany), which measures mitochondrial 
activity. Cells were seeded into 96-well flat-bottom plates (1,5* 103 cells/well 
for SW1353 and PANC1 and 5,0* 103 cells for CH2879, C3842, OUMS27, 
L784 and L869). After 24 hours DMSO, cyclopamine at 5 μM and 10 μM 
and tomatidine (Toronto Research Chemicals), an inactive but structurally 
related compound38, at 10 μM were added in the presence of 5% FCS, each 
condition in quadruplicate. After 3 days of treatment, the metabolic activity 
of the cells was measured on a Victor3 Multilabel Counter 1420-042 (Perkin 
Elmer, MA, USA) at 450 nm.
Statistical analysis
Correlations between histological grade and immunohistochemical results 
were calculated by Chi-square (X2) test. Differences in cell viability in 





Normal EXT1 and EXT2 in central chondrosarcoma
The expression of EXT1 and EXT2 mRNA in central cartilaginous tumours 
is not decreased as compared to growth plate samples, which is in contrast 
to the low EXT1 expression levels previously found in peripheral tumours 
(Figure 3.1A and 3.1B) 22. No correlation of EXT1 or EXT2 expression with 
histological grade was found (not shown). Direct mutation screening and 
MLPA for both EXT1 and EXT2 did not reveal any genetic aberrations (not 
shown). Comparative genomic hybridisation on a 8q BAC tiling array of the 
two central chondrosarcomas with the lowest expression of EXT1 did not 
EXT and HSPG in central chondrosarcoma
reveal any alterations on 8q24, the 
locus for EXT1. Results for L803 
are shown in figure 3.1C, which 
are representative for L1689 (not 
shown). No other gains or losses in 8q 
were detected. Moreover, no losses 
were found in the EXT1 and EXT2 
genes in the 7 chondrosarcomas 
hybridised at the oligonucleotide 
Agilent array. 
Figure 3.1 (A) EXT1 mRNA expression levels 
of central chondrosarcoma are comparable to 
growth plate levels while peripheral tumours 
(published previously16) show a three fold 
decrease. (B) EXT2 mRNA levels are slightly 
higher in central and slightly lower in periph-
eral chondrosarcoma, compared to growth 
plate. Expression levels of the tumours are 
log2 transformed and relative to the growth 
plate levels. (C) 8q tiling array CGH pattern 
of central chondrosarcoma L803 is shown. 
Genomic alterations are absent, despite low 
EXT1 expression at qPCR. L1689 showed 
similar results as L803 (data not shown). For 
comparison an osteochondroma with homo-
zygous loss of multiple clones covering the 
EXT1 gene and hemizygous loss of a larger 
part of 8q, is shown in (D) (figure composed 
of data published previously16).
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Aberrant location of HSPGs SDC2 and CD44v3 in central chondrosarcoma
Cytoplasmic staining of CD44v3 was found in 26 of 30 (87%) central 
tumours (7/8 EC and 14/22 CS). The staining was dot-like suggesting 
localisation in the Golgi apparatus (Figure 3.2A), which was confirmed 
using immunofluorescent confocal microscopy (Figure 3.2B). Central 
chondrosarcomas showed cytoplasmic staining of SDC2 in 28/29 (97%). 
Moreover, additional nuclear staining, shown in figure 3.2C, was found in 
half of the tumours (4/7 EC and 11/23 CS). The soft tissue tumour TMA 
did not show nuclear staining in any of the specimens (not shown). Control 
sections of tonsil showing membranous expression pattern of CD44v3 in 
the epithelial layer and normal growth plate showed SDC2 staining at the 
cell membrane and in the extracellular matrix surrounding hypertrophic 
chondrocytes (not shown). Nuclear localisation of SDC2 as found by IHC was 
verified in the nuclear component of the cell fractionation by immunoblotting 
(Figure 3.2D). 
No aberrations in other genes important for HSPG formation
Since we found normal EXT in central chondrosarcomas, we searched for 
aberrations in other regulators of HSPG formation. Mutation screening of 
the five coding exons of the SDC2 gene did not reveal any mutations in the 
seven tumours (not shown). Using the oligonucleotide tiling array covering 
30 EXT, EXT-like and other genes involved in HSPG biosynthesis we did not 
find any specific genomic losses or gains in these seven tumours. 
Decreased WNT signalling and increased TGFB signalling in high grade 
chondrosarcomas
Nuclear staining for β-catenin (Figure 3.3A) was found in 17% (5/30) of 
enchondromas, in 47% (11/23) of grade I and in 29% (7/24) of grade II 
and in 11% (1/9) grade III chondrosarcoma (Figure 3.3B). The activity 
of canonical WNT signalling was increased in grade I chondrosarcomas 
compared to enchondromas. However upon further increase in histological 
grade the activity decreased again (Pearson X2 p=0,038). Expression of PAI-
1, implicating active TGFB signalling (Figure 3.3C), was also associated 
with increased histological grade (Pearson X2 p=0,002). All high grade 
tumours were positive (35/35), whereas the enchondromas and low grade 
chondrosarcoma were positive in 73% (24/33) and 74% (20/27), respectively 
(Figure 3.3D). Moreover, nuclear localisation of phosphorylated Smad2 
was demonstrated in all of 6 enchondromas and 13 chondrosarcomas, 
suggesting active TGFB signalling (Not shown).
HH signalling in central chondrosarcoma in vivo and in vitro
By qPCR active HH signalling was shown in central chondrosarcoma, 
irrespective of histological grade, since PTCH, GLI1 and GLI2 were expressed 
at similar levels as in the growth plates (Figure 3.4A, B and C). Cyclopamine 
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Figure 3.2 (A) Central chondrosarcoma showing cytoplasmic dot-like accumulation of CD44v3 
at IHC (magnification 40x), suggestive for Golgi retention. This was confirmed by IF, using a 
Golgi specific marker, 58K protein, in green and CD44v3, in red, resulting in a yellow color 
when co-localisation occurs. The white line indicates the position where the staining profile 
(inset) has been taken (B). (C) Central chondrosarcoma showing nuclear staining of SDC2 
(magnification 40x), which was found in 50% of chondrosarcomas in addition to cytoplasmic 
staining. (D) Nuclear localization of SDC2 was verified by immunoblotting in 2 chondrosarco-
mas. In the isolated nuclear fraction heterochromatin protein 1 gamma was present, verifying 
the procedure for separating the nuclear from the cytoplasmic staining.
Figure 3.3. (A-B) The activity of canonical WNT signalling was increased in grade I chondro-
sarcomas compared to enchondromas. However upon further increase in histological grade the 
activity decreased again (Pearson X2 p=0,038). (C-D) PAI-1 expression, indicating active TGFB 
signalling, was found in the majority of central chondrosarcomas. PAI-1 expression was cor-
related to histological grade ( X2 test p=0,002). Magnification 40x.
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Figure 3.4. mRNA levels of GLI1 (A), 
GLI2 (B) and PTCH (C) were measured as 
a readout of IHH signalling. Levels of all 
three genes in chondrosarcomas were in 
the same range of growth plate samples 
and large variations within the groups 
were observed. No relation to histological 
grade was found. Expression levels are 
log10 transformed.
Figure 3.5 (A) In vitro the GLI1 mRNA expression 
decreases to almost half of the level of the DMSO 
control in PANC1 and in CH2879 upon 24 hours 
treatment with 10 μM of cyclopamine (CP), while 
this was not found in the other five chondrosar-
coma cell cultures. (B) None of the chondrosarco-
ma cell cultures showed a negative effect on PTCH 
mRNA expression upon 24 hours 10 μM CP treat-
ment. Both experiments were performed in duplo. 
(C) Both PANC1 and CH2879 demonstrated a de-
crease in cell viability measured by WST-1 assay, 
upon 72 hours of 5 μM and 10 μM CP treatment. 
An increase in viability was observed in L784, 
whereas the other four chondrosarcoma cell cul-
tures did not show an effect of cyclopamine treat-
ment. The black bars represent the inactive com-
pound tomatidine (TM), which demonstrate the 
selective effect of CP. Data represent 3 individual 
experiments performed in quadruplicate. 
* indicates Students t-test for paired data p<0,05.
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treatment resulted in a profound decrease of GLI1 mRNA expression 
combined with decreased cell viability in only one cell culture (CH2879), 
whereas all other cultures did not respond by decreased GLI1 levels or cell 
viability (Figure 3.5). In L869, an increase of GLI1 was observed while L784 
showed increased cell viability. In all chondrosarcoma cell cultures PTCH 
levels were unchanged or even increased after cyclopamine treatment (Figure 
3.5B). The viability of the tomatidine controls showed that the decrease in 
viability in PANC1 and CH2879 is not a toxic side effect of the cyclopamine 
compound. 
Discussion 
We present the first systematic evaluation of EXT and its downstream 
targets in central chondrosarcoma. We confirm that peripheral and central 
chondrosarcomas are clear distinct genetical entities also with respect to 
their EXT expression. Whereas inactivation of EXT is the driving force for 
the development of benign peripheral cartilage tumours22, we demonstrate 
in central cartilage tumours the EXT genes to be normal both at the DNA 
as well as at the mRNA expression level. The absence of larger deletions in 
the EXT1 region is in concordance with the previously reported absence of 
LOH31 and karyotypic abberations39 at 8q24 in central chondrosarcomas. 
The EXT proteins are involved in the biosynthesis of heparan sulphate. 
Despite normal expression of the EXT genes in central tumours, heparan 
sulphate proteoglycans (CD44v3 and SDC2) unexpectedly accumulated in 
the cytoplasm. This is similar to what we previously described for peripheral 
tumours carrying EXT mutations22, while in other tumours membranous 
expression of CD44v3 and SDC2 is described40,41. In addition, 50% of central 
chondrosarcomas also demonstrated nuclear SDC2 expression, which was 
not observed in peripheral chondrosarcomas, nor in 79 soft tissue sarcomas. 
In addition to the general function of SDC2 in modulating extracellular 
ligands, intracellular actions are implicated for SDC2. In osteosarcoma 
SDC2 has been shown to induce apoptosis42,43. We excluded mutations in 
the nuclear localisation signal (NLS), located at the first exon of the SDC2 
gene, however other mechanisms like i.e. aberrant phosphorylation of the 
NLS or mutations in a kinase responsible for the phosphorylation of the NLS 
might explain the aberrant localisation of SDC2 in central chondrosarcoma. 
In addition, it is tempting to speculate that, for example, other 
glycosyltransferases than EXT or the sulphotransferases or epimerases 
that function to complete the formation of heparan sulphate proteoglycans 
are affected in central chondrosarcoma. By using a custom designed 
oligonucleotide tiling array of 30 EXT, EXT-like and other genes involved in 
HSPG biosynthesis we excluded that neither heterozygous nor homozygous 
EXT and HSPG in central chondrosarcoma
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losses, nor gains, are found in these genes. Nonetheless, we can not exclude 
that these HSPG biosynthesis related genes might be subjected to point 
mutations, or other copy number neutral alterations, i.e. inversion or 
methylation. 
In Drosophila, HSPGs are essential for gradient formation of the morphogens 
hedgehog, decapentaplegic and wingless11. In human, the IHH pathway, 
through PTHLH signalling, is vital for chondrocyte proliferation and 
differentiation in the growth plate. We show hedgehog signalling to be active 
in central chondrosarcoma. We previously demonstrated PTHLH signalling, 
which is downstream of IHH, to be active in central chondrosarcomas 
as well44,45. In osteochondromas, IHH signalling is active, while activity 
decreases in peripheral chondrosarcoma with increasing histological 
grade23. Tiet et al. reported active IHH signalling in chondrosarcoma, but 
did not distinguish between peripheral en central tumours46. In a previous 
pilot series we reported lower levels of IHH signalling in central tumours as 
compared to the growth plate 45. In the present larger series IHH signalling 
levels are comparable to growth plate samples. Moreover, in one of the cell 
lines, CH2879, an important role for hedgehog signalling in cell proliferation 
could be shown since inhibiting HH signalling using cyclopamine decreased 
cell viability. IHH signalling has been shown to be activated in many cancers 
such as medulloblastoma, basal cell carcinoma, small-cell lung cancer, 
breast cancer, and pancreatic cancer (reviewed in47). Therefore, targeting 
IHH signalling seems to be promising in cancer therapy48. Previously, Tiet 
et al. also showed that blocking HH signalling using either cyclopamine 
or triparanol, an inhibitor of 7-dehydrocholesterol reductase, reduced 
proliferation and tumour volume in 10 chondrosarcoma xenografts46. 
However, we observed an effect of IHH blockade using cyclopamine only in 
one of 6 chondrosarcoma cell cultures. Surprisingly, PTCH was found to 
be increased in those cultures that were resistant to cyclopamine, which 
might be induced by other pathways. These data suggest that despite 
aberrant cellular HSPG distribution, IHH signalling is active in central 
chondrosarcoma and is vital for cellular proliferation and therefore a putative 
therapeutic target in a small subset of them. Since HSPGs are thought to be 
important for the diffusion of HH to its receptor on target cells, it might be 
that in central chondrosarcoma these diffusion problems are overcome by 
cell autonomous (autocrine) HH signalling, as was previously also suggested 
for osteochondromas49.
The activity of other signalling pathways dependent on HSPG was similar 
to the activity in peripheral chondrosarcoma23. Our results suggest that 
active canonical WNT signalling might be important for the transition from 
enchondroma towards low-grade central chondrosarcoma, however it is 
not crucial for progression towards higher grade (Figure 3.3). In contrast, 
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TGFB signalling was shown to increase with increasing histological grade 
by both the presence of PAI-1 and the finding of nuclear localisation of 
phosphorylated Smad2. This suggests that TGFB has a role in either 
rearrangement of extracellular matrix and/or vessel formation, which are 
the main characteristics of high grade chondrosarcoma50.
Figure 3.6 Overview of the EXT/HSPG pathway involved in both peripheral and central chon-
drosarcomas. Despite the absence of EXT alterations in central chondrosarcomas there is 
cytoplasmic retention of HSPGs, which is similar to peripheral chondrosarcomas and nuclear 
SDC2 localisation that was specific for central chondrosarcomas. In addition, while IHH signal-
ling decreased with grade in peripheral chondrosarcomas, it is still active in high grade central 
chondrosarcomas. 
Active canonical WNT signalling might be important for the transition from benign to malig-
nant cartilaginous tumour type, however is not crucial for tumour progression, while TGFB is. 
Our results therefore suggest that a disturbed HSPG functioning is involved in the histogenesis 
of both central and peripheral chondrosarcoma, although different steps in HSPG biosynthesis 
seem affected. (Figure based on Hameetman et al.22)
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In conclusion, we present a systematic investigation of EXT and its 
downstream targets in central chondrosarcoma. We clearly show that 
the EXT genes are normal in central chondrosarcoma, with nevertheless 
aberrant localisation of HSPGs. Despite this, IHH signalling is active in 
central chondrosarcoma and is important for proliferation and therefore a 
potential therapeutic target in a small subset of central chondrosarcomas. 
The aberrant intracellular accumulation of HSPG in central chondrosarcoma 
which is similar to peripheral chondrosarcoma and the nuclear SDC2 
localisation that is exclusively seen in central chondrosarcoma is difficult 
to explain. Nevertheless, our data, summarised in figure 3.6, suggest 
that a disturbed HSPG functioning is involved in the histogenesis of both 
central and peripheral chondrosarcoma, although different steps in HSPG 
biosynthesis seem affected.
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4. Central chondrosarcoma progression is 
associated with pRb pathway alterations; 
CDK4 downregulation and p16 
overexpression inhibit cell growth in vitro 
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Abstract
Chondrosarcomas are highly resistant to conventional radiation and 
chemotherapy and surgical removal is the only option for curative treatment. 
Consequently, there is nothing to offer patients with inoperable tumours and 
metastatic disease. The aim of this study is to investigate genes involved in 
cell cycle control: CDK4, CDKN2A/p16, cyclin D1, p21, p53, MDM2 and c-MYC, 
which may point towards new therapeutic strategies. The pRb pathway was 
targeted using CDKN2A/p16 overexpressing vectors and shRNA against 
CDK4 in chondrosarcoma cell lines OUMS27, SW1353, and CH2879. Cell 
survival and proliferation were assessed. CDK4, MDM2 and c-MYC expression 
levels were investigated by qPCR and immunohistochemistry (IHC) in 34 
fresh frozen and 90 FFPE samples of enchondroma and chondrosarcoma 
patients. On a subset of 29 high grade chondrosarcomas IHC for cyclin D1, 
p21 and p53 was performed.
Overexpression of CDKN2A/p16 and knock down of CDK4 by shRNA 
in OUMS27, SW1353, and CH2879 resulted in a significant decrease in 
cell viability and proliferation and a decreased ability to form colonies 
in vitro. Expression of CDK4 and MDM2 was associated with high-grade 
chondrosarcoma both at the mRNA and protein level. Combining these 
results with the expression of cyclin D1 and the previously shown loss of 
CDKN2A/p16 expression show that the majority (96%; 28/29) of high-grade 
chondrosarcomas contain alterations in the pRb pathway.This suggests a 





Chondrosarcoma of bone is a malignant cartilage-forming tumour which 
is notorious for its resistance to conventional chemo- and radiation 
therapy. The majority of tumours arise in the medullar cavity of bone 
and are designated primary central chondrosarcomas (80-85%)1. For <1% 
of chondrosarcomas, there is clinical evidence that they arose secondary 
to a pre-existing (benign) enchondroma1,2. Enchondromas occur mostly 
as solitary leasions, although they may occur as multiple leasions in the 
context of non-hereditary enchondromatosis (Ollier disease).
Chondrosarcomas are histologically divided into three grades, which is 
currently the only objective predictor of metastasis. While grade I tumours 
rarely metastasize and the 10 year survival rate is 83%, patients with grade 
III tumours develop metastatic disease in up to 71% of the cases and the 
10 year survival rate decreases to 29%3. Marginal or intraleasional excision 
of tumours can result in local recurrence. Thirteen percent of recurrent 
chondrosarcomas are of a higher grade than the primary tumour4. 
Currently, surgical removal of the tumour is the only option for curative 
treatment. There is no treatment to offer patients with metastatic disease or 
inoperable tumours in the extremities or pelvis. Elucidating the molecular 
background of high-grade chondrosarcomas and the involved pathways that 
lead to tumour progression may help identify targets for future therapeutic 
strategies to improve clinical outcome.
In contrast to other solid tumours, central chondrosarcomas harbour 
relatively few consistent, numerical genomic alterations; however, 
amplification of 12q135,6 and deletion of 9p217-9 are two consistent genetic 
aberrations. Using array Comparative Genomic Hybridisation (CGH), 
we previously showed amplification of 12q13 in 6 of 21 (29%) central 
chondrosarcomas, which correlated with high histological grade6, as was 
also suggested by others9. Several genes in this region are of importance 
for cell cycle control including CDK4 and MDM2, players in the pRb and 
p53 pathway, respectively. Defects in these pathways are found at high 
rates in almost all types of human cancer10,11. Combining the array CGH 
results with those of our genome wide expression profiling experiments 
showed overexpression of the CDK4 proto-oncogene in tumours with 12q13 
amplification6. CDK4 controls progression through the cell cycle by regulating 
the transit of the cell through the G1 restriction point. This occurs by hyper-
phosphorylation of pRb, leading to the release of E2F transcription factors. 
To accomplish this, CDK4 forms a complex with cyclin D1. This complex is 
tightly regulated by the inhibitory protein CDKN2A (CDKN2A/p16), which 
is encoded by the INK4A-ARF locus located on chromosome 9p21. Inhibition 
of the pRb-mediated cell cycle control through amplification of cyclin D1 or 
CDK4 and/or loss of expression of CDKN2A/p16/INK4A has been observed 
in many tumours12. Despite LOH of 13q14 has been found in a subset 
of chondrosarcoma13,14, i.e. in 10/28 tumours by Yamaguchi et al.5, pRb 
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mutations were not found5. Ropke et al. showed pRb expression in 16/17 
chondrosarcomas by immunohistochemistry14.
We and others previously demonstrated that loss of CDKN2A/p16 protein 
expression is correlated with increasing histological grade in central 
chondrosarcoma7,15,16. Cyclin D1 was previously shown to be expressed in 
25 of 34 (73%) high-grade central chondrosarcomas17.
In addition to CDK4, the 12q13 gene region harbours the MDM2 gene which 
is frequently found to be co-amplified with CDK418. The MDM2 gene encodes 
an E3 ubiquitin ligase involved in the degradation of p53 protein. The 
tumour suppressor protein p53 is activated upon various forms of stress, 
including aberrant mitogenic signalling, resulting in cell cycle arrest and/
or the induction of apoptosis11. p53 mutations have been found in a subset 
of chondrosarcomas, and are mostly associated with aggressive behaviour 
(reviewed in Rozeman et al.19). Amplification of MDM2 is frequently found in 
sarcomas (reviewed in Sandberg et al.20).
In addition to 12q13 and 9p21 alterations, Morrison et al. reported 
amplification of the oncogene c-MYC (8q24) in about 33% of high-grade 
chondrosarcomas21. However, these results could not be reproduced in 
other series6. C-MYC amongst others, drives cells into S phase22. Slight 
differences in c-MYC expression were reported between enchondromatosis-
related and solitary chondrosarcomas23.
The aim of our study was to investigate whether the pRb and p53 
pathways harbour potential targets for therapy of inoperable or metastatic 
chondrosarcomas. Because 12q13 and 8q24 amplifications and 9p21 
deletions suggest an important role for cell cycle regulators, especially those 
in the pRb and p53 pathways, we present the first in vitro evidence for an 
important role of CDKN2A/p16 and CDK4 in chondrosarcoma cell survival 
and proliferation. Subsequently, we validated the expression of CDK4, 




Chondrosarcoma cell lines derived from chondrosarcoma grade II (SW1353, 
American Type Culture Collection, Manassas, VA), and chondrosarcoma 
grade III (CH287924 and OUMS2725) were cultured in RPMI 1640 (Gibco, 
Invitrogen Life-Technologies, Scotland, UK). The breast carcinoma cell line 
MCF7 was grown in Dulbecco’s modified Eagle medium. Media for both 
cell lines were supplemented with 10% heat-inactivated foetal calf serum 
(Gibco). Cells were grown at 37ºC in a humidified incubator with 95% air and 
5% CO2. The cartilaginous phenotype was confirmed by RT-PCR, showing 
mRNA expression of collagens I, 2B, 3, and 10; Aggrecan; and SOX926.
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Overexpressing and short hairpin (sh) RNA lentiviral vectors 
The CDKN2A/p16-expressing lentiviral vector (kindly provided by Dr. R. 
Hoeben, department of Molecular Cell Biology, Leiden University Medical 
Center) has been described previously27. To generate vectors expressing 
shRNA against CDK4, oligonucleotides (for sequences see supplementary 
table 4.1) were cloned into the pTER vector28. Subsequently, fragments 
containing the H1-promoter and cloned oligonucleotides were recloned 
into the lentiviral pRRL-CMV-GFP vector29. Production of lentiviruses by 
transfection into 293T cells has been described previously29. For infection 
of the chondrosarcoma cell lines, 105 cells were seeded into 6-cm dishes 
and allowed to attach overnight. Virus was quantitated by antigen capture 
ELISA measuring HIV p24 levels (ZeptoMetrix Corporation, NY). This value 
has been converted to an infectious titer using the approximation that 1 
ng of p24 equals 2500 infectious units (multiplicity of infection (MOI)). To 
obtain overexpression, cells were infected with the CDKN2A/p16-expressing 
lentivirus with a MOI of 1. An empty vector was used as a negative control for 
infections. To obtain specific knock down, a mixture of three CDK4-shRNA-
expressing lentiviral vectors was used (MOI 3); shRNA against murine 
MDM4 was used as a control. Cells were transduced in the presence of 8 µg/
ml polybrene (Sigma Aldrich, Zwijndrecht, The Netherlands). Microscopic 
evaluation of green fluorescent protein (GFP) expression three days post 
transduction showed 80-90% transduction efficiency for all conditions. 
Immunoblotting 
Proteins were extracted from cell cultures using Giordano lysis buffer (50 
mM Tris-HCl pH 7.5, 250 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, and 
15% glycerol). Protein concentrations were measured using a Bradford assay 
(Bio-rad Laboratories, Hercules, CA, USA). 10 mg of total protein lysate from 
each sample was separated on SDS-PAGE. Lysates of normal human skin 
fibroblast cell line VH10, which was density-arrested and serum starved 
during two weeks, and subsequently reseeded in 20% serum, served as 
positive control for hyper-phosphorylated pRB (p-pRb). Two p16 negative 
melanoma cell lines were used as a control for loss of p16 staining in the 
chondrosarcoma cell lines. Proteins were transferred onto polyvinylidene 
difluoride membranes (Immobilon-P, Millipore, Billerica, MA, USA). 
Equal protein loading was verified by α tubulin staining. The membranes 
were pre-incubated with blocking solution (10% Non-fat dry milk in Tris 
buffered saline pH 8.0, 0.2% Tween-20). After incubation with primary 
(Supplementary table 4.2) and secondary antibodies, the membranes were 
developed with Super Signal West Dura (Pierce Biotechnology, Rockford, IL, 
USA) and visualised by exposure to X-ray films or via the Chemigenius XE3 
(Syngene, Cambridge, UK). 
Rb pathway analysis in central chondrosarcoma
74
Proliferation assays
Cell counts were performed in duplicate using a Bürker chamber. A WST-1 
colorimetric assay (Roche Diagnostics GmbH, Penzberg, Germany) was used 
to measure metabolic activity which represented the amount of viable cells. 
Briefly, cells were seeded into 96-well flat-bottom plates (1000 cells/well), 
each condition in quadruplicate. On days 3 and 6 post transduction, the 
metabolic activity of the cells was measured on a Victor3 Multilabel Counter 
1420-042 (Perkin Elmer, MA, USA) at 450 nm. 
Clonogenic survival assay
Cells (1000, 5000 and 10000) were plated on 6-well plates. Cells were 
allowed to form colonies over a period of 14 days and subsequently fixed 
with methanol/acetic acid and stained using Giemsa. 
Patient material
Conventional central chondrosarcomas were selected based on accepted 
clinicopathological and radiological criteria1. Peripheral-, juxtacortical-, 
mesenchymal-, dedifferentiated-, and clear-cell chondrosarcomas were 
excluded. In total, specimens from 105 patients were studied including 45 
high-grade chondrosarcomas. The clinical details are outlined in table 4.1. 
Histological grading was performed according to Evans3. All specimens 
were handled according to the ethical guidelines described in “Code for 
Proper Secondary Use of Human Tissue in The Netherlands” of the Dutch 
Federation of Medical Scientific Societies.
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 Enchondromas Chondrosarcomas
 FFPE fresh frozen FFPE fresh frozen
Total number of 
tumours 20 7* 70 27
Grade I  -  - 25 11
Grade II  -  - 28* 7
Grade III  -  - 17* 9
    
Male 11 3 36 17
Female 9 4 34 10
Enchondromatosis 6 5 11 7
Median age at 
diagnosis years (range) 33.6 (11-66.4) 18 (12-37) 51.4 (17.8-84) 40 (17.8-84)
Median follow up 
months (range) 100 (6-221)  84 (5-247)  
Table 4.1 Clinicopathological data of the 105 enchondromas and chondrosarcomas. 
Abbreviations: FFPE Formalin fixed paraffin embedded. All fresh frozen enchondromas were 
located in the phalanx. * A subset of 29 FFPE high grade chondrosarcomas (grade II and III) 
was selected to study pRb and p53 pathway (Table 4.3).
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Quantitative real time reverse transcriptase PCR (qPCR)
Fresh frozen tumour tissue was available for RNA isolation, performed as 
described previously, from 34 cases30. Growth plate samples (n=4) were 
used as controls. mRNA expression of CDK4, MDM2, and c-MYC (for primer 
sequences see supplementary table 4.3) were studied using quantitative 
RT-PCR, as previously described31. Four control genes (CYPA, CPSF6, 
SRPR, and HNRPH1) were selected because of their invariable expression in 
chondrosarcoma31. As a reference for normalisation and statistical analysis, 
a mixture of 15 cell lines23 was included. Normalisation was performed using 
GENORM32.
Immunohistochemistry (IHC) 
Formalin-fixed, paraffin-embedded material from 90 tumours was used, 
including 45 high-grade (grade II and III) chondrosarcomas to study 
CDK4, MDM2 and c-MYC by IHC. Twenty-nine of these 45 high-grade 
chondrosarcomas were previously investigated for CDKN2A/p1615 protein 
expression (Table 4.1 and 4.3) and 14 of these were negative for p16. To 
obtain a full overview of the pRb pathway in high grade chondrosarcomas, 
we further studied these 29 tumours for expression of other players in the 
pRb and p53 pathway by means of IHC for cyclin D1, p21 and p53. For 
19 tumours, corresponding fresh frozen tissue was available (Table 4.1). 
Details of the primary antibodies used, are described in supplementary table 
4.2. As negative controls, slides were incubated in PBS/BSA 1% without 
primary specific antibodies. An IHC protocol optimised for cartilaginous 
tissue was applied to avoid detachment of sections13. Antigen retrieval was 
performed using citrate buffer at 98°C for 20 minutes in a water bath. 
Slides were independently semi-quantitatively scored for nuclear staining, 
as described previously13 by two observers (YS, JVMG). Both were blinded 
to the clinicopathological data. Scores were given for intensity (1 = weak, 2 
= moderate, 3 = strong) and for the percentage of positive cells (1 = 0-24%, 
2 = 25-49%, 3 = 50-74% and 4 = 75%-100%). To avoid tumours with single 
positive cells being regarded as positive, cut off levels for statistical analysis 
were applied (sum of score CDK4 and p53 ≥4, and of cyclin D1, MDM2 and 
c-MYC ≥3. Tumours were regarded as negative for p21 with a sum of score 
≤1, similar to the previous p16 staining15).
Statistical analysis
Normalised expression levels of different tumour groups were compared 
with growth plates using the Student’s T-test or one-way ANOVA with 
Bonferroni correction, after log10 transformation. Correlation between 
immunohistochemical staining and histological grade was analysed using 
Pearson chi-square. Immunohistochemical data were correlated with follow 
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up by calculating the Kaplan-Meier curves and corresponding Log Rank 
tests. P-values <0.05 were considered significant.
Results
Functional analysis of the pRb pathway in vitro
Immunoblotting showed an absence of CDKN2A/p16 in all three 
chondrosarcoma cell lines, while pRb was mainly present in its inactive, 
hyper-phosphorylated form (Figure 4.1A). Overexpression of CDKN2A/
p16 caused a shift of hyper-phosphorylated pRb to hypo-phosphorylated 
pRb (4.1B), and a decrease in total pRb levels in SW1353, OUMS27 and 
CH2879. The relative number of cells decreased in SW1353, OUMS27, 
and CH2879 upon overexpression of CDKN2A/p16 (p =0.035, 0.002, and 
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Figure 4.1 Immunoblot analysis of chondrosarcoma cell lines upon overexpression of CD-
KN2A/p16 (A) or knock-down of CDK4 (E). (B) Characteristic band shift of pRb on 7.5% gel 
in the chondrosarcoma cell lines SW1353 and OUMS27. VH10 that was density-arrested and 
serum starved and subsequently reseeded in 20% serum (+) served as a control for hyper-pho-
sporylated pRb. (F) Decreased ability of OUMS27 to form colonies after knock-down of CDK4. 
Relative cell numbers (C, G) and cell viability (D, H) compared with controls are shown (both 
measured 6 days after treatment). * indicates significant differences.
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0.014, respectively; figure 4.1C). In all cell lines, the WST-1 assay detected 
decreased metabolic activity, referred to as cell viability, to almost half of 
the metabolic activity of the controls for OUMS27 and CH2879 (p =0.003 
and p=0.0455; figure 4.1D); this was less pronounced in SW1353 (p=0.059). 
All three cell lines showed high levels of CDK4 mRNA expression (see 
supplementary figure 4.1). shRNA targeting CDK4 in the chondrosarcoma 
cell lines and MCF7 was effective (Figure 4.1E). Decrease in hyper-
phosphorylated pRb expression is indicative of cell cycle arrest and was found 
upon knock down of CDK4 in all the cell lines, although to a lesser extent 
in OUMS27. Again, a reduction of total pRb with hypo-phosphorylation of 
existing pRb is observed. Enhanced degradation of pRb has been described 
previously after inhibition of cyclin D1 in p21WAF1 expressing lung cancer 
cells33. Interestingly, the CH2879 cells, in which the effect on pRb levels 
is most prominent (Figure 4.1E), show a relatively high level of p21WAF1, 
correlating with the wild-type p53 status in these cells (data not shown). 
The number of cells in the CDK4 shRNA transduced cells was significantly 
decreased (SW1353 p=0.002; OUMS27 p=0.003; CH2879 p=0.015; figure 
4.1G). Metabolic activity was decreased in CDK4 shRNA transduced 
OUMS27 and CH2879 cells (p=0.0002 and p<0.0001, respectively; figure 
4.1H). In SW1353 an increase in metabolic activity was observed, analogous 
to the non-significant changes after overexpression of p16. SW1353 has 
a less cartilaginous appearance in vitro34, despite its expression of typical 
cartilage mRNAs, and has a higher rate of proliferation than OUMS27 and 
CH2879, which may explain the divergent results in the WST-1 assay for 
this cell line. The capacity of all chondrosarcoma cell lines to form colonies 
in vitro was reduced upon knock down of CDK4 (E.g. OUMS27, figure 4.1F).
Expression of pRb and p53 components in clinical samples 
Quantitative PCR
The increase in CDK4 and MDM2 mRNA expression correlates with increasing 
histological grade (Figures 4.2A and 4.2C) (Pearson R=0.684, p<0.0001 and 
R=0.508, p=0.007, respectively). Expression of MDM2 was significantly 
higher in tumours demonstrating 12q13 amplification at array-CGH6 than in 
tumours without amplification (Student’s t test p=0.044, confidence interval 
[-0.83 -0.014], supplementary figure 4.2). c-MYC mRNA expression was not 
associated with histological grade (data not shown). In enchondromatosis 
related tumours, c-MYC mRNA expression was significantly higher than 
in solitary tumours (Student’s t test p=0.011, confidence interval [-0.80; 
-0.116]; supplementary figure 4.3).
Immunohistochemistry
Results of CDK4, MDM2 and c-MYC staining on the series of 90 FFPE 
sections are shown in table 4.2. Nuclear expression of CDK4 and MDM2 
protein, as illustrated by figures 4.2B en 4.2D, was correlated with 
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Figure 4.2 CDK4 (A) and MDM2 (C) mRNA expression levels relative to the growth plate are 
shown. Nuclear protein expression of CDK4 (B) and MDM2 (D) was determined (magnification 
40x).
increasing histological grade in chondrosarcomas (Pearson’s R=0.368, 
p=0.009 and figure 2E, R=0.356, p=0.007, respectively). Of the 29 high-grade 
chondrosarcomas that were previously studied for CDKN2A/p16 protein 
expression15 (Table 3.3) and that were selected for further study, cyclin D1 
was expressed in 62% (17/27). Moreover, 8 of 28 tumours were negative for 
p21, a CDK4/Cyclin D1 inhibitor activated by p53. Eight of 24 high grade 
CDK4 MDM2 cMYC
Enchondroma 6/12 50% 0/20 0% 0/20 0%
Chondrosarcoma grade I 4/20 20% 1/19 5% 3/25 12%
Chondrosarcoma grade II 11/21 52% 7/25 28% 2/28 7%
Chondrosarcoma grade III 6/9 67% 6/13 46% 3/17 18%
Table 4.2 Immunohistochemical staining of 90 FFPE samples of enchondroma and 
chondrosarcoma patients
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pRb pathway p53 pathway
L-number p16 CDK4 Cyclin D1 p21 MDM2 p53
1 147 + - - - n/a -
2 164 + + + + - -
3 171 - + - + - -
4 172 - + + + n/a -
5 181 - + - - - -
6 182 + + - + - -
7 184 - + + + + +
8 187 - + + - - -
9 190 - + - - n/a -
10 250 + - + + - +
11 253 - - n/a - + n/a
12 260 + - + + - +
13 265 + - + + + +
14 266 - - + - - +
15 278 + + - + + -
16 286 - - - + n/a -
17 304 + - + + + -
18 333 - - + + - +
19 536 + - + - - -
20 629 + + + + - +
21 654 - - + + - +
22 795 - + + + + +
23 802 + + - + - -
24 813 + + n/a n/a - n/a
25 822 + - + + - +
26 861 - + - - n/a -
27 903 + - + + - -
28 908 + + + + + +
29 1066 - + - + + -













Summary 28/29 (96%) 21/29 (72%)
Table 4.3 Twenty-nine high-grade chondrosarcomas and associated alterations in the 
key players of the pRb and p53 pathways. + and - indicate positive and negative results, 
respectively. Immunohistochemical results for p16 were published previously15 N/a: data not 
available.
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chondrosarcomas (33%) were positive for MDM2 and in 11/27 p53 was 
overexpressed. These results emphasise that aberrations in the pRb pathway 
occur in the majority (28/29, 96%) of high-grade chondrosarcomas. In fact, 
central cartilaginous tumours harbouring aberrations in the pRb pathway 
had shorter disease-free survival (Log Rank test p=0.018), although this was 
not independent of histological grade. 
While a correlation between mRNA expression of CDK4 and MDM2 with 
12q13 amplification was evident, only in 2 of 4 tumours with an amplification 
(L795 and L1066) CDK4 and MDM2 protein expression was found (data not 
shown). Nuclear c-MYC protein expression was found in 0/20 enchondromas 
and in only 8/70 (11%) chondrosarcomas (Table 4.2). The difference in 
c-MYC mRNA expression between enchondromatosis and solitary tumours 
could also not be confirmed at the protein level (X2 p=0.983).
Discussion
The aim of our study was to investigate whether the pRb and p53 
pathways harbour potential targets for therapy of inoperable or metastatic 
chondrosarcomas. We present the first in vitro evidence for an important 
role of CDKN2A/p16 and CDK4 in chondrosarcoma cell survival and 
proliferation. 
Unfortunately, there is nothing with curative intent to offer patients with 
inoperable or metastatic high-grade chondrosarcoma. 12q13 and 8q24 
amplifications and 9p21 deletions are reported and suggest an important 
role for cell cycle regulators. Therefore, we investigated whether the pRb 
and p53 pathways carry a specific target that could be used for future 
targeted therapy of high grade central chondrosarcoma, similar to the 
attempts currently being made for other types of cancers. We demonstrate 
alterations of the pRb pathway in the vast majority of high-grade central 
chondrosarcomas. 
Increased CDK4 expression, both at the mRNA and protein level, was found in 
16 of 29 high-grade central chondrosarcomas and correlated with increasing 
histological grade and, consequently, poor prognosis. Increased CDK4 
expression was also shown previously in a pRb negative chondrosarcoma 
cell line by Asp et al.16. Reducing CDK4 expression in chondrosarcoma cell 
lines resulted in decreased survival and cell proliferation, confirming the 
important role of CDK4 in chondrosarcoma progression. 
Loss of p16 was previously shown in chondrosarcoma specimens and cell 
lines by Asp et al.7, 16 and by us15. We now show the functional implications 
of the p16 loss in central chondrosarcoma by overexpressing p16 in three 
p16 negative chondrosarcoma cell lines. We found decreased cell growth 
upon p16 overexpression, which is probably caused by senescence, since 
increased apoptosis was not observed (data not shown). 
Other players in the pRb pathway are also affected in central chondrosarcoma, 
as was also reported previously7,14-17,35. We show that the pRb pathway is 
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affected in 96% of the high-grade central chondrosarcomas, either by a 
decrease in the amount of CDKN2A/p16 (48%), an increase in the amount 
of CDK4 (55%), or expression of cyclin D1 (62%) (Table 4.3, figure 4.3). In 
addition, we show that MDM2 overexpression is correlated with increased 
histological grade. Thirteen of 38 (34%) high-grade tumours showed staining 
for MDM2, indicating that p53 degradation through MDM2 is also associated 
with tumour progression in a subset of central chondrosarcomas. Thus, 
alterations in p53 and pRb pathways are non-redundant in high grade 
central chondrosarcoma. Crosstalk between the pRb and p53 pathway 
occurs via the p53 response gene, p21WAF1. The p21WAF1 protein can inhibit 
the CDK4-cyclin D1 complex upon overexpression (Figure 4.3). Surprisingly, 
p21 expression was also shown to be associated with increasing grade in 
chondrosarcoma36.
The reported amplification of the c-MYC locus (8q24)21 could not be verified 
in our previous arrayCGH experiments6. cDNA microarray demonstrated 
differences in mRNA expression of the oncogene c-MYC in enchondromatosis-
related versus solitary tumours23, which we confirmed in the present 
study using qPCR. C-MYC overexpression is observed in a large number 
of malignancies22. Based on the low c-MYC protein expression levels we 
detected in chondrosarcoma, the importance of oncogene c-MYC in central 
chondrosarcoma development or progression is questionable.
Chondrosarcomas are highly insensitive to classical chemotherapeutics that 
interfere with the cell cycle, like methotrexate and 5-fluorouracil, and to 
radiation therapy. Surgery is currently the only therapeutic option. We now 
Figure 4.3 Changes in the pRb and p53 pathway promoting cell cycle passage in high-grade 
central chondrosarcoma, as found in the present and previous studies. Correlations are posi-
tive, unless stated otherwise.
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show that central chondrosarcomas gain defects in the pRb pathway upon 
progression in grade, and that in the majority of high-grade chondrosarcomas 
either CDKN2A/p16 expression is inhibited, CDK4 is activated, or both. 
Our in vitro experiments with shRNA against CDK4 and overexpression of 
CDKN2A/p16 gene suggests that a number of therapeutic strategies may 
become possible including the use of CDK4 inhibitors. Functionally intact 
pRb signalling is a prerequisite for the effectivity of CDK4 inhibition. Despite 
LOH of 13q14 has been found in a subset of chondrosarcoma5,13,14, pRb 
mutations were not found5. Moreover, we show deliberate pRb expression 
in three chondrosarcoma cell lines.
In MCF7 breast cancer cells, CDK inhibitors were effective in treating 
tumours that overexpress the CDK4-cyclin D1 complex or that have lost 
INK4a function37. Heat shock protein 90 (HSP90) inhibitors could also be 
potential proliferation blockers in chondrosarcoma, since the stabilisation 
of CDK4, among other proteins, is regulated by HSP90 (reviewed in Whitesell 
et al.38). Our results indicate that studying the effect of compounds targeting 
CDK4, as soon as they are made available for (pre-)clinical use, would be 
the next step to investigate alternative, targeted treatment for high-grade 
central chondrosarcomas.
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Supplementary figure 4.1 Central chondrosarcoma 
cell lines SW1353, OUMS27, and CH2879 show high 
levels of CDK4 mRNA in qPCR, comparable to the levels 
in high grade chondrosarcoma.
Supplementary figure 4.2 Central chondrosarcomas, 
showing gain at 12q13 at arrayCGH, express signifi-
cantly higher mRNA levels of MDM2.
Supplementary figure 4.3 c-MYC mRNA levels are sig-




1 gatccgGACATATCTGGACAAGGCttcaagagaGCCTTGTCCAGATATGTCCTT  ttttggaaa
2 gatccgCCCACACAAGCGAATCTCTttcaagagaAGAGATTCGCTTGTGTGGGTTttttggaaa
3 gatccgTCTTTGCCTTTATCTCTGAttcaagagaTCAGAGATAAAGGCAAAGATT ttttggaaa
Supplementary table 4.1. CDK4 shRNA oligonucleotide sequences. 
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CDK4 Biosource DCS-31 1:40 Mouse Citrate Skin
Cyclin D1 NeoMarkers SP4 1:200 Rabbit Tris-EDTA Tonsil




cMYC Epitomics Y69 1:100 Rabbit EDTA Burkitt lymphoma
p21 Calbiochem Ab-1 1:400 Mouse Citrate Sigmoid
p53 NeoMarkers DO-7 1:1000 Mouse Citrate Colon caricinoma
Immunoblotting
CDKN2A/p16 NeoMarkers 16P04 1:800 Mouse
CDK4 Santa Cruz Biotechnology C-22 1:200 Rabbit
Abcam DCS-35 1:250 Mouse
MDM2 Mol Cell Biol 1993;13:4107-14 4B2 1:3 Mouse
+ Santa Cruz 







Total pRb Pharmingen BD G3-245 1:500 Mouse
α Tubulin Sigma Aldrich DM1A 1:2000 Mouse
Supplementary table 4.2. Procedures and details of the primary antibodies used for 
immuohistochemistry (IHC) and immunoblotting.







Supplementary table 4.3. Primer sequences used for qPCR. 
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Abstract 
Chondrosarcomas are notorious for their resistance to conventional chemo- 
and radiotherapy, indicating there are no curative treatment possibilities 
for patients with inoperable or metastatic disease. We therefore explored the 
existence of molecular targets for systemic treatment of chondrosarcoma 
using kinome profiling. Peptide array was performed for 4 chondrosarcoma cell 
lines and 9 primary chondrosarcoma cultures with GIST882, mesenchymal 
stem cells, and colorectal cancer cell lines as controls. Activity of kinases 
was verified using immunoblot and active Src- and PDGFR signalling 
were further explored using imatinib and dasatinib on chondrosarcoma in 
vitro. The AKT1/GSK3B pathway was clearly active in chondrosarcoma. In 
addition, the PDGFR pathway and the Src kinase family were active. PDGFR 
and Src kinases can be inhibited by imatinib and dasatinib respectively. 
While imatinib did not show any effect on chondrosarcoma cell cultures, 
dasatinib showed a decrease in cell viability at nanomolar concentrations in 
7 out of 9 chondrosarcoma cultures. However, inhibition of phosphorylated 
Src (Y419) was found both in responsive and non-responsive cells. In 
conclusion, using kinome profiling we found the Src pathway to be active 
in chondrosarcoma. Moreover, we showed in vitro, that the inhibitor of the 
Src pathway, dasatinib, may provide a potential therapeutic benefit for 




Curative treatment of chondrosarcoma of bone is restricted to surgery, 
since this tumour is reported to be extremely chemo- and radiotherapy 
resistant against conventional therapeutic modalities1-3. Therefore, there is 
not much to offer with curative intent to patients with metastatic disease 
or with tumours at inoperable sites. Whereas low-grade chondrosarcomas 
(grade I) are treated by marginal or intraleasional excision, followed by 
margin improvement by application of fenol or cryosurgery3,4, high-grade 
chondrosarcoma is treated by, often mutilating, large en-bloc resection or 
amputation. The metastatic rate of chondrosarcoma is directly related to 
histological grade5, currently being the only predictor of outcome, while 
histological grade is highly subjected to interobserver variability6,7. Grade I 
chondrosarcomas almost never metastasize, while metastases occur in 10% 
of grade II chondrosarcomas and in 71% of grade III chondrosarcomas8. The 
10 year survival rate for patients with high grade chondrosarcoma is poor: 
64% for grade II and only 29% for grade III tumours. 
Few recurrent genetic alterations were found in chondrosarcoma, pointing 
towards a loss of cell cycle control of chondrosarcoma, such as gain of 
CDK49,10 and loss of p1611,12. Decreased cell viability was demonstrated 
after restoration of p16 expression or the knock-down of CDK4 by shRNA 
in chondrosarcoma cells in vitro10. So far there is little evidence for a role 
for kinase inhibitors in chondrosarcoma treatment. In addition to CDK410, 
AKT13 and Flk-1/KDR, PDGFRB14 and FGFR115 were shown to be activated 
and suggested as possible targets in the treatment of chondrosarcoma.
In the present study we explored new treatment options for chondrosarcoma 
using kinome profiling. Kinases are enzymes that phosphorylate tyrosine/
serine or threonine residues on other proteins. They play a major role 
in signalling cascades that determine cell cycle entry, cell survival and 
differentiation fate, which are often deregulated in tumours. Kinases are 
excellent targets for anti-cancer therapy since they work as a molecular 
switch; their regulation is reversible, rapid (merely in seconds) and does not 
require new protein synthesis (reviewed in16).
Kinome profiling allows the detection of kinase activity in cell lysates 
by detecting the level of substrate phosphorylation. This produces a 
comprehensive description of cellular signal transduction in a particular 
sample, which can be assigned to specific pathways, as has been shown by 
Diks et al.17. Kinome profiling identified the AKT1/GSK3B pathway, PDGFRB 
and the Src pathway, as potential targets for chondrosarcoma treatment. 
We showed that inhibition of the Src pathway by dasatinib indeed resulted 
in decreased cell viability in 7 out of 9 chondrosarcoma cell cultures in vitro. 





Imatinib mesylate (Glivec/Gleevec, STI571) was obtained from Novartis 
(Basel, Switzerland) and dasatinib (Sprycel, BMS- 354825) from Bristol-
Myers Squibb (New York, USA). Both drugs were dissolved in DMSO. 
Cell culture 
Chondrosarcoma cell lines, chondrosarcoma primary cultures (Table 5.1) and 
a gastro intestinal stromal tumour cell line, GIST882 18 were cultured in RPMI 
1640 (Gibco, Invitrogen Life-Technologies, Scotland, UK), supplemented with 
10% heat-inactivated foetal calf serum (Gibco). GIST882, a gastrointestinal 
stromal tumour cell line carrying a homozygous exon 13 missense mutation 
(K642E) in KIT18 and known to be imatinib sensitive, was used, treated and 
untreated, as a proof of principle of the Pepchip® technique. Two cell cultures 
of normal bone marrow derived mesenchymal stem cells (MSCs) (L2361 and 
L2370) were used as non-neoplastic counterpart control. In addition, an 
independent set of 5 colorectal carcinoma cell lines were tested (HT29, RKO, 
LS180, SW480, SW837) to estimate specificity. 
Cells were grown at 37ºC in a humidified incubator with 95% air and 5% 
CO2. The cartilaginous phenotype of the chondrosarcoma cultures was 
confirmed by RT-PCR, showing mRNA expression of collagens I, 2B, 3, and 
10, Aggrecan and SOX919.
 Sample Type Grade Gender Age Passage
1 OUMS2739 Cell line III m na 19
2 CH287940 Cell line III f 35 58
3 SW1353* Cell line II f 72 53
4 C384241 Cell line II m 38 16
5 L784 Primary culture II m 40 11
6 L821 Primary culture I f 53 12
7 L835 Primary culture III m 55 15
8 L869 Primary culture II m 52 27
9 L1081 Primary culture II f 47 11
10 L1250 Primary culture III f 38 10
11 L2252 Primary culture I f 29 7
12 L2279 Primary culture I f 43 7
13 L2388 Primary culture II m 42 4
Table 5.1 Chondrosarcoma cultures. na: not available. *SW1353 was obtained 
from American Type Culture Collection (Manassas, VA, USA). 
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Kinome array analysis
A kinase substrate peptide array was used containing 1024 different kinase 
substrates spotted in triplicate with 16 negative, and 16 positive controls 
(Pepchip Kinomics, Pepscan Presto, Lelystad, the Netherlands). Cells were 
harvested during their exponential growth phase. Cells were washed 3 times 
with cold PBS. Cell lysis buffer (Cell Signalling Technology, Cambridge, MA, 
USA) supplemented with 1mM PMSF was used. Lysates were processed 
through a QIAshredder (Qiagen, Germantown, MD, USA) for 10 minutes 
and a filter (Millipore, Billerica, MA, USA) for 5 minutes both at 4°C to retain 
optimal kinase activity. For concentration of the lysates and discarding of 
the lysis buffer, a 10kD spin column (Millipore) was used for 30 minutes 
at 4°C. Concentration of the protein lysate was measured using the DC 
Protein Assay (Biorad, Hercules, CA, USA). For kinase array analysis 50μg 
of the protein was diluted in kinase buffer (Cell Signalling Technology) 
in the presence of complete mini EDTA free (Roche, Basel, Switzerland) 
and 1 mM PMSF. To 62,5μl of the lysate 12,5μl activation mix (TrisHCl 
pH7.5 20mM, MgCl2 10mM, Glycerol 5%, Brij-35 0.01%, BSA 0,05mg/
ml, ATP 5μM and [γ-33P]ATP 20μCi) was added. A 24x60 mm cover slip 
was used. The slides were incubated in a humid chamber for 2 hours at 
37°C. Subsequently, slides were rinsed in PBS/Triton X-100 1% twice, then 
washed twice in NaCl 2.0M/Triton X-100 1% for 15 minutes, followed by 
washing in distilled water. All buffers were used at 37°C and washing was 
performed in a rotation stove at 37°C. Subsequently the slides were dried 
in a 50 ml tube in a centrifuge at 2000 rpm. The measurement of the 33P 
signal was performed using a Biomolex reader for real time digital imaging 
of radioisotopes (Biomolex, Oslo, Norway). At least 1x106 hits were collected. 
Data analysis
Biomolex Readback V3.6 and Biosplit software (Biomolex) were used 
to create a list with intensities using a grid. For further data mining 
R-packages Affyio and Limma were used (http://www.bioconductor.org). 
Quality of the triplicates and distribution of the data was assessed and 
quantile normalisation (Affyio) was performed. Phosphorylated substrates 
in chondrosarcoma cultures were compared with those in MSCs using 
Limma which provides functions to summarise results using a linear model 
to perform hypothesis tests and adjust the p-values for multiple testing20. 
In addition, the data set of 13 chondrosarcoma cell cultures was compared 
with an independent set of 5 colorectal carcinoma cell lines using Limma. 
Subsequently, phosphorylation signals of all chondrosarcoma cultures were 
averaged and the top 100 (the common denominators) were imported for core 
analysis in Ingenuity Pathway Analysis (http://www.ingenuity.com). IPA is 
a literature based program that calculates the probability of involvement 
of identifiers, in this case combinations of kinases, in 74 known canonical 
pathways. 
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Immunoblotting
10 mg of each sample, stored in kinase buffer at -80°C, was run on SDS-
PAGE. Proteins were transferred onto polyvinylidene difluoride membranes 
(Immobilon-P, Millipore) using electrophoresis. Membranes were pre-
incubated with 5% skinned milk in phosphate buffered saline-Tween 0.05%. 
After incubation with first and secondary antibodies, the membranes 
were developed with ECLTM Western blotting detection reagent (Amersham 
Biosciences, Buckinghamshire, UK) and visualised by exposure to X-ray 
films (Hyperfilm ECL, Amersham Biosciences, Buckinghamsire, UK). 
Rabbit monoclonal antibodies against phospho-c-Raf (Ser338) (56A6), 
phospho-MEK1/2 (Ser217/221) (41G9), phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (D13.14.4E), phospho-p90RSK (Ser380) 
(9D9), phosphorylated AKT (Ser473) (D9E), phosphorylated AKT (Thr308) 
(C31E5), pan AKT (C67E7), GSK3B (27C10) and rabbit antibodies against 
phosphorylated c-Raf (Ser259) and phosphorylated GSK3B (Ser9) were 
obtained from Cell signalling Technology. Jurkat cells, treated with 
LY294002 or Calyculin A were used as a negative and postive control for AKT 
phosphorylation, respectively. Polyclonal antibody to phosphorylated Src 
(Y419) was obtained from R&D Systems (Minneapolis, MN USA). Monoclonal 
antibody to total Src (clone GD11) was obtained from Upstate Biotechnology 
(Lake Placid, NY, USA). Pro-caspase-3 (37 kDa) and beta-tubulin antibodies 
were from Cell Signalling Technology and Sigma Aldrich (St. Louise, MO, 
USA), respectively.
In vitro proliferation assays
Response of chondrosarcoma primary cultures to escalating doses of imatinib 
(range 1.0 – 100 μM) was measured by cell count using a Bürker chamber. 
GIST882 was used as positive control. Response of chondrosarcoma cell 
lines and primary cultures to escalating doses dasatinib (range 5.0 nM – 1.0 
μM) was measured either by tritium incorporation assay (OUMS27, CH2879, 
SW1353, L784, L869) or WST-1 colorimetric assay (Roche Diagnostics 
GmbH, Penzberg, Germany) (L1081, L1250, L2252, L2388), which measures 
mitochondrial activity as described previously21. C3842, L821 and L835 did 
not reach an adequate proliferation rate to allow inhibition experiment. 
Results were compared to a poor responding (ALL CR) and a well responding 
acute lymphoblastic leukemia (ALL CM) cell line and as well as to GIST882, 
known to respond to dasatinib at ~10 nM22. In brief, 20,000 cells were 
seeded in a 96 wells plate and were allowed to incubate with the drugs for 
72 hours. 3H was added and the following day cells were harvested using 
the FilterMate system (Perkin Elmer, Waltham, MA, USA). 3H-thymidine 
incorporation was measured using a TopCount scintillation counter (Perkin 
Elmer). All experiments were performed in duplicate and in the presence of 
a maximum of 0.1% DMSO. In vitro experiments were performed at least 
three times. Graphs show data from one representative experiment. Error 
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bars indicate the standard error of the mean. 
Results
Identification of active kinases in chondrosarcoma cultures.
Through kinome profiling of 13 chondrosarcoma cultures we created a list of 
phosphorylated targets and their corresponding active kinases. The top 100 
of chondrosarcoma targets was analysed using IPA, ranking the importance 
of the corresponding kinases in chondrosarcomas. The specificity of this list 
of substrates for chondrosarcoma was verified by comparing the intensity of 
the signals with those for normal MSCs, using Limma (Supplementary table 
5.1). Based on the average spot intensity and how frequent their targets 
were present in the top 100 of substrates, 21 kinases were identified by 
IPA analysis (Table 5.2). The AKT pathway (AKT1 and GSK3B) was found 
to be the most active pathway in chondrosarcoma, followed by Titin and 
RPS6 kinase. Also the Src pathway (FYN and LCK) and the Ras/Raf/MEK/
ERK pathway stimulated by PDGFRB were active in chondrosarcoma. In 
addition, Aurorakinase B and CDC2 were found. 
Verification of kinome profiling 
Kinome profiling of untreated GIST882 revealed an active Ras/Raf/MEK/
ERK pathway, which is activated by KIT (Supplementary table 5.2). GIST882 
carries an activating KIT mutation18. Subtracting the average intensities 
of untreated GIST882 from the 1.0 μM imatinib treated GIST882 revealed 
that indeed the Ras/Raf/MEK/ERK pathway was targeted by imatinib, 
which was confirmed by analysis using IPA (data not shown). Inhibition 
of the Ras/Raf/MEK/ERK pathway in GIST882 by imatinib was verified 
by immunoblot, using the same lysates as hybridised on the kinase array. 
Staining for cRaf, MEK1/2, ERK1/2 and 90RSK was decreased after 1.0μM 
imatinib treatment (Figure 5.1A), confirming that the Ras/Raf/MEK/ERK 
pathway was targeted by imatinib.
In addition, comparison of the substrate phosphorylation patterns of all 
substrates of 13 chondrosarcoma cell cultures and the two MSC cultures 
(Supplementary table 5.2) and the 5 colorectal carcinoma cell lines 
(Supplementary table 5.3) was performed, revealing 167 and 175 differently 
phosphorylated spots, respectively (adjusted p<0.01).
Phosphorylation of AKT in chondrosarcoma cell cultures could be verified 
by immunoblot at both the serine 473 and the threonine 308 position in 
all cultures (Figure 5.2). Whereas total GSK3B was present in nearly all 
samples, phosphorylation levels of GSK3B at serine 9 were indeed very low 
in the chondrosarcoma cell cultures confirming active GSK3B. cRaf, which 
links the AKT pathway with the MEK/ERK pathway, was also detected by 
immunoblot in all primary cultures.  

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.1: Chondrosarcoma cultures are susceptible to dasatinib but not to imatinib. 
(A) Treatment of GIST882 with 1.0 μM imatinib leads to a decrease in levels of cRaf, phos-
phorylated MEK 1/2, ERK 1/2 and p90RSK verifying interference with the Ras/Raf/MEK/ERK 
pathway by imatinib. (B) Imatinib treatment decreases cell numbers in the imatinib responsive 
GIST882 cell line. However four chondrosarcoma cultures did not respond to imatinib treat-
ment, unless toxic concentrations of 30 and 100 μM were used. (C) Dasatinib causes decreased 
cell viability in 5 of 6 chondrosarcoma primary cell cultures. A decrease in cell viability of 20% 
at 15 nM and 40-50% at 1000 nM was observed in L1081, L1250, L2252 and L2388. Primary 
culture L869 responded with a 50% decrease in cell growth at 15 nM treatment. (D) Cell lines 
OUMS27 and SW1353 showed a decrease in viability at 50 nM dasatinib, whereas both primary 
culture L783 and cell line CH2879 showed a response only at low concentrations (5 and 15 
nM), while at higher concentrations no effect was found. (E) In postitive controls ALL CM and 
GIST882 a decrease in cell viability of more than 80% was observed, while a limited effect was 
found in dasatinib resistant leukemia cell line CR.
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Figure 5.2 Chondrosarcoma cultures are characterized by AKT phosphorylation. Findings 
of kinome profiling by Pepchip® analysis were verified by immunoblot. All cultures showed 
phosphorylation of AKT at serine 473 and threonine 308, although levels of pan AKT were 
variable. While pan GSK3B was detected in nearly all samples, phosphorylation at serine 9 
was absent confirming active GSK3B. Phosphorylated Raf was detected in nearly all samples. 
Jurkat treated with LY294002 (-) or Calyculin A (+) served as a negative and positive control of 
AKT phosphorylation, respectively.
Chondrosarcomas do not respond to imatinib treatment in vitro
In table 5.2 the currently used kinase inhibitors specific for the active 
kinases in chondrosarcoma are shown. Dasatinib and imatinib, targeting 
the Src kinase family and KIT/PDGFR pathway respectively, were available 
to us. Sensitivity of chondrosarcoma cells to both drugs was tested. Whereas 
GIST882 showed a profound decrease of cell number relative to the DMSO 
control at lower dosages of imatinib, the chondrosarcoma primary cultures 
did not show any effect, only at high concentrations of imatinib, probably 
due to non specific toxicity, rather than on target effects (Figure 5.1B).
Chondrosarcomas are responsive to dasatinib treatment in vitro
Seven out of 9 chondrosarcoma cell cultures responded to dasatinib 
treatment with a decrease in cell growth. Primary cultures L1081, L1250, 
L2252, L2388 showed 20% decreased cell viability at 15 nM and 40-50% 
decreased viability at 1000 nM of dasatinib treatment, as measured by 
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either 3H incorporation or WST-1 assay (Figure 5.1C).The strongest effect 
was observed in primary culture L869, with a 50% reduction in cell viability 
compared to the DMSO control at 15 nM dasatinib (Figure 5.1C). Inhibition 
of cell growth of the chondrosarcoma cell lines SW1353, OUMS27 occurred 
at 50 nM (Figure 5.1D). In contrast, both primary culture L784 (Figure 5.1C) 
and cell line CH2879 (Figure 5.1D) did not show any effect. Positive controls 
ALL CM and GIST882 and negative control ALL CR are shown in figure 5.1E. 
Dasatinib treatment of chondrosarcoma decreased Src-phosphorylation but 
does not result in caspase-3 mediated apoptosis
To investigate the effect of dasatinib on Src signalling, GIST882, a good 
responsive chondrosarcoma cell culture (L869) and a non-responsive 
chondrosarcoma cell line (CH2879) were treated with increasing doses of 
dasatinib for 6 hours. Whereas levels of total Src do not decrease upon 
dasatinib treatment, a decrease in phosphorylated Src (pSrc) (Y419) was 
found in GIST882 (Figure 5.3A). At a dosis of 6.25 nM dasatinib the pSrc 
staining has disappeared. Also in L869, the responsive cell culture, levels of 
phosphorylated Src decrease gradually, although both bands of the staining 
are present (Figure 5.3B). Strikingly, in CH2879 the level of phosphorylation 
of Src decreased upon dasatinib treatment as well (Figure 5.3C), while 
no effect on cell viability was found. Staining for pro-caspase 3 (37 kDa) 
showed a gradual decrease in GIST882 upon dasatinib treatment starting at 
12.5 nM, suggesting pro-caspase-3 cleaving and active caspase-3 mediated 
apoptosis (Figure 5.3A)23. Caspase-3 staining seems to increase slightly at 50 
nM and then decreases further until 200 nM allthough tubulin was slightly 
variable. Pro-apoptotic action of dasatinib has been described previously22. 
However, caspase-3 mediated apoptosis could not be demonstrated in both 
chondrosarcoma cell cultures (Figure 5.3B and 5.3C). 
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Discussion
Chondrosarcomas are highly resistant to conventional chemo- and 
radiotherapy, and as a consequence there is no curative treatment option 
for patients with inoperable or metastatic disease. Kinome profiling was 
used to search for drugable kinases in chondrosarcoma. 
A major caveat in large scale phosphorylation studies is the promiscuity of 
kinases in the absence of in vivo regulation signals, which may lead to false-
positive results. Ideally, by comparing kinase profiles with and without a 
certain stimulus, for instance a kinase inhibitor, kinases being activated or 
deactivated upon the stimulus can be detected, as was previously reported17. 
However, since there are no compounds available that are known to have 
any effect in chondrosarcoma, we averaged 13 chondrosarcoma cultures 
to get an impression of the most active kinases and the pathways they are 
involved in. 
Using GIST882 we demonstrated that the Pepchip® kinome profiling platform 
correctly identified the pathways that are known to play an important role 
in GIST and that their activity is decreased by imatinib treatment. Using 
mesenchymal stem cells and an independent set of colorectal carcinoma cell 
Figure 5.3 Decrease in cell vi-
ability by dasatinib seems to be 
unrelated to inhibition of phos-
phorylated Src and to caspase 3 
mediated apoptosis in chondro-
sarcoma. (A) while levels of total 
Src do not decrease upon dasatinib 
treatment in GIST882, a decrease 
in phosphorylated Src (pSrc) (Y419) 
is shown upon dasatinib treatment. 
At a dosis of 6.25 nM dasatinib the 
upper band of the pSrc staining has 
disappeared (arrow). Staining for 
pro-caspase 3 shows a gradual de-
crease in GIST882 upon dasatinib 
treatment. (B) in L869, the dasatinib 
sensitive cell culture, levels of pSrc 
decrease gradually, although both 
bands of the staining are present. A 
decrease of pro-caspase 3 could not 
be demonstrated in L869.
(C) also in CH2879, the non-respon-
sive cell culture, the level of phos-
phorylation of Src decreases upon 
dasatinib treatment. Again, no de-




lines we also demonstrated tumour specificity and tumour type specificity, 
respectively. 
Analysing kinome profiles of 13 chondrosarcoma cell cultures identified 
several drugable targets. Validation of the results by immunoblot as well 
as the inhibition of chondrosarcoma cell viability in vitro by dasatinib 
demonstrate that this is an elegant approach to identify targets for treatment 
of tumours for which so far no systemic treatment options are available.
Analysing the top 100 activated substrates of the 13 chondrosarcoma 
cell cultures revealed 21 active kinases, of which AKT and GSK3B were 
shown to be the most active. The phosphorylation of AKT was confirmed 
by immunoblot. This pathway can be blocked by Enzastaurin, a PKCB-
selective inhibitor, that has been shown to suppress angiogenesis and 
induces apoptosis in colorectal cancer and glioblastoma xenografts, by 
targeting AKT and GSK3B24. In contrast to AKT, GSK3 is constitutively 
active and becomes functionally inactivated after phosphorylation. GSK3 
has a central function in physiological (i.e. transcription, apoptosis and cell 
cycle progression) and pathological (i.e. diabetes mellitus, Alzheimer and 
carcinogenesis) processes (reviewed in25). In chondrosarcoma cell cultures 
we demonstrated the absence of phosphorylation at serine 9, indicative for 
active GSK3B. An important role for the AKT kinase in chondrosarcoma 
survival was previously suggested by Jang et al.13. 
Kinome profiling of chondrosarcoma also revealed an active Src pathway. Src 
plays a role in the regulation of embryonic development and cell growth26. 
Mutations in Src are involved in the malignant progression of colorectal 
cancer27. We identified activity of Fyn and Lck in chondrosarcoma, which 
are, together with Yes, Fgr, Hck, Blk, Lyn and Frk, members of the Src 
family. The Src pathway can be targeted by dasatinib. Dasatinib is well-
known for its efficacy in the treatment of chronic myelogenous leukemia and 
Philadelphia chromosome–positive ALL28,  in which dasatinib inhibits the 
Abl-kinases29. Recently, dasatinib has also been shown to be effective in the 
treatment of cells derived from solid tumours, i.e. prostate cancer30 and head 
and neck squamous cell carcinoma31. In previous research, also expression 
of Abl kinase was shown in chondrosarcoma by immunohistochemistry 
with interestingly, a negative correlation with histological grade32. We show 
decreased cell viability after dasatinib treatment in the majority (7/9) of 
chondrosarcoma cell cultures, although a maximum of 60% of inhibition of 
cell growth was reached, while the effect in GIST882 and the leukemia cell 
lines were more profound. This difference may be explained by secondary 
events which stimulate cell growth in chondrosarcoma, ie. the loss of 
cell cycle inhibition, which was previously shown to occur in 96% of the 
tumours10. Likewise, GISTs have been shown to become refractory to initial 
successful response to imatinib due to loss of cell cycle control33.
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Strikingly, dose dependent inhibition of Src kinase phosphorylation by 
dasatinib, as measured by autophosphorylation at Y419, was found both 
in a responsive (L869) and in a non-responsive (CH2879) cell culture. This 
suggests that growth inhibition induced by dasatinib might be independent 
of Src kinase phosphorylation. Thus, dasatinib might exert its function 
via other pathways in chondrosarcoma, ie. by inhibition of Abl kinases, 
fibroblast growth factor receptor kinases or PDGF receptor kinases34 or 
AKT35. Activity of the latter two is demonstrated in the present study. 
While dasatinib was suggested to induce caspase-3 mediated apoptosis in 
the control GIST882 cell line, this was not observed in chondrosarcoma cell 
cultures. This suggests that dasatinib inhibits chondrosarcoma cell growth 
through other mechanisms, for example by inducing G1 arrest. However, 
immunoblotting for pSrc and caspase-3 was performed on one responsive 
and one non-responsive cell line only and extrapolating these results to all 
chondrosarcomas should be done with caution. 
More experiments are needed to further explore the mechanism underlying 
growth inhibition and whether the effects of dasatinib on chondrosarcoma 
growth can be increased by combination with another cytostatic compound 
to reach higher growth inhibition rates.  
Despite the finding of PDGFRB activity using the Pepchip® and the fact that 
PDGFRA protein expression 36 and activity of the alpha and beta receptor were 
reported previously in the absence of gain-of-function mutations14, we were 
not able to decrease cell viability of chondrosarcoma cell cultures by imatinib 
treatment. In contrast Klenke et al. showed SU6668, which inhibits tyrosine 
kinases PDGFRB, Flk-1/KDR and FGFR1, to repress chondrosarcoma 
growth via antiangiogenesis in vivo15. One must take into account that we 
studied the effect of dasatinib and imatinib in chondrosarcoma in vitro, and 
that an additional effect in vivo through the inhibition of angiogenesis may 
be possible, as has been described for dasatinib37.
Also Flavopiridol and AZD-1152, inhibitors of CDC2 and Aurora kinase 
activity respectively, were suggested for chondrosarcoma treatment, by our 
Pepchip® approach (Table 5.2). Flavopiridol is a pan cyclin-dependent kinase 
inhibitor, not only targeting CDC2, also known as cyclin dependent kinase 
1, but also cyclin dependent kinase 2 and 4. Previously we reported the 
amplification of 12q139, the locus of CDK4, increased expression of CDK4 
and a decrease in cell viability using shRNA to knock down CDK4 expression 
in vitro10. We suggested the use of CDK4 inhibitors in the treatment of 
chondrosarcoma, which is now being emphasised accordingly in the present 
study. Also RPS6kinase was found to be active in chondrosarcoma, which 
was found to predict the response to mTOR inhibitors in sarcoma38. RPS6 
kinase is responsible for the phosphorylation of ribosomal protein S6, 
which we previously found to be deleted and downregulated in a subset of 
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chondrosarcomas9. This suggests that the tumour cells may try to overcome 
this deletion by phosphorylation. No array CGH data were available for the 
cell cultures described here.
In the present study we report the kinome profiling of 13 chondrosarcoma 
cell cultures and by averaging the profiles we identified activity of the Src 
pathway. Accordingly, Src inhibitor dasatinib decreased cell viability in 
seven out of nine chondrosarcoma cell cultures. Our experiments suggest 
that dasatinib is a potential treatment option in chondrosarcoma treatment. 
Future studies in vivo should be performed to confirm these data and to 
investigate the combination with conventional chemotherapy and possible 
additional effects through the inhibition of angiogenesis.  
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Supplementary table 5.1 Top 100 phosphorylated substrates and their corresponding 












1043.42 RKKKVSSTKRH Cytohesin-1 S394 PKC 1.83 0.001
746.95 RKGYRSQRGHS Vitronectin S381 PKC 1.00 0.056
709.03 RARSTSLNERP Tuberin S939 AKT1 1.64 0.008
559.42 SPPRSSLRRSS Transcription elongation factor A-like1 S37 PKC; GSK3 0.18 0.684
515.29 LRRSLSRSMSQ Telethonin S157 Titin 0.77 0.082
510.00 MQPDNSSDSDY CD5 T434 PKA -0.35 0.671
476.27 GGRGGSRARNL Heterogeneous nuclear ribonucleoprotein K S302 PKCdelta 1.03 0.028
455.97 LKPGSSHRKTK Bruton’s tyrosine kinase S180 PKCbeta 1.55 0.001
444.65 RRRMASMQRTG E1A binding protein p300 S1834 AKT; p70S6 kinase; pp90Rsk 0.53 0.195
440.26 HLRSESQRQRR Guanine nucleotide binding protein, alpha Z polypeptide S27 PKC 0.88 0.199
424.12 RPRNYSVGSRP 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 S483 AKT 1.32 0.003
419.61 KKKIATRKPRF Metabotropic glutamate receptor 1 T695 PKC 1.75 0.001
391.21 DNSSDSDYDLH CD5 T453 Lck; Fyn -2.09 0.001
377.39 LRQLRSPRRAQ Ras associated protein Rab4 S204 CDC2 0.63 0.091
376.28 SSQRVSSYRRT Desmin S12 Aurora kinase B 0.56 0.255
369.05 ARIGGSRRERS EP4 receptor S354 PKC 0.29 0.543
367.99 EPKRRSARLSA HMG14 S7
RPS6 kinase 
alpha 3; PKA; 
PKC
-0.01 0.996
349.08 SRKGYSRKGFD Peptidylglycine alpha amidating monooxygenase S930 PKC 0.21 0.678
347.92 RRRLSSLRAST Ribosomal protein S6 S236 PAK2 0.02 0.985
346.84 RSNPPSRKGSG Connexin 32 S233 PKC; PKA 0.54 0.190
346.69 AAKRASRIYNT Regulator of G protein signalling 10 S176 PKA 0.50 0.170
338.52 LRRRLSDSSFI Synapsin II S10 PKA 0.33 0.543
337.91 RGRGSSVGGGS ASK1 S83 AKT1 1.00 0.085
326.09 RTRRISQTSQV Ryanodine receptor 2 S2808 PKA 2.40 0.000
324.60 RKRKPSTSDDS DNA topoisomerase II aplha S1469 CK2 1.92 0.001
319.79 RPRRRSSAVSL Cyclic GMP inhibed phosphodiesterase B S295 AKT1 1.79 0.001






307.96 APKAPSKKEKK DAB2 S24 PKC 1.40 0.003






303.16 IKRQLSMTLRG PCTAIRE protein kinase 1 S12 PKA 2.26 0.000
300.32 STPAPSRTASF ATP citrate lyase S450 GSK3 0.55 0.228
298.00 RERKSSAPSHS GAB2 S159 AKT1 1.55 0.009
293.33 NRSFLSLKHTP Notch2 nd 3.03 0.000
290.18 RKRRWSAPESR Ataxin 1 S776 ATK1 2.46 0.000
288.71 SDSRKSMRQST TCFL1 S132 PKC -0.08 0.888
280.59 LRRRLSDSNFM Synapsin I S9 CaMKI; PKA -0.15 0.737
278.56 LARRPSYRKIL Activating transcription factor 1 S63 CaMKI; PKA; S6K 1.73 0.009
277.57 TRVPPSRRGPD Alpha 2A adrenergic receptor S232 PKC 1.89 0.000
277.25 APERASSVYTR CCR5 S336 GRK 0.33 0.614
106
276.73 KQQPGSPRRIS Retinoblastoma like 1 S975 nd 1.20 0.060
276.59 TKALQSPKRPR TFII-I S668 EphB2 1.72 0.003
276.04 AVRLRSSVPGV Vimentin S72 Rho kinase 1.17 0.029
272.05 PTPPLSPSRRS c-Myc T58 CK2; GSK -0.01 0.996
270.99 VSRSTSFRGGM Keratin 18 S52
CAMK; RPS6 
kinase alpha 3; 
PKCepsilon
-0.21 0.678
269.23 KPKDASQRRRS c-Src S12 PKC -0.80 0.082
267.23 GLRRSSKFALK Beta-2-adrenergic receptor S262 PKC 1.39 0.007
266.07 SKRRNSEFEIF Tryptophan hydroxylase S58 PRKA1 1.77 0.000




regulatory type I 
alpha)
1.13 0.008
264.80 LTRIPSAKKYK PEA15 S104 PKC 0.75 0.062
264.72 GEKRASSPFRR Nucleolar phosphoprotein p130 S623 PKA 0.33 0.367
263.62 LSRRPSYRKIL cAMP response element-binding protein 1 S133
PKA; MAPK; 
CaMK; RSK2 -0.22 0.617
257.08 GPRRRSRKPEA Centromeric protein a S7 Aurora kinase B 1.27 0.009
251.37 RRRAASMDSSS AFX 1 S196 AKT1 1.57 0.002
250.33 MRRQRSAPDLK Kinesin family member 1C S1092 CK2 0.76 0.126
249.76 KIRRLSAAKQQ LKB1 S424 p90RSK; MSK1; S6K1; PKA; LKB1 0.69 0.083
246.15 RRKAATMRERR Myogenic differentiation antigen 1 T115 PKC 0.59 0.216
244.00 PSRSYSERDFE Solute carrier family anion exchange, member 3 S67 PKCepsilon -0.82 0.209
243.41 SVRMLSGSKEK Opioid receptor mu S268 CAMKII 1.57 0.008
241.37 GQLRGSATRAL Casein kinase 1, epsilon S323 CK1epsilon 1.58 0.008
237.13 RQRSTSTPNVH RAF1 S259 PKA; AKT1 -0.35 0.553
235.65 VAARATLRRSN Calcium sensing receptor T888 PKC 3.77 0.000
235.20 YRERMSSNRPN Meprin,beta subunit S687 PKC 1.97 0.003
235.05 KKGARSRRLFS Guanine nucleotide binding protein, alpha 15 subunit S336 PKCalpha 2.42 0.000
234.35 LLSELSRRRIR eIF2 alpha S52 1.64 0.001
229.53 GKNRPSSGSLI Quinoid dihydropteridine reductase S223 CAMKII 1.72 0.001
227.56 VSEDNSEDEIS Acetyl-CoA carboxylase alpha S29;S66 CK2 0.38 0.671
227.44 LARRPTKGIHE Guanine nucleotide binding protein, alpha13 T203 PKA 1.22 0.059
226.89 RDRSSSAPNVH B-Raf S364 AKT; SGK 1.58 0.001
226.56 TWRRGSTAGGA Calpain, large polypeptide L1 T80 nd 0.68 0.122
225.54 RKGHEYTNIKY SHP2 Y542 PDGFRbeta 1.51 0.020
224.28 ASVPPSPSLSR Glycogen synthase 1 S645 GSK3beta 1.18 0.008
223.11 LSGRGSNYGSL NPRA S538 nd 0.13 0.847
220.60 IVPGKSPTRKK RAP1 GTPase activating protein 1 S484 CDC2 0.97 0.092
220.52 RKRKNSRVTFS NIPP1 S199 PKA 1.62 0.001
220.49 RAREGSFESRY Phospholipase C, gamma1 S1248 PKCmu -0.46 0.446










212.91 VPSYDSFDSED C ets 1 protein S285 CaMK2 -1.33 0.029
212.35 LLREASARDRQ Vanilloid receptor 1 S801 PKCepsilon 1.42 0.003
212.11 ALVRGTPVRGA Sam68 T317 CDC2 1.96 0.000
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210.65 RLRPRTRKVKS Neutrophil cytosolic factor 4 40kDa T154 PKC 0.03 0.984
207.46 KFRTPSFLKKN Adducin 3 S693 PKCalpha -0.51 0.185
207.21 VLAQPSTSRKR CHK2 S19 PKA; PKG -0.47 0.281
206.28 LLRSGSSPNLN E1A binding protein p300 S89 PKCdelta 1.11 0.009
204.18 APDEGSDLFYD Cell division cycle 34 S203 CK2 -2.00 0.001
203.93 IAVRKSRDKAK CCAAT/Enhancer binding protein, beta T235 ERK2 1.59 0.001
202.48 GARRSSWRVIS 14-3-3-Eta S59;S60 SDK1 -0.55 0.296
201.66 RPDPSSFSRPR Opioid receptor S344 PKC 0.02 0.985
200.16 EAKRKSPKKKE Coilin S184 CDK2-cyclin E -0.09 0.911
199.29 RDRHLSFSGSG CD44 S291 PKC 1.00 0.059
199.21 PSSRASSRASS Connexin 43 S367 nd 1.81 0.001
197.56 QLRRPSDRELS NFKB3 S263 PKA 0.33 0.451
196.98 NSRRPSRAMWL Vitronectin S397 PKA 0.97 0.013
196.61 KKKKPSRLKGD APC S2054 PKA -0.57 0.138
196.07 VHRDLSRDRPL Kell blood group protein S63 PKC 2.02 0.000
193.15 ALRRESQGSLN Regulator of G protein signalling 14 S260 PKA 2.14 0.001
192.06 HSLPLSPASTR NFKB1 S907 GSK3beta 0.59 0.216
191.92 GFTRKSVRKAQ Protein phosphatase 2, regulatory subunit B56, alpha S28 PKR -0.49 0.302
187.50 GLYSRSGSLSG PKN S374 PKN -0.03 0.984
186.47 LQRSSSFKDFA SH3 protein expressed in lyphocytes S27 nd 0.00 0.996
Supplementary table 5.2 Limma analysis of substrate phosphorylation of 13 




adj.P.Val Substrate Protein Corresponding kinase Psite
-3.20 2.11E-06 IDRTESLNRSI Lymphocyte specific protein MAPkinase S204
-3.42 2.82E-06 AGDLESPLSEE PPAR MAPK S21
3.77 3.03E-06 VAARATLRRSN Calcium sensing receptor PKC T888
-3.96 3.64E-06 FESIESYDSAD C ets 1 protein CaMK2 S257
-3.56 9.58E-06 SQRRESFLYRS “cAMP-specific 3’,5’-cyclic phosphodiesterase 4B” PKA S133
-2.48 2.87E-05 TLVIAYLMMRQ Dual specificity phosphatase 3 ZAP70_ Y138
-2.61 3.01E-05 SptCtrl Used for production/QC nd  
2.46 3.22E-05 RKRRWSAPESR Ataxin 1 ATK1 S776
2.93 3.46E-05 QKIHISKKWGF Ribosomal protein L10 RPL10 S168
2.31 3.46E-05 YKFPSSPLRIP Retinoblastoma 1 CDK4 S795
3.03 4.01E-05 NRSFLSLKHTP Notch2 nd  
2.12 5.65E-05 EVPRRSGLSAG Methyl CpG binding domain protein 3 Aurora_kinase_A S24
2.40 8.03E-05 RTRRISQTSQV Ryanodine receptor 2 PKA S2808
2.03 8.84E-05 PAARASKKILL Beta-adrenergic receptor kinase1 PKC S29
-2.28 9.04E-05 ETNNDYETADG CD32 Lyn;Blk;Fyn;SYK Y279
-2.37 9.95E-05 LEVSDSESDEA SPIB transcription factor CK2 S146
2.31 9.95E-05 RARLLSDAANV Crystallin beta A2 nd S31
-2.57 9.95E-05 IDAFSDYANFK
“Protein tyrosine 
phosphatase, receptor type, 
alpha”
nd Y798
-2.89 1.08E-04 NegCtrl Mixed peptides without STY nd  
2.35 1.08E-04 TKWYRSPRLLL MAPK4 MAPK4 S196
-2.27 1.14E-04 RSRSGSIVELI Huntingtin AKT S421
-1.91 2.00E-04 NADDSYEPPPV B-cell linker protein SLP-76 Y96
1.97 3.15E-04 SAIRQSPSPPP “cAMP-specific 3’,5’-cyclic phosphodiesterase 4A” nd S447
2.26 3.17E-04 IKRQLSMTLRG PCTAIRE protein kinase 1 PKA S12
2.34 3.66E-04 RTRTDSYSAGQ mTOR AKT S2448
-2.75 4.00E-04 SLYASSPGGVY Vimentin CDC2 S56
-2.77 4.04E-04 TTGGESADELE Occludin CK2beta S408
-2.31 4.27E-04 IESDIYAEIPD Focal adhesion kinase 2 FAK2 Y402
-2.22 4.27E-04 PDEILYVNMDE AXL receptor tyrosine kinase auto Y821
-2.00 4.30E-04 DDRHDSGLDSM I-Kappa-B-alpha nd S32
1.77 5.34E-04 SKRRNSEFEIF Tryptophan hydroxylase PRKA1 S58
2.42 5.50E-04 KKGARSRRLFS “Guanine nucleotide binding protein, alpha 15 subunit” PKCalpha S336
2.02 5.50E-04 VHRDLSRDRPL Kell blood group protein PKC S63
2.26 5.74E-04 GSRRSSAIGIE RAP1 GTPase activating protein 1 PKA S499
-2.01 5.91E-04 PGADLSQYKMD CtIP ATM S664
2.14 6.09E-04 IFRRPSLPAIS Cyclic GMP inhibited phosphodiesterase B PKA S318
-1.80 6.09E-04 SSLDVYDGRFL Acetylcholinesterase nd S164
1.96 6.09E-04 ALVRGTPVRGA Sam68 CDC2 T317
-2.42 6.09E-04 AEGSAYEEVPT “Phospholipase C, gamma1” FGFR1 Y472
1.57 6.19E-04 KKRKRSRWNQD Splicing factor 1 PKG-1 S20
-1.74 6.50E-04 DVLKFYDSNTV PAK2 Src Y130
1.85 6.50E-04 GERKKTLAGTP Polo like kinase nd T210
-1.85 6.58E-04 PTAAGTPNKET CALDESMON 1 CDC2_Kinase S759
1.86 6.58E-04 IKRLRSQVQVS Hepatocyte nuclear factor 4-alpha AMPK S304
-1.78 8.34E-04 VLDDEYVSSFG Protein tyrosine kinase TXK Fyn Y420
-2.14 8.34E-04 KDEGSYTLEEP Syndecan 3 Tyrosine_specfic_kinase Y361
-1.75 1.08E-03 EEPSIYESVRV DAPP1 Lck;PI3-kinase Y139
1.83 1.08E-03 KVEPASPPYYS “Peroxisome proliferator activated receptor, gamma” ERK2_JNK1 S112
1.64 1.18E-03 PELARYLNRNY Hrs EGFR Y329
1.78 1.33E-03 FSEITSPSKRS ORC1 CDK2 S273
-2.07 1.33E-03 SptCtrl Used for production/QC nd  
1.89 1.33E-03 TRVPPSRRGPD Alpha 2A adrenergic receptor PKC S232
-1.61 1.43E-03 KLFSSSVSEGF Kell blood group protein CK2 S383
-1.95 1.56E-03 NVVPLYDLLLE “Estrogen receptor, alpha” c-Src;Lck SY537
1.92 1.60E-03 RKRKPSTSDDS DNA topoisomerase II alpha CK2 S1469
2.02 1.61E-03 RPPTLSPIPHI Retinoblastoma 1 Cyclin_D1;Cdk4 S780
2.02 1.65E-03 GKRHRYRVLSS Antisense ERCC1 PKA Y80
1.43 1.65E-03 PosCtrl Mixed kinase substrate peptides nd  
-1.69 1.65E-03 DKQVEYLDLDL GAB1 Insulin_receptor;EGFR;HGFR Y627
-2.00 1.65E-03 APDEGSDLFYD Cell division cycle 34 CK2 S203
1.81 1.70E-03 PSSRASSRASS Connexin 43 nd S367
1.61 1.92E-03 RGKKKSGALVL RhoA PKA S188
1.75 1.94E-03 KKKIATRKPRF Metabotropic glutamate receptor 1 PKC T695
-1.42 1.94E-03 EPLPPSYVAAS Erythropoietin receptor JAK2 Y504
-1.92 1.94E-03 ILDREYYSVQQ Ron Ron Y1238
2.37 2.03E-03 SVSVETQGDDW Hematopoietic cell specific LYN substrate 1 CK2alpha_1 T16
1.87 2.03E-03 QLGPPSPVKMP Pituitary tumour-transforming protein 1 CDC2 S165
-1.51 2.03E-03 RIRTQSFSLQE Nitric oxide synthase 3 AKT1 S1176
1.62 2.03E-03 RKRKNSRVTFS NIPP1 PKA S199
1.78 2.03E-03 GGARASPATQP Sam68 ERK S58
1.41 2.06E-03 QSKRSTMVGTP PAK3 “Pyruvate_dehydrogenase_kinase,_isoenzyme_1” T423
-1.55 2.14E-03 FMAKVYSDPQP FGF receptor 1 FGFR1 Y280
1.79 2.25E-03 RPRRRSSAVSL Cyclic GMP inhibited phosphodiesterase B AKT1 S295
1.68 2.31E-03 PGLRRSPIKKV B-Myb CDK2 S577
-1.52 2.52E-03 VDPMLTPEERH Amyloid precursor like protein 2 CDC2-kinase T736
-1.73 2.52E-03 TDDEMTGYVAT MAPK14 MAP2K3 T180
-2.35 2.52E-03 NegCtrl Mixed peptides without STY nd  
-1.90 2.52E-03 ELDQGSLATSF IKK beta NIK;MAP3K7;MEKK1;_IKK_alpha S177
2.14 2.52E-03 ALRRESQGSLN Regulator of G protein signalling 14 PKA S260
1.88 2.52E-03 RRRFSSLHFMV Caspase 9 ERK1;ERK2;MEK1;MAP2K2 T125
1.56 2.52E-03 FSEHRTQVSLK Cell cycle checkpoint kinase II CHK2 T432
1.58 2.53E-03 RDRSSSAPNVH B-Raf AKT;SGK S364
-2.55 2.57E-03 NDDDVYRSLEE VAV2 EGFR Y142
-1.47 2.59E-03 ASGYISSLEYP “Complement component 1, subcomponent r” CK2 S206





1.42 2.66E-03 APLLSTPKRER Kinesin like 4 Cyclin_B2 T463
1.64 2.66E-03 LLSELSRRRIR eIF2 alpha PKR;GCN2;Eukaryotic_translation_initiation_factor_ S52
-1.84 2.87E-03 DESVDYVPMLD “PDGF receptor, beta” SHP2 Y751
1.59 2.93E-03 IAVRKSRDKAK “CCAAT/Enhancer binding protein, beta” ERK2 T235
-1.77 3.19E-03 AFEEGSQSTTI ATM Auto S1981
-2.01 3.25E-03 KEVSKYSDIQR “PDGF receptor, alpha” PDGFRalpha Y754
1.78 3.25E-03 YETFKSIMKKS NFKB3 PKCzeta S298
2.26 3.29E-03 VPKRKSLVGTP p21 activated protein kinase 6 Nd S560
1.49 3.29E-03 KNKPRSPVVEL Beta-adrenergic receptor kinase1 MAPkinase S670
1.57 3.29E-03 SHLRNSPEDKR
Eukaryotic translation 






-1.63 3.29E-03 VLDDQYVSSVG Bone marrow kinase BMX c-Src Y566
-1.92 3.36E-03 GQESEYGNITY SHP1 c-Abl;Lck Y536
1.55 3.39E-03 LKPGSSHRKTK Bruton’s tyrosine kinase PKCbeta S180
1.82 3.50E-03 MRRSVSEAALA Lipase hormone sensitive nd S554
1.83 3.50E-03 RKKKVSSTKRH Cytohesin-1 PKC S394
-1.78 3.52E-03 PGIDLSQVYEL ABL AKT S465 466
-1.60 3.52E-03 SptCtrl Used for production/QC nd  
1.54 3.52E-03 PosCtrl Mixed kinase substrate peptides nd  
-1.49 3.52E-03 ISEGTTLKDLI “TGF beta receptor, type I” “TGF_beta_receptor,_type_II” T176
1.26 3.77E-03 PosCtrl Mixed kinase substrate peptides nd  
1.97 3.85E-03 LTTGVYVKMPP CD152 “JAK2,_Protein_tyrosine_kinase_TXK” Y201
-2.09 3.92E-03 DNSSDSDYDLH CD5 Lck;Fyn T453
1.39 4.03E-03 AKIQASFRGHM Neurogranin PKCalpha S36
1.39 4.11E-03 GQVIMSIRTKL Ribosomal protein L10 Ribosomal_protein_L10 S137
-1.76 4.11E-03 PEPYASPPQPG Steroidogenic factor 1 ERK2 S203
-1.50 4.17E-03 RLLDSSQIVII E2F transcription factor 1 ATM;ATR S31
-1.85 4.17E-03 KEDPIYDEPEG Docking protein 1 Insulin_receptor Y362
-1.72 4.17E-03 FEGFSYVNPQF Protein kinase C alpha SYK Y658
1.45 4.17E-03 IRSSMSGLHLV Acetyl-CoA carboxylase alpha AMPK S80
1.72 4.19E-03 GKNRPSSGSLI Quinoid dihydropteridine reductase CAMKII S223
1.90 4.25E-03 RPRSATWPLPR FKHR AKT1 T24
-2.04 4.28E-03 FDDPSYVNVQN Shc TRK-T3;Insulin_receptor;MAP_kinase;Fyn;Lck Y427
-1.36 4.42E-03 KDDKLTPKIGF Ezrin CDK5 T234
1.47 4.42E-03 PGTRLSLARMP Glial fibrillary acidic protein CaMKII;PKC;Rho_kinase S38
-1.77 4.56E-03 TTVELYSLAER “Protein kinase C, theta” Lck Y90
1.51 4.59E-03 LDSAQSPGPSW CDX2 MAPkinase S60
-1.63 4.59E-03 FDAHIYEGRVI Protein kinase C delta PDGF;Lyn_kinase Y64






1.84 4.68E-03 FRRQLSEPANS ETS variant gene 1 Ribosomal_protein_S6_kinase_alpha_5; S191
-2.44 4.83E-03 IRESESTAGSF Lck PKC S158
1.62 5.02E-03 NSIAKTYVGTN MAP2K5 nd T315
-2.00 5.02E-03 IGADSSEEKFL Statherin nd S22
1.57 5.42E-03 RRRAASMDSSS AFX 1 AKT1 S196
1.42 5.50E-03 ALDFRTPRNAK Opioid receptor mu 1 Beta-adrenergic_receptor_kinase_2 T182







“Solute carrier family 
4, sodium bicarbonate 
cotransporter, member 4”
PKA S982
-1.44 5.70E-03 TAEAPSVLELG Crystallin beta A4 nd S35
1.30 5.86E-03 YQQRNSPGVPT Golgin 95 CDC2;PP2A S25
-1.25 6.09E-03 FKTEGPDSD p53 CK2alpha_1;p38_MAP_kinase;PKR;CDK2 S392
-1.41 6.16E-03 FMMTPYVVTRY JNK1 MAP2K4 Y223
1.40 6.16E-03 APKAPSKKEKK DAB2 PKC S24 
1.62 6.45E-03 SQKYMSFTDKS PAK1 PAK1 S144
-1.24 6.61E-03 NegCtrl Mixed peptides without STY nd  
1.52 6.76E-03 QVKALYDFLPR Protein tyrosine kinase TXK Protein_tyrosine_kinase_TXK Y91
-1.35 6.76E-03 FPDQAYANSQP SIT nd Y188






1.92 6.76E-03 MRKKISNAQLQ Cullin 5 PKA S730
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1.74 6.76E-03 KDFSSSKRMNT Syntaxin binding protein 1 PKC S313
1.36 6.76E-03 IHMVYSKRSGK Small nuclear ribonucleoprotein 70 kD nd S137
1.97 6.76E-03 YRERMSSNRPN “Meprin,beta subunit” PKC S687
-1.36 6.76E-03 IIGEKSFRRSV “Protein kinase C, mu” PKCmu S738
-2.36 7.28E-03 AEEEFSDSEEE Histone deacetylase 1 CK2 S421
1.42 7.42E-03 LLREASARDRQ Vanilloid receptor 1 PKCepsilon S801
1.34 7.50E-03 RTAPYTPNLPH SMAD4 ERK2 T277
1.41 7.64E-03 GTDLEYLKKVR O-linked N-acetylglucosamine transferase Tyrosine_kinase T989
-1.37 7.64E-03 HKGHLSEGLVT MAPK6 MAPK6 Y189
1.88 7.64E-03 SRKRLSQDAYR p47-phox PKCalpha;PKCbetaII;PKCdelta S320
1.53 7.64E-03 KSEPISPPRDR Myocyte specific enhancer factor 2A CDK5 S408
-1.47 7.93E-03 ENTLPTPMVLQ Mnk2 nd T379
1.38 8.24E-03 SVPTPSPLGPL “CK2, alpha 1” CK2alpha_1 Y182
1.31 8.24E-03 PTRKISASEFD Phosphodiesterase 5A cGMP_dependent_protein_kinase S102
1.25 8.43E-03 PQPPKSPGPHS RAD9 nd S336
-1.29 8.63E-03 VTKLLTDVQLM Heat-shock transcription factor 1 CK2 T142
1.72 8.80E-03 TKALQSPKRPR TFII-I EphB2 S668
-2.10 8.87E-03 PIGEDEESESD Vesicular monoamine transporter 2 CK1;CK2 S511
1.43 9.18E-03 TKRNSSPPPSP ATP2B1 PKA S1178
-1.33 9.43E-03 SptCtrl Used for production/QC nd  
-1.37 9.45E-03 TATEGQYQQQP Lyn Csk_homologous_kinase Y508
-1.09 9.65E-03 GSAAPYLKTKF STAT3 JAK1;c-Src Y705
Limma comparison of substrate phosphorylation of chondrosarcoma cultures with 
mesenchymal stem cell cultures was performed, quantifying (fold change) the differential 
expression (log scores). Note that positive log score means higher substrate phosphorylation 
in chondrosarcoma than in MSC. Psite: phosphorylation site on the spotted substrate. Nd. Not 
determined.
Supplementary table 5.3. Limma analysis of substrate phosphorylation of 13 





adj.P.Val Substrate Protein Corresponding kinase Psite
-2.91 5.04E-09 SQRRESFLYRS “cAMP-specific 3’,5’-cyclic phosphodiesterase 4B” PKA S133
-2.68 8.45E-09 IDAFSDYANFK “Protein tyrosine phosphatase, receptor type, alpha” nd Y798
-2.26 1.00E-08 MEDYDYVHLQG p130CAS FAK Y666
-3.12 2.81E-08 IESDIYAEIPD Focal adhesion kinase 2 FAK2 Y402
2.70 2.81E-08 LKPGSSHRKTK Bruton’s tyrosine kinase PKCbeta S180
-2.46 4.96E-08 SILPFTPPVVK SMAD2 ERK T8
-3.34 4.96E-08 LGQRIYQYIQS DYRK1B DYRK1B Y271
2.10 8.04E-08 SKRRNSEFEIF Tryptophan hydroxylase PRKA1 S58
-2.35 1.24E-07 EDENLYEGLNL CD79A nd Y188
1.95 1.97E-07 KKRKRSRWNQD Splicing factor 1 PKG-1 S20
-2.34 2.20E-07 LEVSDSESDEA SPIB transcription factor CK2 S146
2.17 9.93E-07 GSKNKSPSKAA High mobility group AT-hook 2 Cdc2_kinase S59
-1.98 1.24E-06 TAPEYYAPEVH Titin nd Y24917
1.79 1.24E-06 PSEVPTPKRPR High mobility group AT-hook 1 CDC2_kinase T52
2.99 1.24E-06 RKKKVSSTKRH Cytohesin-1 PKC S394
2.77 1.36E-06 RKRKPSTSDDS DNA topoisomerase II alpha CK2 S1469
2.51 1.38E-06 RERKSSAPSHS GAB2 AKT1 S159
1.69 1.56E-06 LTRIPSAKKYK PEA15 PKC S104
1.95 1.76E-06 NSIAKTYVGTN MAP2K5 nd T315
-2.27 1.76E-06 LALSLTADQMV “Estrogen receptor, alpha” MAPK14 T311
-2.39 1.87E-06 IKRQLSMTLRG PCTAIRE protein kinase 1 PKA S12
2.31 2.27E-06 EAKRKSPKKKE Coilin CDK2-cyclin_E S184
1.87 2.28E-06 APKAPSKKEKK DAB2 PKC S24 
-1.59 4.00E-06 SSRRQSVLVKS “Glutamate receptor, ionotropic kainate 2” PKA S715
-1.60 4.72E-06 ERGQEYLILEK Tec tyrosine kinase Tec_tyrosine_kinase Y206
1.95 4.74E-06 RSRSRSPRPRG ErbB3 Phospholipid_kinase_Phosphoinositide_kinase S1123
1.73 6.10E-06 NNTSSSPQPKK p53 CDK2 S315
-1.71 1.35E-05 RGQEVYVKKTM TEK receptor tyrosine kinase nd Y992
2.22 1.78E-05 ARIGGSRRERS EP4 receptor PKC S354
1.88 1.79E-05 SRKGYSRKGFD Peptidylglycine alpha amidating monooxygenase PKC S930
1.85 2.45E-05 QHRSSSSAPHH Calcium channel  voltage dependent  beta 2 subunit
DNA-dependent_protein_
kinase_catalytic_subunit S478
1.62 2.45E-05 KKPKKKSALLL Ras related protein 1A PKA S180
1.59 2.76E-05 YQRRASDDGKL RAF1 PKA S43
-1.80 2.92E-05 PVAPLSPARLQ ELK3 MAPK14;EphB2 S363
1.51 3.57E-05 RARLLSDAANV Crystallin beta A2 nd S31
-2.29 3.75E-05 PosCtrl Mixed kinase substrate peptides nd  
1.75 4.14E-05 KAARKSAPSTG “H3 histone, family 3A” nd S10
1.70 4.19E-05 KFSKFSLYKQL PLD1 PKCalpha S561
1.36 4.19E-05 RKKRISVKKKQ Cytohesin 2 PKC S392
-1.76 5.12E-05 QERRGSNVALM Protein tyrosine phosphatase nonreceptor 7 PKA S83
1.67 5.12E-05 ESRSGSNRRER Wiskott-Aldrich syndrome protein interacting protein PKCtheta S488
2.15 5.12E-05 LQRSSSFKDFA SH3 protein expressed in lymphocytes nd S27
1.67 5.12E-05 PSRKGSGFGHR Connexin 32 PKC S229
-1.40 5.75E-05 TAEPDYGALYE “Phospholipase C, gamma1” Lyn Y771
1.55 6.23E-05 RRRMASMQRTG E1A binding protein p300 AKT;p70S6_kinase;pp90Rsk S1834
1.84 6.59E-05 RRRLSSLRAST Ribosomal protein S6 PAK2 S236
-2.04 7.19E-05 VGKIFSNVRIN Caveolin 1 CK2 S88
1.75 9.28E-05 RKRHNSISEAK “Phospholipase C, beta 3” PKG S1105
1.56 1.01E-04 SYSHHSGLEYA Caveolin 2 c-Src Y19
-1.41 1.02E-04 FEGFSYVNPQF Protein kinase C alpha SYK Y658
1.70 1.04E-04 RGRLRSADSEN MEKK3 PKA S337
-2.04 1.24E-04 PSEEGYQDYEP Synuclein alpha SYK Y136
1.36 1.31E-04 GTDLEYLKKVR O-linked N-acetylglucosamine transferase Tyrosine_kinase T989
1.47 1.51E-04 AMRNFSRSDHL Early growth response  protein 1 CK2 S301
-1.54 1.90E-04 IDPFTYEDPNE EphB3 EphB3 Y614
1.68 2.01E-04 RLRTHSIESSG MAP2K4 AKT1 S80
-1.30 2.15E-04 ILDREYYSVQQ Ron Ron Y1238
-1.29 2.16E-04 ASGLSSQSDIL BRCA1 ATM S1387
1.25 2.30E-04 SRRPKSSLPPV Myosin light chain kinase PAK2 S1208
1.71 2.45E-04 PPRRSSIRNAH p47-phox PKCzeta;PKCalpha;PKCbetaII;PKCdelta S304
-1.36 2.58E-04 PLVQRGSANGL Beta-adrenergic receptor kinase1 PKA S685
-1.38 2.58E-04 NegCtrl Mixed peptides without STY nd  
1.20 2.69E-04 SptCtrl Used for production/QC nd  
1.18 3.65E-04 KGGKYSVKDKE L1 cell adhesion molecule p90rsk S1152
1.65 4.25E-04 RDRSSSAPNVH B-Raf AKT;SGK S364
1.30 4.66E-04 KRRQTSMTDFY Cyclin-dependent kinase inhibitor 1A AKT1 S146
1.45 4.66E-04 MAKRNTVIGTP Serine/Threonine protein kinase4
Serine/threonine_
protein_kinase_3 T180
1.37 4.71E-04 QQREKTRWLNS Adducin 1 Rho-kinase T445
-3.41 5.25E-04 MNEVTYSTLNF Carcinoembryonic antigen-related cell adhesion molecule 1 MAP3K10 S508
-1.19 6.51E-04 STEPQYQPGEN c-Src Csk;Fgr_PTPase Y530
1.33 6.51E-04 RDKYKTLRQIR Moesin Rho-Kinase T564
-1.26 6.51E-04 TSLAQYDSNSK Bone marrow kinase BMX BTK;ITK;Tec Y216
-1.35 6.51E-04 TEENIYQVPTS DAB1 c-Src Y220
1.36 6.51E-04 TDGNRSSHSRL BH3 interacting domain death agonist CK1;CK2 S65
-1.15 7.57E-04 LSNPAYRLLLA Discoidin domain receptor Discoidin_domain_receptor Y513
-1.37 7.57E-04 RTAASSLALVS Uridine nucleotide receptor nd S334
-1.43 7.58E-04 DDEDAYGNYDN 3-Phosphoinositide dependent protein kinase 1 c-Src Y373
1.22 8.18E-04 GERKKTLAGTP Polo like kinase nd T210
1.25 8.77E-04 VRRRQSVELHS Aquaporin 2 PKA S256
1.32 9.04E-04 GVERSSPSKAP BRCA1 CDK2 S1497
1.54 9.04E-04 NQNSSSDSEAE T-cell transcription factor 4 CK2 S60
1.39 9.04E-04 ALVRGTPVRGA Sam68 CDC2 T317
-1.18 9.04E-04 GFSRKSHTFLP CNPase PKC S9
1.25 9.04E-04 IVPGKSPTRKK RAP1 GTPase activating protein 1 CDC2 S484
-1.95 9.68E-04 NDDDVYRSLEE VAV2 EGFR Y142
0.92 9.92E-04 PNSSKTYGIKW “Calpain, large polypeptide L1” nd S360
1.84 1.05E-03 VLAQPSTSRKR CHK2 PKA;PKG S19 
1.17 1.28E-03 RRRAVSMDNSN Forkhead box protein O3A AKT1 S253
-1.34 1.29E-03 RESSVYDISEH NR2B CaMKII S383
1.11 1.46E-03 TTTAPSLSGKG Beta-catenin CK1 S45
-1.13 1.46E-03 SNDKVYENVTG FAK GRB2 Y925
-1.16 1.46E-03 IKDDEYNPAQG Fgr Fgr Y412
1.08 1.46E-03 SptCtrl Used for production/QC nd  
-1.25 1.46E-03 PGMKIYIDPFT EphB1 EphB1 Y594
-0.92 1.58E-03 NGRPDYIIVTQ Aryl hydrocarbon receptor auto Y378
2.99 1.59E-03 LARRPTKGIHE “Guanine nucleotide binding protein, alpha13” PKA T203
-0.97 1.59E-03 GPRLVSNHSLH Filamin A CAMKII S2523
2.28 1.61E-03 EDEESYDTESE I-Kappa-B-alpha CK2 S288
-1.11 1.84E-03 AEKPFYVNVEF BCR BCR Y177
1.50 1.84E-03 RKGYRSQRGHS Vitronectin PKC S381
-0.98 1.84E-03 FMMTPYVVTRY JNK1 MAP2K4 Y223
-0.94 1.84E-03 LSRRPSYRKIL cAMP response element-binding protein 1 PKA;MAPK;CaMK;RSK2 S133
-0.90 1.84E-03 NSRRPSRAMWL Vitronectin PKA S397
1.13 1.84E-03 TKALQSPKRPR TFII-I EphB2 S668
-1.04 2.02E-03 MPDNLYTFVLK LNK ZAP70 Y273
1.36 2.05E-03 KPKDASQRRRS c-Src PKC S12
-1.29 2.05E-03 AKKEESEESDD Ribosomal phosphoprotein large  P1 nd S101
1.14 2.13E-03 EKPRLSFADRA “Protein kinase C, theta” nd S676
-1.17 2.16E-03 LTIDRYLAIVH CCR2 JAK2 Y139
-1.31 2.31E-03 AGDLESPLSEE PPAR MAPK S21
-1.00 2.43E-03 QQLQLSPLKGL Ribonucleotide reductase M2 subunit CDC2 S20





-0.85 2.63E-03 ESRASTFAGTP Protein kinase C delta Lck T507
-1.33 2.65E-03 RKGHEYTNIKY SHP2 PDGFRbeta Y542
-1.01 2.82E-03 SASPYTPEHAA p73 Cyclin_A;Cyclin_B;CDC2;CDK2;Cyclin_E T86
-0.97 2.86E-03 AEPHTYEEPGR EphA8 EphA8 Y616
0.79 2.93E-03 LHRDKTPLHQK B-Myb CDK2 T494
1.40 3.02E-03 GSRRGSFDATG Desmoplakin PKA S2849
-1.08 3.20E-03 GTLRTSISVER Bradykinin receptor 2 PKC S373
-1.21 3.49E-03 EDSTYYKASKG FAK c-Src Y577
1.04 3.49E-03 DDRHDSGLDSM I-Kappa-B-alpha nd S32
-1.19 3.63E-03 FFPFHSPSRLF “Crystallin, alpha B” nd S19
-1.15 3.66E-03 VYESPYSDPEE ZAP70 ZAP70 Y319
-0.87 3.66E-03 TDEDIYLLGKA Sialyltransferase 1 nd Y391
0.93 3.66E-03 PELARYLNRNY Hrs EGFR Y329
1.07 3.66E-03 KSEPISPPRDR Myocyte specific enhancer factor 2A CDK5 S408
-1.20 3.66E-03 GWMVHYTSKDT “Protein kinase C, mu” c-Src;ABL Y432
-0.84 3.71E-03 LARRPSYRKIL Activating transcription factor 1 CaMKI;PKA;S6K S63
1.30 3.76E-03 GPRRRSRKPEA Centromeric protein a Aurora_kinase_B S7
-1.03 3.76E-03 KVVALYDYMPM Bruton’s tyrosine kinase BTK;ABL Y223
-1.24 3.80E-03 LGSQSYEDMRG CD19 Lyn_kinase;Bruton’s_tyrosine_kinase Y531
-1.15 3.96E-03 EGKHLYTLDGG RACK1 Src Y228





-1.03 4.39E-03 LEDNDYGRAVD AKT1 c-Src Y326
-0.94 4.39E-03 DVHMVSDSDGD FAS associated factor 1 CK2beta S289
-0.79 4.69E-03 HVEDLYVEGLP TFII-I Bruton’s_tyrosine_kinase Y398
-0.92 4.80E-03 GLQMGSNRGAS Transgelin PKC S181
-0.76 4.80E-03 YTRVQSMALPP Forkhead box protein L2 PAK1 S263
1.00 4.80E-03 EEGEMYEDDEE “Tubulin, beta-4” MAPkinase Y437
1.44 5.01E-03 IRESESTAGSF Lck PKC S158
-0.94 5.18E-03 DVLKFYDSNTV PAK2 Src Y130
-1.26 5.20E-03 EELAEYAEIRV SIGLEC4A Fyn Y620
0.83 5.42E-03 SptCtrl Used for production/QC na  
-1.66 5.47E-03 TTEAIYEEIDA TOM1 like 1 Fyn Y460
1.11 5.53E-03 PDVPRTPVGKF CDC25C Polo_like_kinase S198
-1.34 5.60E-03 KTRDQYLMWLT “Phosphatidylinositol 3 kinase, regulatory subunit, alpha” Insulin_receptor Y580
-1.67 5.70E-03 MGQAGSTISNS Connexin 43 CK1delta S325
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-0.86 5.80E-03 EADGVYAASGG FES tyrosine kinase FES_tyrosine_kinase Y713
-1.13 5.82E-03 KTKFASDDEHD Autoantigen La nd S366
-0.97 5.82E-03 SANAIYSLAAR CBL EGFR Y774





-1.10 6.09E-03 QESEDYSQPST Oncoprotein Mdm2 c-abl_kinase Y394
1.05 6.33E-03 RDRHLSFSGSG CD44 PKC S291
0.82 6.99E-03 ALTEDSTQTSD Formyl peptide receptor 1 Beta-adrenergic_receptor_kinase1 S328
0.94 7.18E-03 TQRQNSAQLGM CDC 25A Cell_cycle_checkpoint_kinase S123
1.18 7.34E-03 KERRRTESINS HAND1 PKA;PKCalpha T107
1.36 7.40E-03 DFEGFSYVNPQ Protein kinase C alpha PKCalpha S657
0.88 7.44E-03 GFFSSSESGAP Clathrin light polypeptide B CK2 S11 
-1.08 7.55E-03 GFTEESGDDEY TCFL1 CK2 S41
1.04 7.55E-03 SQKYMSFTDKS PAK1 PAK1 S144
-1.00 7.55E-03 GDDEASATVSK Rhodopsin RK S334
-0.93 7.55E-03 GSDSDSEVDKK PC4 CK2alpha_1 S19
1.02 7.77E-03 HYLDETEQWEK Complement component 3 CK T1031
-1.07 7.81E-03 VSSAASVYAGA Keratin 18 p34cdc2 S33
0.95 7.99E-03 LRRSLSRSMSQ Telethonin Titin S157
1.00 8.29E-03 SptCtrl Used for production/QC na  
1.27 8.34E-03 DAPPLSPFPHI Retinoblastoma like 1 CDK4 S964
0.77 8.37E-03 IIGEKSFRRSV “Protein kinase C, mu” PKCmu S738





0.84 8.43E-03 KKKKPSRLKGD APC PKA S2054
0.93 8.43E-03 GFTRKSVRKAQ “Protein phosphatase 2, regulatory subunit B56, alpha” PKR S28
-1.02 8.61E-03 QQQEVYGMMPR Spectrin Csk Y1176
1.05 9.02E-03 FMRRTSLGTEQ EP4 receptor PKA S222
-1.42 9.89E-03 EGDEIYEDLMR VAV1 Lck Y174
0.78 9.95E-03 KIRRLSAAKQQ LKB1 p90RSK S424
Limma comparison of substrate phosphorylation of chondrosarcoma cultures with colorectal 
carcinoma cell lines was performed, quantifying (fold change) the differential expression (log 
scores). Note that positive log score means higher substrate phosphorylation in chondrosarcoma 
than in colorectal carcinoma. Psite: phosphorylation site on the spotted substrate. Nd. Not 
determined.
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Supplementary table 5.4. Top 25 activated kinases in untreated GIST882
 Average intensity Substrate Corresponding kinase
1 2313.85 IKRQLSMTLRG PKA
2 1126.63 RKGHEYTNIKY PDGFRbeta
3 893.56 GLRRSSKFALK PKC
4 756.77 LSRRPSYRKIL PKA;MAPK;CaMK;RSK2
5 698.83 RTRRISQTSQV PKA
6 640.91 NRSFLSLKHTP Nd
7 608.82 RRRFSSLHFMV ERK1;ERK2;MEK1;MAP2K2
8 581.82 LARRPSYRKIL CaMKI;PKA;S6K
9 541.54 KKWKQSVRLIS Death associated protein kinase 1
10 520.65 IHMVYSKRSGK Nd
11 499.88 GFSRKSHTFLP PKC
12 485.98 LGQRIYQYIQS DYRK1B
13 473.90 SSRRQSVLVKS PKA
14 455.12 MRKKISNAQLQ PKA
15 437.41 RKRRWSAPESR ATK1
16 430.21 RKAKRSLAPRF PKR
17 420.23 LNRIQTQIRVV PKC
18 409.27 GARRSSWRVIS SDK1
19 403.69 RPPTLSPIPHI Cyclin D1;Cdk4
20 394.64 KKGARSRRLFS PKCalpha
21 386.26 YKFPSSPLRIP CDK4
22 379.85 TKWYRSPRLLL MAPK4
23 372.94 RKRKNSRVTFS PKA
24 369.24 GGRGGSRARNL PKCdelta
25 365.05 LSGRGSNYGSL Nd
Nd: Not determined
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Chondrosarcomas are resistant to conventional chemo- and radiotherapy. 
A subset of chondrosarcomas arises secondarily in the benign tumour 
syndromes Enchondromatosis (EC) and Multiple Osteochondromas (MO) 
and prevention of tumour development would greatly improve prognosis. 
We therefore investigated the effect of selective COX-2 inhibition on 
chondrosarcoma growth. 
COX-2 expression was studied in central- and peripheral cartilaginous 
tumours. The effect of COX-2 inhibition was assessed in four chondrosarcoma 
cell lines using celecoxib and NS-398 treatment. COX-2 activity (prostaglandin 
E2 (PGE2) ELISA) and cell viability were measured. The (prophylactic) effect 
of celecoxib on chondrosarcoma growth in vivo was studied during 8 weeks 
using a xenograft model of cell line CH2879 in immunoincompetent nude 
mice. 
High COX-2 protein expression was mainly found in solitary peripheral 
chondrosarcoma and in enchondromatosis-related central chondrosarcoma, 
which was confirmed by qPCR. After 72 hours of celecoxib treatment, a 
significant decrease in cell viability was observed in three chondrosarcoma 
cell lines. In vivo, celecoxib initially slowed tumour growth in chondrosarcoma 
xenografts, however after prolonged treatment relapsed tumour growth was 
observed. Tumour volume was negatively associated with celecoxib serum 
levels, and seemed smaller in the high-dose prophylactic treatment group.
We confirmed expression of COX-2 in 65% of chondrosarcomas, and COX-
2 inhibition by celecoxib diminished cell viability in vitro. However, the in 
vivo data suggest no role for celecoxib in the treatment of adult high grade 
chondrosarcoma. The role of high-dose prophylactic celecoxib in preventing 
development of benign and malignant cartilage tumours in EC and MO 




Chondrosarcoma of bone is a malignant cartilage-forming tumour, which 
is highly insensitive to classical chemotherapeutics and radiation therapy. 
Chondrosarcomas are histologically divided into three grades, which is 
currently the only objective predictor of metastasis. Grade I tumours rarely 
metastasize with a 10 year survival rate of 83%, while 10 year survival for 
grade III tumours decreases to 29% due to metastatic disease1. Marginal 
or intralaesional excision of tumours can result in local recurrence with 
increased histological grade2. Currently, surgical removal of the tumour is 
the only option for curative treatment. There is no treatment with curative 
intent for patients with metastatic disease or inoperable tumours.
The majority (80-85%) of conventional chondrosarcomas arise in the medullar 
cavity of bone and are designated as primary central chondrosarcomas3. 
For less than 1% of central chondrosarcomas, there is clinical evidence 
of a pre-existing (benign) enchondroma3,4. Enchondromas occur mostly 
as solitary leasions, although they may occur as multiple leasions in the 
context of enchondromatosis (Ollier disease), which is a rare non-hereditary 
syndrome5. The risk of malignant progression is increased up to 30-35% in 
enchondromatosis patients6 as compared to solitary enchondroma (<1%). 
At the surface of bone, peripheral chondrosarcomas arise secondary to 
a pre-existing osteochondroma. Multiple osteochondromas (MO) is an 
autosomal dominant hereditary disorder which occurs in children and 
young adolescents. Malignant progression of hereditary osteochondroma is 
slightly more frequent than in solitary leasions (1-5% vs. 1%). Preventing 
new tumour formation and malignant progression in enchondromatosis and 
multiple osteochondroma patients would greatly benefit their prognosis.  
In colorectal cancer, a protective effect of prostaglandin synthesis inhibitors 
(also known as non-steroidal anti-inflammatory drugs (NSAIDs)) has been 
suggested against development and growth of the tumours. Celecoxib 
and rofecoxib, both selective COX-2 inhibitors, were shown to reduce the 
number and size of colorectal polyps in the adjuvant treatment of Familial 
Adenomatous Polyposis (FAP) patients7, 8. Also aspirin was found to have a 
chemopreventive effect on adenoma recurrence in patients in which a non-
FAP related adenoma had been removed9. NSAIDs block attachment sites 
for arachidonic acid on the COX enzyme, thereby inhibiting prostaglandin 
production10. Whereas COX-1 is constitutively expressed under physiologic 
conditions, COX-2 is induced by cytokines and free radicals, making it a 
suitable target for (anti-cancer) therapy. 
Endo et al. reported high COX-2 expression in a substantial amount of 
chondrosarcomas (16/72) by immunohistochemistry, which was associated 
with high histological grade and poor prognosis11. However, Sutton found 
no correlation of COX-2 protein expression and histological grade in 24 
chondrosarcomas (6/9 grade I tumours; 4/6 grade II and 1/6 grade III), 
whereas 8 enchondromas were negative12. 
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We investigated whether COX-2 inhibition 
could play a role in either the treatment of high 
grade chondrosarcomas or the prevention of 
malignant progression of tumours associated 
with Enchondromatosis or Multiple 
Osteochondromas. Therefore we determined 
COX-2 mRNA and protein expression in 
patient material. We investigated the effects 
of COX-2 inhibition on COX-2 protein 
expression, PGE2 levels, and cell viability 
in 4 high grade chondrosarcoma cell lines 
in vitro. In addition, a chondrosarcoma 
xenograft model of immunoincompetent 
nude mice was used to study the effects of 
COX-2 inhibition in vivo.
Material and methods 
COX-2 expression in patient material of 
cartilaginous tumours
Conventional central and peripheral 
cartilaginous tumours were selected 
based on accepted clinicopathological 
and radiological criteria3. Juxtacortical-, 
mesenchymal-, dedifferentiated-, and clear-
cell chondrosarcomas were excluded. In 
total, formalin-fixed paraffin-embedded 
specimens from 66 patients (Table 6.1) and 
fresh-frozen material of 34 patients was 
studied. Histological grading was performed 
according to Evans1. All specimens were 
handled according to the ethical guidelines 
described in “Code for Proper Secondary 
Use of Human Tissue in The Netherlands” 
of the Dutch Federation of Medical Scientific 
Societies.
COX-2 immunohistochemistry (Table 
6.2) of tumour tissue was independently 
semi-quantitatively scored for cytoplasmic 
staining, as described previously13, without 
knowledge of the clinicopathological data. 
Scores were given for intensity (1 = weak, 2 
= moderate, 3 = strong) and percentage of 
positive cells (1 = 0-24%, 2 = 25-49%, 3 = 50-


















































































































































































































































































with single positive cells being 
regarded as positive a cut-
off level of total sum ≥3 was 
applied.
RNA was isolated from fresh 
frozen tumour tissue of 34 
central tumours as described 
previously14. Growth plate 
samples (n=4) were used as 
normal counterpart controls. 
Messenger RNA expression 
of COX-2 was studied using 




GGTGGAACA), as previously 
described15. For normalisation 
GENORM was used16.
Inhibition of COX-2 in 
chondrosarcoma in vitro 
Chondrosarcoma cell lines 
derived from chondrosarcoma 
grade II (SW1353, American 
Type Culture Collection 
(ATCC), Manassas, VA), 
grade III (CH287917 and 
OUMS2718) and a recurrent 
chondrosarcoma grade II in 
enchondromatosis (C384219) 
were cultured in RPMI 1640 
supplemented with 10% 
heat-inactivated foetal calf 
serum (Gibco, Invitrogen 
Life-Technologies, Scotland, 
UK). Cell line HT29 (ATCC), 
expressing high COX-2 levels, 
was used as a control. Cells 
were grown at 37ºC in a 
humidified incubator with 
95% air and 5% CO2. The 
cartilaginous phenotype of 
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was confirmed by RT-PCR, showing mRNA expression of collagens I, 2B, 3, 
and 10; Aggrecan; and SOX920. Protein extraction and immunoblotting were 
performed as described previously21. A WST-1 colorimetric assay (Roche 
Diagnostics GmbH, Penzberg, Germany) was used as described previously21 
to measure metabolic activity representing the amount of viable cells in 
response to celecoxib (Pfizer, NY, USA) and NS-398 (Cayman chemicals, 
Ann Arbor, MI, USA). 5.0*103 chondrosarcoma cells (CH2879, OUMS27 and 
C3842) and 1,5*103 HT29 and SW1353 cells were seeded. Celecoxib and 
NS-398 were diluted in DMSO. After 24 hours, increasing concentrations 
of the drugs were added (5, 10 and 25 μM) or 0,1% DMSO. C3842 was not 
included in the NS-398 assay.
For measuring PGE2 levels, cells of OUMS27, CH2879, C3842, and HT29 
were seeded in a 24 wells plate at a density of 5.5*104, and SW1353 at a 
density of 2.0*104. Twenty-four hours after seeding, cells were treated with 
celecoxib in increasing dosages (5, 10 and 25 μM) or with 0.1% DMSO. After 
72 hours, PGE2 concentration in the medium was determined by a PGE2-
specific enzyme-linked immunoassay (Cayman chemicals, Ann Arbor, MI, 
USA) according to the manufacturer’s protocol. mRNA was extracted and 
CYP19A1 mRNA levels were determined to assess aromatase activity20. Five 
percent serum supplementation was used for all experiments.
In vivo chondrosarcoma model 
Sixty Swiss male nude mice (Crl:NU(Ico)-Foxn1nu (IFFA-CREDO, Lyon, 
France)) were randomly assigned to one of five groups (Figure 6.1). Low 
doses contained 500ppm celecoxib, high doses 1000ppm. The selective 
COX-2 inhibitor celecoxib (CS-58635) was incorporated into a modified 
nude mouse diet (Altromin Gesellschaft fur Tierernahrung mbH, Lage, 
Germany) and irradiated to accomplish sterility. Mice were able to feed and 
drink ad libitum. Amount of food consumed was monitored individually. 
Prophylaxis was started 7 days prior to inoculation, as steady-state levels 
of celecoxib are reached in five days in humans (Pfizer). At week 1 all mice 
were injected with 2*106 CH2879 cells, subcutaneously on the back. Since 
chondrosarcomas have a relatively slow growth rate, we waited 21 days 
for the tumours to reach a size large enough for external analysis, before 
treatment with celecoxib was started. Treatment was prolonged for 30 
days, after which the mice were sacrificed. The mice were weighted once 
a week. Calipers were used to measure the tumour volume in vivo using 
the following formula: (length*whith2)/2. Blood samples, obtained by aortal 
punction at time of sacrifice, were allowed to coagulate and were centrifuged 
for 10 minutes at 13000 rpm; supernatants were collected and stored at 
-20°C until HPLC analysis. HPLC was performed by Case Bel (Borgerhout, 
Belgium) as described previously22.
The excised tumours were fixed in 0,1% formalin for 24 hours and embedded 
in paraffin. To study possible toxicity of celecoxib, tissue of the heart, lungs, 
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liver, and kidney were taken at autopsy for histological analysis. Xenografted 
tumours were analysed by H&E, Toluidine blue and immuhistochemistry 
for COX-2, Ki-67, cleaved caspase-3 and CD31 (Table 6.2). COX-2 staining 
was scored as negative, very weak or positive. Ki-67 and cleaved caspase-3 
staining were digitally scored using confocal microscopy (Nuance 2.6.0 
Cambridge research and Instrumentation Inc. Woburn, MA, USA). A 
minimum of 2000 cells were counted and the percentage of positive cells 
was automatically calculated (ImageJ 1.37V, Wayne Rasband, National 
Institutes of Health, USA)), to assess microvessel density, CD31-positive 
vessels were counted in 10 high-power fields per tumour. An independent 
experiment was performed using grade II chondrosarcoma xenograft model, 
with high celecoxib prophylaxis (n=12) and treatment (n=12) group. 
Statistics
Comparison between groups was performed using Pearson Chi-Square 
(immunohistochemistry) and Students’s t-test (RT-PCR). P values <0.05 
were considered significant.
Results
Higher COX-2 expression in chondrosarcoma and in enchondromatosis.
In total, in 65% of the chondrosarcomas tumour cells demonstrated 
cytoplasmic COX-2 protein expression (Figure 6.2A). Malignant tumours 
were more often positive for COX-2 than benign tumours (58% vs. 20%, 
p=0.040 for central and 68% vs. 18%, p=0.002 for peripheral, Pearson Chi-
Square). In the group of central chondrosarcomas positivity was mainly 
seen in enchondromatosis-related chondrosarcomas (6/6), whereas 
peripheral solitary tumours were more often positive (12/13) than MO 
related chondrosarcomas (3/9). Results are summarised in table 6.1. 
Also at mRNA level enchondromatosis-related tumours tend to show higher 
COX-2 expression, as compared to solitary tumours (p=0.056 Student’s 
t-test) (Figure 6.2B). However, no difference in COX-2 mRNA expression 
between benign (n=7) and malignant tumours (n=27) was found (Student’s 
t-test p=0.58) (not shown).
Figure 6.1 Sixty immunoincom-
petent nude mice were randomly 
assigned to either prophylactic low 
dose celecoxib (PLX_low), prophylac-
tic high dose celecoxib (PLX_high), 
treatment low dose celecoxib (TRM_
low), treatment high dose celecoxib 
(PLX_high) or control group (Con-
trol).
COX-2 inhibition in chondrosarcoma
124
COX-2 inhibitors decrease proliferation of chondrosarcomas in vitro 
All four chondrosarcoma cell lines demonstrated COX-2 protein expression 
in variable levels (Figure 6.3A). After 72 hours of 25 μM celecoxib treatment, 
a decrease in cell viability was observed, comparable to HT29, in the three 
cell lines that were derived from solitary tumours (Figure 6.3B). For OUMS27 
a decrease in cell viability was observed already at 10 μM celecoxib. C3842 
did not respond to celecoxib (Figure 6.3B), not even when treatment was 
prolonged for 48 hours (data not shown). Effects of NS-398 were more subtle 
(Figure 6.3C).
Response to celecoxib is independent of COX-2 activity 
By PGE2 ELISA we showed that in CH2879, OUMS27 and C3842 the COX 
enzymes are active and that a dose of 5,0 μM celecoxib was enough to 
significantly decrease PGE2 levels (Figure 6.3D). Remarkably, we were not 
able to detect COX activity in HT29 and SW1353, which both responded 
well to celecoxib treatment. Relative CYP19A1 mRNA levels were decreased 
twofold upon celecoxib treatment in SW1353, whereas in CH2879 and 
C3842 CYP19A1 levels were increased twofold (data not shown). 
Figure 6.2 (A) Cytoplasmic COX-2 ex-
pression in central chondrosarcoma 
grade I. (B) COX-2 mRNA was higher ex-
pressed in central cartilaginous tumours 
compared to growth plate (GP) samples 
and tumours related to enchondroma-
tosis (EC) showed higher expression of 
COX-2 than solitary tumours.
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Celecoxib initially slows tumour growth in chondrosarcoma xenografts 
During the in vivo study, all mice had comparable body weights and amounts 
of food administered (6.4A). Six mice died during the experiments, both in 
the celecoxib and the control groups. Serum levels of celecoxib corresponded 
to the dose of celecoxib administered, although levels were variable (Figure 
6.4B). Tumour size was negatively correlated to celecoxib serum levels 
(r=-0.39) (Figure 6.4C). At 4 weeks, the tumour volume seemed smaller in 
the groups receiving celecoxib prophylaxis, which was significant for the 
high dose -, as compared to the control group (Student’s t-test p=0.053 
(low dose) and p=0.028 (high dose) respectively) (Figure 6.4D). Histological 
evaluation of the heart, lungs, liver, spleen, and kidneys of the mice did not 
reveal any signs of toxicity.
Relapse of tumour growth in xenografts after prolonged treatment 
At week 6 a relapse was observed, most clearly in the low celecoxib 
prophylaxis-, and treatment groups. At the end of the experiment (week 
8), only the high prophylaxis group showed smaller tumour volumes than 
the control group (Figure 6.4E). However due to large variation in tumour 
volume within the groups, statistical calculations are not meaningful. The 
growth curves of the tumours showed that at week 6 the tumours started 
to grow even faster than the control group (Figure 6.4F). This was exactly 
the time point at which the growth curves of the mice flattened (Figure 
Figure 6.3 (A) COX-2 protein expression in cell lines (B) decreased viability (SW1353, OUMS27 
and CH2879) upon 25 μM celecoxib treatment. (C) NS-398 has a moderate effect (d) COX-2 ac-
tivity is absent in SW1353 and decreased upon 5 μM celecoxib treatment in OUMS27, CH2879 
and C3842.
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6.4A), suggesting the end of puberty. The independent experiments, in 
which high celecoxib doses were used, showed similar results for the grade 
II chondrosarcoma xenograft model (data not shown).
Evaluation of tumour tissue 
Tumours were highly cellular with limited cytonuclear atypia and a limited 
amount of extracellular matrix (Figure 6.5A). Toluidine-blue staining 
confirmed the deposition of proteoglycans (Figure 6.5B). Whereas in all 
celecoxib-treated groups COX-2 staining was absent or very weak (Figure 
6.5C), strong COX-2 expression was observed in 50% of the control tumours 
Figure 6.4 (A) Mice body weight increases till week 6 (B) Celecoxib blood levels correspond 
to celecoxib dose (C) tumour volume is negatively correlated with celecoxib serum levels 
(r=-0.39). (D) Lower tumour volume in prophylaxis group at week 4, (E) tumours exposed to 
low dose celecoxib are larger than controls at week 8, although variation within the groups 
is considerable. (F) Overall growth curve of the tumours showing relapse at week 6 for those 
exposed to low dose celecoxib. (*: significantly different from controls).
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(Figure 6.5D). Proliferation was seen in all groups (Figure 6.5E), with higher 
Ki-67 expression in the treated tumours at week 8 (Student’s t-test low dose 
p=0.040 and high dose p=0.018) (Asterisks, figure 6.5F). Cleaved caspase-3 
expression was low (mean 0.746%, range 0.2-1.7%), as was microvessel 
density (mean 18.9 per 10 hpf, range 4.0-40.0 per hpf) and no differences 
between groups were found (Figures 6.5G-H). 
Discussion
Since there is nothing to offer with curative intent to patients with 
metastatic or inoperable chondrosarcoma, there is a desperate need for new 
therapeutic options. Furthermore, the prevention of development of new 
tumours and especially of malignant transformation of benign precursor 
leasions in patients with enchondromatosis and multiple osteochondromas 
would greatly improve the prognosis of these children and young adults. In 
this study, we investigated the potential of selective COX-2 inhibition for the 
treatment of chondrosarcoma.
We demonstrated expression of COX-2 in a subset of enchondromas 
(20%), osteochondromas (18%), and central- (58%) and peripheral (68%) 
chondrosarcomas, confirming published results11,12. Interestingly, COX-
2 protein and mRNA expression was mainly found in enchondromatosis- 
related tumours, whereas correlation with histological grade could not be 
confirmed. 
Chondrosarcoma cell viability decreased after administration of high (super-
physiologic) levels of celecoxib and NS-398, while a physiologic dosage of 
celecoxib was able to abolish most COX-2 activity in three cell lines. Despite 
the lack of COX-2 activity in SW1353, a decrease in cell viability was found 
in response to celecoxib, which suggests a COX-2 independent mechanism, 
which was previously suggested for colorectal cancer (reviewed by Grosch et 
al.23). In breast cancer COX-2 inhibitors were found to suppress aromatase 
activity in both a PGE2 dependent and independent manner
24, and Cleton-
Jansen et al. showed that chondrosarcoma growth could be inhibited by 
aromatase inhibitors in vitro20. The decrease in CYP19A1 activity in SW1353 
during celecoxib treatment suggests that this growth inhibitory effect is 
exerted via the inhibition of aromatase. 
Since three of four chondrosarcoma cell lines responded to celecoxib in vitro, 
we also tested celecoxib in chondrosarcoma xenografts. Celecoxib treatment 
was initially effective in slowing the growth rate of chondrosarcoma. Moreover, 
tumour size was inversely correlated with celecoxib serum levels, measured 
at the end of the experiment. However, a relapse was observed in week 6, 
which was especially prominent in the mice receiving low dose celecoxib. 
In addition, the treated tumours showed an increased proliferation rate. 
Interestingly, at week 6 the growth curve of the mice flattened, suggesting 
the end of puberty, which suggests hormonal influences on tumour growth. 
Here, this effect cannot be attributed to estrogens, since CH2879 is estrogen 




One of the mechanisms of tumour inhibition of celecoxib is thought to be the 
inhibition of angiogenesis. The relapse at week 6 might reflect a time point 
where celecoxib can no longer inhibit angiogenesis allowing vessel ingrowth. 
At sacrifice no differences in microvessel density were found, suggesting 
that either differences in microvessel density are completely overcome or 
a different mechanism was responsible for the initial decreased tumour 
growth. Unfortunately, we were not able to study tumour characteristics or 
blood parameters during the experiment.
In analogy to the prevention of new adenoma formation in familial 
adenomatous polyposis, prevention of development and malignant 
transformation of enchondromas and osteochondromas in patients with 
enchondromatosis and multiple osteochondromas might be beneficial. 
Although we showed COX-2 expression to be higher in enchondromatosis 
related tumours compared to solitary tumours, the enchondromatosis 
derived cell line C3842 did not respond to celecoxib treatment in vitro. In 
vivo, a growth-inhibiting effect was shown in the first 4 weeks of the study, in 
the prepubertal mice, which was abolished at the moment the mice reached 
adulthood. This might suggest that celecoxib is more effective in prepubertal 
patients. Moreover, there was a trend for high-dose prophylactic celecoxib 
treatment to have smaller tumours at the end of the study. However, the 
high dose prophylaxis group showed a higher proliferation rate as compared 
to the control. Thus, our results are not conclusive on whether the paediatric 
population of multiple osteochondromas and enchondromatosis patients 
might benefit from celecoxib treatment and further studies should be 
performed. In addition, it should be noted that our model is suboptimal to 
study the effect of celecoxib on prevention of malignant transformation, since 
we used high grade chondrosarcoma xenografts. Unfortunately, there is no 
suitable in vivo model for enchondromatosis or multiple osteochondromas, 
and xenografts from low-grade chondrosarcomas are difficult to obtain.
During long-term clinical trials, COX-2 inhibitors were shown to have 
cardiovascular side effects. Celecoxib trials were discontinuated earlier25 and 
rofecoxib was withdrawn by the FDA26. However, children and adolescents 
are at low risk of cardiovascular disease, which renders the use of celecoxib 
relatively safe. Accordingly, celecoxib is prescribed to juvenile rheumatoid 
arthritis patients from the age of 2 years (reviewed in Frampton et al.27). 
Next to its potential anti-tumour effect, celecoxibs analgetic effect will be 
beneficial for multiple osteochondromas and enchondromatosis patients.
left page Figure 6.5 (A) H&E staining of the CH2879 xenograft. (B) Toluidine blue staining 
confirmed proteoglycan content. (C) Absent or very weak COX-2 staining in treated tumours 
(D) strong COX-2 staining in 50% of the controls.(E,F) Higher proliferation rate (Ki-67) in the 
celecoxib treated tumours . (G) Caspase 3-mediated apoptosis is limited. (H) Microvessels 
detected by CD31.
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In conclusion, we confirmed expression of COX-2 in 65% of chondrosarcomas, 
and COX-2 inhibition diminished cell viability in vitro, although this 
was independent of COX-2 activity. However, using a grade II and III 
chondrosarcoma xenograft model, we observed a switch from tumour 
inhibitory to tumour promoting effects when mice reached adulthood, 
suggesting that even though tumour volume was negatively associated with 
celecoxib serum levels, there is no role for celecoxib in the treatment of adult 
high-grade chondrosarcoma. The role of high-dose prophylactic celecoxib 
in preventing development of benign and malignant cartilage tumours in 
prepubertal EC and MO patients deserves further investigation. 
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7.1 Histological distinction between benign and low-grade malignant 
cartilaginous tumours
In the clinical management of asymptomatic enchondroma a wait-and-
see approach is justified, whereas grade I chondrosarcomas are treated by 
curettage followed by the application of a local adjuvant such as cryosurgery, 
or phenolisation1-3. The difficult histological distinction between benign- and 
malignant central cartilaginous tumours of bone was assessed in chapter 2 
of this thesis. A panel of 18 specialised bone tumour pathologists affiliated 
to Eurobonet, an European Commission granted network of excellence to 
study the biology and pathology of bone tumours, was asked to evaluate a set 
of 16 cases. A low-weighted kappa value (κ=0.78) confirmed the variability 
between the observers, which was most striking in the distinction between 
enchondroma and low-grade central chondrosarcoma (κ=0.54). A similar 
study was conducted in the United States of America, showing similar 
results with regard to interobserver variability4.   
In chapter 2 a second separate set of 20 enchondromas and 37 
chondrosarcomas of which full clinical, radiological and pathologic 
data were available, were analysed for individual morphologic criteria. 
Diagnostic power of these criteria was evaluated using 10 years follow-
up data, including radiological assessment as golden standard. The two 
most significant findings to discriminate grade I chondrosarcoma from 
enchondroma were entrapment of host lamellar bone and mucoid/myxoid 
matrix degeneration. The application of a combination of 5 parameters 
allowed optimal differentiation between enchondromas and grade I central 
chondrosarcomas: the finding of host bone entrapment, high cellularity, 
open nuclear chromatin, mucoid/myxoid matrix degeneration and patient 
age of above 45 years. In addition, clinical symptoms were shown to be 
helpful in the differentiation between benign and malignant cartilaginous 
tumours, since spontaneous pain was reported in 35% of the patients with 
an enchondroma and in 62% of patients with a grade I chondrosarcoma. 
Incisional surgical and the closed trocar (Jamshidi) biopsy are the most 
frequently used techniques for obtaining a representative tissue sample for 
histologic evaluation5. Evaluation of some of the above mentioned histological 
parameters, especially entrapment of host lamellar bone, may however 
be difficult on small needle biopsies. Based on the findings presented in 
chapter 2, it is advisable to evaluate at least the mucoid/myxoid matrix 
degeneration and, if possible, entrapment of host lamellar bone when 
grading cartilaginous tumours in daily practice. These two findings were the 
most discriminating and are considered more objective than high cellularity 
or open chromatin.
In conclusion, objective markers that discriminate on a molecular level are 
still needed to guide clinical decision making. In chapter 3 it was shown 
that the expression of WNT strongly differed between enchondromas 
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and grade I chondrosarcomas. While only 17% of enchondromas showed 
nuclear accumulation of β-catenin, this was present in 48% of grade I 
chondrosarcomas. Although this certainly is an interesting finding from a 
biological point of view, the differences are not large enough to promote 
the use of β-catenin immunohistochemistry as a diagnostic marker to 
distinguish enchondroma and grade I chondrosarcoma. Until molecular 
markers are found that discriminate between benign and malignant 
cartilaginous tumours, clinical decision making will be based on histological 
assessment by the pathologist using mucoid/myxoid matrix degeneration 
and entrapment of host lamellar bone as important criteria and is facilitated 
by a multidisciplinary approach, including also radiologists and surgeons. 
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7.2 Prognostic markers superior to subjective histological grading
In the majority of bone tumour referral centres, grade I chondrosarcomas 
are treated by intraleasional surgery followed by some kind of local adjuvant 
treatment. Grade II chondrosarcomas however, are surgically resected with 
a wide margin, by en-bloc resection, or sometimes even amputation. In this 
respect the differentiation between grade I and grade II is even more important 
than the differentiation between benign and grade I chondrosarcoma, which 
was discussed in the previous paragraph.
In chapter 2 it was shown that not only the distinction between benign and 
low-grade malignant cartilaginous tumours is difficult. Also at the other 
end of the spectrum, the bone tumour specialised pathologists differed 
considerably in grading the malignant tumours. A weighted kappa value 
of κ=0.80 was found for the variance amongst the observers in discerning 
grade I from grade II chondrosarcomas, which is slightly better than the 
κ-value calculated for the discrimination between enchondroma and grade 
I chondrosarcoma. Statistically, κ=1 indicates complete agreement between 
all observers, while κ=0 indicates there is no agreement among the raters 
(other than what would be expected by chance). In clinical practice staging 
of a cartilaginous tumour by a pathologist guides the operative modality 
used. Under-grading followed by a less aggressive treatment might lead to 
a higher percentage of recurrences and worse prognoses for the patients 
and is therefore not acceptable. On the contrary, over-grading followed by a 
therapy that is too aggressive, might lead to unnecessary morbidity. Again, 
this stresses the urgent need for molecular markers that are able to predict 
outcome of cartilaginous tumours.
A search for biomarkers alternative to histological grading is described in 
chapter 3, in which growth signalling was studied in a large series of central 
chondrosarcomas. In order to find new prognostic markers, biomarkers 
should be correlated to long term follow up. The expression of TGFB was 
found to be gradually upregulated with grade, as was previously described 
for peripheral chondrosarcomas6 (Figure 7.1). Unfortunately, a correlation 
with outcome was not found in this study. From a biological point of view 
the increased expression of TGFB is interesting. TGFB is important in 
many signalling pathways promoting cell proliferation, cell survival, tissue 
vascularisation and extracellular matrix remodelling7. Acquisition of a 
malignant phenotype due to increase in TGFB expression was also suggested 
in peripheral chondrosarcomas6 (Figure 7.1).
In chapter 4 cyclin dependent kinase 4 (CDK4) and MDM2 were found 
to be positively correlated with histological grade, although correlation 
with clinical outcome was not found in this study, despite the availability 
of long term follow up data. Both CDK4 and MDM2 are located at 12q13, 
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a genetic locus that is often found to be amplified in high grade central 
chondrosarcomas8-10. Like was discussed for TGFB, the expression of both 
CDK4 and MDM2 could also be described as a crescending spectrum 
depending on histological grade. 
In the considerable number of reports in literature in which prognostic 
markers for chondrosarcoma are investigated, conclusions are drawn from 
comparing data from chondrosarcoma groups that were separated based 
on parameters that are shown to be highly observer dependent (chapter 
2). In order to find new prognostic markers, it is recommended to only use 
tumours of which a long follow up including distant staging is available in 
order to find prognostic markers that are independent from and superior 
to histological grading. For example outcome measurements as metastasis 
free survival or disease free survival after wide margin surgery could be used 
as such objective markers. 
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7.3 New therapeutic strategies in chondrosarcoma treatment
In chapter 3 it was hypothesised that pathways in the human growth plate 
that are responsible for normal growth regulation of bone are involved in 
the development of enchondromas and central chondrosarcomas. Central 
cartilaginous tumours were shown to have normal EXT1 and EXT2 
expression, which is in contrast to peripheral tumours with low EXT1 and 
EXT2 expression due to genetic loss in sporadic tumours11 or inactivating 
mutations in hereditary tumours12-14. In central cartilaginous tumours, active 
Indian hedgehog signalling was found. Indian hedgehog is important for the 
regulation of normal longitudinal bone growth. Cyclopamine, a hedgehog 
pathway inhibitor, was hypothesised to inhibit central chondrosarcoma cell 
growth. Cyclopamine is currently used in the treatment of children with 
medulloblastoma15. A pre-clinical evaluation of the use of cyclopamine 
in central chondrosarcoma treatment was performed in vitro in six 
chondrosarcoma cell cultures in chapter 3. Despite the finding of hedgehog 
activity in chondrosarcomas in vivo and in vitro, cyclopamine had a growth 
inhibitory effect in only one of six chondrosarcoma cell cultures in vitro. In this 
cell culture the transcription of GLI1 decreased upon cyclopamine treatment, 
while the other cell cultures did not respond with respect to GLI1 expression 
levels. Unexpectedly, growth was even stimulated by cyclopamine in one of 
the cultures, although GLI1 levels were not increased. Therefore selecting 
the eligible subjects for cyclopamine treatment will be difficult. In addition, 
a drawback of the clinical use of cyclopamine is the inhibition of Sonic 
hedgehog, which is important for brain development16. Also the interference 
of cyclopamine with the signalling in the human growth plate could lead 
to growth retardation in paediatric patients. The use of cyclopamine could 
be more save in adult patients. However in medulloblastoma, which is the 
most common malignant brain tumour in children carrying an activating 
PTCH mutation, the use of cyclopamine is being investigated, although not 
clinically implemented due to these side effects17. 
Ninety-six % of high-grade central chondrosarcomas were shown to carry 
one or more alterations in the expression of proteins important for cell 
cycle regulation, especially in the pRB pathway, studied in chapter 4. The 
importance of loss of p16 for chondrosarcoma cell proliferation was shown 
by overexpressing p16 by lentiviral transduction in vitro, which caused 
inhibition of cell growth in three chondrosarcoma cell lines. By using shRNA 
against CDK4, also CDK4 expression was shown to be important for cell 
growth. Although these cell cycle proteins are expressed in every cell in 
the human body, there are certain treatment strategies directed against 
these proteins. Flavoperidol is the most well known, shown to induce G1 
arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in 
human breast carcinoma cells18. However, in a phase II consortium study 
conducted in 2000 in metastatic renal cancer no significant effect was 
Discussion and future prospectives
140
observed and major side effects such as asthenia and severe diarrhoea were 
reported in the majority of patients19. In addition, Flavoperidol is described 
as a sensitising agent to doxorubicin in small cell lung cancer cells that were 
pRb-negative, both in vitro and in vivo20. 
Another indirect strategy is suggested, by using Heat Shock Protein (HSP) 
inhibitors that inhibit the stabilisation of CDK4 by HSP9021. In addition, 
the kinomics study presented in chapter 5 also revealed flavoperidol as a 
potential target for therapeutic treatment of chondrosarcoma. Unfortunately, 
Flavoperidol was not available to conduct an in vitro study on the effect 
on chondrosarcoma growth. In the future, the use of Flavoperidol or HSP 
inhibitors in chondrosarcoma treatment should be studied more in detail in 
a preclinical setting in vitro and in vivo using animal models. 
In addition to the hypothesis driven approaches concerning EXT and cell 
signalling pathways, new treatment options for chondrosarcoma were studied 
using kinome profiling. Kinases play a major role in signalling cascades that 
determine cell cycle entry, cell survival and differentiation fate, which are 
often deregulated in tumours. Kinases are excellent targets for anti-cancer 
therapy since they work as a molecular switch; their regulation is reversible, 
rapid and does not require new protein synthesis22. Antineoplastic activity 
of imatinib mesylate, which inhibits KIT, PDGFR, and BCR-ABL kinases, 
was shown to be successful in the treatment of gastrointestinal stromal 
tumours (GISTs)23 and chronic myeloid leukemia24. GISTs harbour an 
activating mutation of the KIT receptor kinase or PDGFRα receptor kinase, 
and are refractory to conventional chemotherapy. 
In chapter 5, 13 chondrosarcoma cell cultures (both cell lines as well as 
short term cultures of clinical samples) were assessed for the activity of 
kinases. The common denominators in this respect between these 13 cell 
cultures were activity of the AKT1/GSK3β pathway, PDGFRβ and the Src 
pathway. 
AKT and GSK3 have a central function in physiological processes as 
transcription, apoptosis and cell cycle progression, and also in pathological 
processes as diabetes mellitus, Alzheimer and carcinogenesis25. AKT was 
previously shown to be important in chondrosarcoma survival26. 
PDGFRA protein expression27 and activity of the alpha and beta receptor 
were reported previously in the absence of gain-of-function mutations28, 
and its expression was shown to be correlated with adverse prognosis in 
chondrosarcoma27.
Like AKT, Src is a major regulator of cellular processes, as well. For instance, 
Src plays a role in the regulation of embryonic development and cell growth29. 




The AKT1/GSK3β pathway can be inhibited by Enzastaurin hydrochloride, 
also known as LY317615. Enzastaurin is an acyclic bisindolylmaleimide 
that was initially developed as an adenosine triphosphate-competitive, 
selective inhibitor of PKCß31. Enzastaurin was shown to suppress signalling 
through the AKT pathway, induce apoptosis, and suppress growth of 
human colorectal cancer and glioblastoma xenografts32. In a phase II trial, 
Enzastaurin was well-tolerated and associated with prolonged progression 
free survival in patients with relapsed or refractory diffuse large B-cell 
lymphoma, the most common type of non-Hodgkin’s lymphoma33. Therefore, 
the effect of Enzastaurin on chondrosarcoma cell growth in vitro is currently 
under investigation at our department. 
Chapter 5 was focussed on the inhibition of the Src pathway by dasatinib, 
which indeed resulted in decreased cell viability in seven out of nine 
chondrosarcoma cell cultures in vitro. Interestingly, these inhibiting effects 
were not moderated by the Src pathway alone, since decrease of active Src 
was found both in the non-responsive and in the responsive cell cultures. 
This suggests that other pathways might be targeted by dasatinib, such as 
AKT34, in chondrosarcomas.
More experiments are needed to further explore the mechanism of growth 
inhibition by dasatinib. Since an intermediate response of 50% of cell growth 
inhibition was found in four of the seven responding chondrosarcoma 
cultures, the effect of dasatinib might be increased by combination with 
another cytostatic compound and higher growth inhibition rates might be 
established. A combinatory therapy with a mTOR inhibitor is a good candidate 
for this, since also RPS6kinase was found to be active in chondrosarcoma. 
RPS6kinase was found to predict the response to mTOR inhibitors in 
sarcoma35. RPS6 kinase is responsible for the phosphorylation of ribosomal 
protein S6, which we previously found to be deleted and downregulated in a 
subset of chondrosarcomas9. 
The in vitro results described in chapter 5 should be further studied in 
a preclinical model in vivo. The presence of blood vessels or cartilaginous 
matrix might have extra effects on growth inhibition on chondrosarcoma 
cells by dasatinib. Also, in vitro data are not always reproducible in vivo, 
as was shown for celecoxib in chapter 6. Currently, a phase II clinical 
trial using dasatinib in advanced sarcomas opened for amongst others 
chondrosarcomas for which patients will be recruited until 2013 (www.
clinicaltrials.gov Identifier NCT00464620). 
Although PDFGRβ was shown to be active as a kinase in chondrosarcoma 
cell cultures by kinome analysis, and despite the finding of receptor activity 
correlated with adverse outcome27, the inhibition of PDGFRβ by imatinib 
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mesylate did not provoke any effect on the cell growth of chondrosarcoma 
cell cultures. Imatinib resistance has been shown to occur in GIST 
due to loss of cell cycle control as well36. Although in GISTs these are 
secondary events, loss of cell cycle control, which was shown to occur in 
96% of chondrosarcomas (chapter 4), might cause imatinib resistance in 
chondrosracoma cells. Alternative to secondary events, it was shown that 
after switching off mutated receptors in GIST by imatinib, heterologous wild-
type receptors maintain signalling activation37. Such a mechanism could be 
present in chondrosarcomas, explaining their resistance. Also, it would be 
interesting to investigate whether this pathway can be attacked at another 
level, for example by the use of monoclonal antibodies against the PDGF 
receptor.
Another kinase that was shown to be particularly active in chondrosarcomas 
is Aurorakinase B. Aurorakinase B functions in the attachment of the mitotic 
spindle to the centromere. While Aurorakinase A localises to centrosomes, 
aurorakinase B localises to microtubules near kinetochores, specifically 
to the specialised microtubules called K-fibers38. Overexpression of these 
Figure 7.1 Implications for potential therapeutic strategies in peripheral chondrosar-
coma. A multistep model of the progression of osteochondroma towards secondary peripheral 
chondrosarcoma as introduced in chapter 1 is shown. Expression of COX-2 and celecoxib as 
a new potential target for therapeutic strategy in peripheral chondrosarcomas is described in 
chapter 6 of this thesis. Celecoxib was not tested in vitro (question mark). 
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kinases causes unequal distribution of genetic information, leading to 
aneuploidy characteristic of high-grade central chondrosarcomas (figure 
7.2). Inhibition of Aurorakinase B by the pyrazoloquinazolines class of drug 
AZD-1152 is a recent topic of preclinical cancer studies. In 2007, AZD-
1152 was shown to induce growth arrest, apoptosis, and sensitisation for 
vincristine and daunorubicin in acute leukemia cells, both in vitro and in 
vivo39. Also the growth of human colorectal and lung tumour xenografts 
in immunodeficient mice was inhibited by AZD-115240. In addition to 
sensitising tumour cells to chemotherapeutical agents, AZD1152 can also 
sensitise to ionising radiation. Interestingly, it was shown that p53-deficiency 
Figure 7.2 Implications for potential therapeutic strategies in central chondrosarcoma
A multistep model of the progression of central chondrosarcoma as introduced in chapter 1 
is shown. Markers and their corresponding treatment options as investigated in this thesis 
are shown. In vitro inhibitory effects of IHH inhibitor cyclopamine, selective COX-2 inhibitor 
Celecoxib and Src inhibitor Dasatinib in chondrosarcoma were described in chapter 3, chap-
ter 6 and chapter 5, respectively. Imatinib mesylate was shown not to be a potential drug in 
the treatment of chondrosarcoma (chapter 5). A possible role for Flavoperidol was suggested 
(chapter 4 and 5), as was suggested for Enzastaurin and AZD1152, based on the finding of 
AKT and Aurorakinase B using kinomics (both chapter 5). 
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of tumour cells exacerbated this effect41. So far, inhibition of Aurorakinase 
B in central chondrosarcomas seems to be a potential therapeutic strategy 
which deserves more investigation in a pre-clinical setting. The sensitising 
effect to ionising radiation should be addressed, as well.
The last hypothesis driven approach to find new targets for the therapeutic 
treatment of chondrosarcoma was based on the presence of COX-2 
expression in chondrosarcomas. In chapter 6 the effect of the specific COX-
2 inhibitor celecoxib on chondrosarcoma cell growth was investigated. In 
addition, Chapter 6 illustrates that success of an agent in vitro does not 
guarantee its success in vivo. Growth of chondrosarcoma cell cultures was 
strongly inhibited by celecoxib in vitro and a similar effect was found during 
the first 6 weeks of treatment of xenotransplanted nude mice. A promising 
role of high-dose prophylactic celecoxib in preventing development of 
chondrosarcoma was found which deserves further investigation, especially 
in the context of enchondromatosis and multiple osteochondromas in which 
the importance of prevention of malignant progression is evident to improve 
prognosis.  
However, in a later stage of the celecoxib treatment, a disconcordant effect 
was found in the groups treated with low dosage celecoxib, showing catch 
up growth of the tumours. Future studies should also gain more insight 
in the mechanisms causing this growth advantage of low dose celecoxib 
in chondrosarcomas by collecting serum parameters, such as sex steroid 
hormones, of the animals during the study.  
An in vivo model in which the tumours can be monitored real time, for example 
using chondrosarcoma cell lines transduced with luciferase constructs 
would be of great use in future studies and is currently under development. 
Also studying the effect of celecoxib on a low-grade chondrosarcoma in vivo 
model would be interesting, since this study was performed using a grade 
II and grade III chondrosarcoma cell line. In addition an in vivo model of 
peripheral chondrosarcoma, which were also shown to express COX-2, 
should be studied to further elucidate the role of celecoxib in the treatment 
of benign and malignant cartilage tumours in MO patients, although such a 
model is still to be developed (figure 7.1). 
7.4 Concluding remarks 
The results presented in this thesis have created insight into the major 
difficulty in the classification and histological grading of cartilaginous 
tumours. A new algorithm, based on 5 patient-related, and tumour-related 
characteristics, is proposed to separate benign from malignant cartilaginous 
tumours, with host bone entrapment and mucoid/myxoid changes being 
the most important findings in support of  malignant potential.
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Grading of malignant cartilaginous tumours using a three-tiered grading 
scheme was shown to be highly variable between different observers, even 
among those being specialised in bone tumour pathology. The distinction 
between grade I and grade II guides clinical management to either intraleasional 
surgery or wide-margin surgery. Despite many attempts, including the ones 
in this thesis, no molecular markers superior to histological grading were 
discovered so far. More studies to reveal new markers need to be performed 
in the near future; for example using protein identification by proteomics, 
which could lead to the discovery of yet unknown or unexpected biomarkers 
that i.e. are important in the formation of metastasis in chondrosarcoma. 
However, it is most important to interpret the results of these studies based 
on long term follow up, not on subjective histological grading. Thereby, 
the importance of long term storage including standardisation, automated 
enrichment of annotations from hospital information systems and disease 
registries, insight in overlapping collections of different forms of tissue 
banking and cooperation in national and international networks of patient 
material is stressed42.
This thesis presents the identification of new targets for therapeutic treatment 
of chondrosarcoma, using a relatively new array technique to identify 
active kinases in chondrosarcoma cell cultures. Src inhibitor dasatinib 
was investigated more in detail, and in the majority of chondrosarcoma cell 
cultures cell growth was inhibited. In the near future, the growth inhibition 
of chondrosarcoma by dasatinib and the underlying mechanism should be 
tested in a chondrosarcoma model in vivo.  
In addition to dasatinib, CDK inhibitor Flavoperidol, Heat Shock Protein-
inhibitor, Aurorakinase inhibitor AZD1152 and AKT inhibitor Enzastaurin 
were identified as candidates for therapeutic intervention in chondrosarcomas 
and their actions and mechanisms should be studied pre-clinically in vitro 
and if promising subsequently in vivo (Figure 7.2). Moreover, the use of 
selective COX-2 inhibition was evaluated preclinically. More experiments 
are needed to investigate its precise mechanism of growth inhibition since 
in vitro and in vivo results were inconclusive.
The results described in this thesis have led to a better understanding 
of molecular events that are important in the growth of conventional 
chondrosarcoma. Based on these and previous findings targets for 
therapeutical treatment of chondrosarcoma were investigated in vitro and 
in vivo. In addition, new targets were identified using large scale kinomics, 
which are expected to lead to the implementation of new therapy modalities 
for patients that have inoperable or metastatic chondrosarcoma.  
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Chondrosarcomen: entiteit, gradering, behandeling en prognose
Chondrosarcomen zijn kwaadaardige, kraakbeenvormende tumoren die in 
of op het bot groeien. In de groep conventionele chondrosarcomen, veruit 
de grootste groep (85%), wordt onderscheid gemaakt tussen centrale 
chondrosarcomen, die ontstaan in de mergholte van de lange pijpbeenderen, 
en de perifere chondrosarcomen, die ontstaan aan het oppervlak van het bot. 
Naast de conventionele chondrosarcomen, beschreven in dit proefschrift, 
omvat de groep chondrosarcomen ook zeldzame chondrosarcoom soorten, 
zoals het clear cell chondrosarcoom, het mesenchymale chondrosarcoom en 
het gededifferentieerde chondrosarcoom. 
Conventionele chondrosarcomen komen voor bij ongeveer 1 op 50.000 
personen, bij mannen en vrouwen even vaak. De leeftijd waarop de 
diagnose chondrosarcoom gesteld wordt, is tussen de 30 en 60 jaar. 
Chondrosarcomen worden met name aangetroffen in de lange pijpbeenderen 
(dus vooral in benen en armen) die groeien volgens enchondrale ossificatie, 
dat wil zeggen, met behulp van een groeischijf. In de groeischijf bevinden 
zich kraakbeencellen die blijven delen, totdat een individu onder invloed 
van hormonen aan het einde van de puberteit komt en de groeischijven 
dichtgaan, oftewel verbenen. De meeste chondrosarcomen worden gevonden 
in de heupbotten, de bovenbenen, de armen en de ribben. 
Van zowel centrale als perifere chondrosarcomen worden ook benigne 
(goedaardige) voorloperstadia gevonden. Centraal groeiende benigne 
kraakbeentumoren worden enchondromen genoemd, perifeer groeiende 
benigne kraakbeentumoren osteochondromen. De kans dat een enchondroom 
kwaadaardig wordt, en dus verandert naar een chondrosarcoom, wordt 
geschat op minder dan 1%. In 40% van de centrale chondrosarcomen 
worden echter resten van een goedaardige voorloper teruggevonden. 
Ook osteochondromen worden in minder dan 1% kwaadaardig. Perifere 
chondrosarcomen ontstaan per definitie uit een osteochondroom. 
Om deze reden worden perifere chondrosarcomen ook wel secundaire 
chondrosarcomen genoemd.
Conventionele kraakbeentumoren worden meestal als solitaire (enkele) 
afwijkingen gevonden. Echter, bij zowel perifere als centrale kraakbeentumoren 
is er een syndroom bekend waarbij meerdere goedaardige kraakbeentumoren 
voorkomen. Multipele Osteochondromen (MO) betreft een erfelijke ziekte 
waarbij meerdere osteochondromen ontstaan in combinatie met deformatie 
van de botten van de armen. MO openbaart zich al op kinderleeftijd en 
vaak blijven de patiënten klein van gestalte. MO-patiënten hebben een licht 
verhoogde kans dat de osteochondromen kwaadaardig worden, geschat 
op 1-3%. Het voorkomen van meerdere enchondromen is zeer zeldzaam 
en wordt enchondromatosis (EC) genoemd, beter bekend als de ziekte van 
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Ollier. In tegenstelling tot MO is EC geen erfelijke ziekte. De enchondromen 
groeien vooral in de handen en voeten, wat tot ernstige disfunctie leidt. 
EC wordt op zowel kinderleeftijd als bij volwassenen manifest. De kans dat 
een enchondroom kwaadaardig wordt, is sterk verhoogd bij EC-patiënten, 
namelijk tot circa 33%. 
Chondrosarcomen maken deel uit van een klinisch-pathologisch gedefinieerd 
spectrum, dat verdeeld wordt in vier groepen: benigne tumoren, graad I 
chondrosarcomen, graad II chondrosarcomen en graad III chondrosarcomen. 
De onderverdeling van dit spectrum gebeurt internationaal nog immer aan 
de hand van de in 1960 door Evans opgestelde criteria. Aan de hand van deze 
criteria worden behandelplannen opgesteld en de prognose voorspeld. Graad 
I en II chondrosarcomen geven zelden metastases (0% en 10%), terwijl 71% 
van de graad III chondrosarcomen metastaseert. De daaraan gerelateerde 
5-jaarsoverleving is respectievelijk 83%, 64% en 29% voor graad I, II en III 
chondrosarcomen. Wat de behandeling betreft, worden enchondromen vaak 
expectatief vervolgd, tenzij er sprake is van pijn of pathologische fracturen. 
Bij graad I chondrosarcomen wordt tegenwoordig intralesionale chirurgie 
toegepast, waarbij zoveel mogelijk tumorweefsel verwijderd wordt en de 
ontstane holte opgevuld wordt met cement of botchips. Adjuvant worden 
vaak de randen nabehandeld met fenolisatie of cryochirurgie om de maligne 
cellen die achtergebleven zijn te doden. Een agressiever beleid wordt gevolgd 
ten aanzien van de graad II en graad III chondrosarcomen, waarbij en-bloc 
resectie of soms zelfs amputatie noodzakelijk is.
Vraagstellingen in dit proefschrift
Het onderzoek aan chondrosarcomen beschreven in dit proefschrift is 
gebaseerd op drie vragen. De eerste vraag die beantwoord werd, is of er 
moleculaire markers zijn die onderscheid kunnen maken tussen benigne 
en maligne kraakbeentumoren. De tweede vraag is eenzelfde vraag naar 
markers die de prognose van kraakbeentumoren kunnen voorspellen, 
onafhankelijk van subjectieve histologische gradering. Het derde vraagstuk 
behelst de behandeling van chondrosarcomen en het ontwikkelen van 
nieuwe strategieën voor medicamenteuze therapie. 
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Benigne versus maligne kraakbeenvormende tumoren
In hoofdstuk 2 werd bevestigd dat de criteria voor gradering van 
chondrosarcomen van Evans relatief subjectief zijn en dus afhankelijk van 
de patholoog die de gradering uitvoert. Achttien pathologen, geaffilieerd aan 
Eurobonet, een Europees netwerk waarbinnen de biologie en pathologie van 
bottumoren wordt bestudeerd, beoordeelden zestien casus. De variabiliteit 
tussen de beoordelingen bleek ruim te zijn, uitgedrukt in een kappawaarde 
van 0.78. De concordantie was het kleinst in het onderscheid tussen 
benigne en graad I chondrosarcomen, namelijk κ=0.54. In dezelfde studie 
werden van een grote groep van 20 enchondromen en 37 chondrosarcomen 
gegevens verzameld, waarvan tien jaar follow-up bekend was en die in 
een multidisciplinair verband gediagnosticeerd waren, door pathologen, 
radiologen en chirurgen. Hieruit bleek dat een accurate diagnose gesteld 
kon worden aan de hand van slechts twee histologische criteria, te weten 
invanging van pre-existent lamellair bot en mucoide/myxoide veranderingen 
van de extracellulaire matrix. Hiermee werden 54 van de 57 (94.7%) casus 
juist gediagnosticeerd (sensitiviteit 95% and specificiteit 95%). Wanneer de 
beslissing op vijf parameters gebaseerd werd, werd slechts één van de 57 
gevallen verkeerd gediagnosticeerd. Deze vijf parameters waren: invanging, 
hoge celrijkdom, open chromatine in de kern, mucoide/myxoide degeneratie 
van de matrix en de leeftijd van de patiënt (ouder dan 45 jaar). 
De Indian hedgehog (IHH), WNT en Transforming growth factor β (TGFB) 
signaaltransductie regelkringen spelen een belangrijke rol in de normale 
groei en differentiatie van kraakbeencellen in de groeischijf. IHH doet dit 
via het intracellulair (in de kraakbeencel) gelegen “Smoothened” (SMO) 
en “Patched” (PTCH), waardoor “Gliobastoma” (GLI) naar de celkern 
getransporteerd wordt. In de celkern bindt GLI aan het DNA en zorgt er voor 
dat er weer nieuwe SMO, PTCH en GLI worden afgeschreven waardoor het 
signaal versterkt wordt (Figuur 1.4). Het gaat uiteindelijk om het signaal 
dat door deze kraakbeencel via de binding van “parathyroid hormone 
like hormone” (PTHLH) wordt doorgegeven aan de parathyroid hormoon 
receptor (PTHR1). PTHR1 zorgt er vervolgens voor dat de kraakbeencellen 
in de prolifererende zone (Figuur 1.3) niet verder differentiëren, waardoor 
de botten in de lengterichting groeien. Voor het doorgeven van deze 
signalen door de extracellulaire matrix waarin de kraakbeencellen gelegen 
zijn,  worden de lange eiwit-suikermoleculen gebruikt die in de matrix 
aanwezig zijn; de zogenoemde heparan sulfaat proteoglycanen (HSPG’s). 
Voor het verlengen van de suikerketens zijn twee genen belangrijk, EXT1 
en EXT2. Uit genetische studies weten we dat bij patiënten met MO een 
van beide EXT-genen gemuteerd is en dus niet of minder goed werkt. Ook 
in perifere chondrosarcomen die solitair voorkomen, dus niet in verband 
met de erfelijke ziekte MO, is de expressie van het EXT-gen verminderd 
vergeleken met de expressie in de normale groeischijf. Interessant genoeg 
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blijkt de PTHLH signaaltransductiecascade echter niet aangedaan te zijn 
in hooggradige perifere chondrosarcomen. Gesuggereerd wordt dat er 
ofwel kraakbeencellen zijn die zelf PTHLH produceren of dat de functie van 
IHH overgenomen wordt door TGFB, dat juist in de hooggradige perifere 
chondrosarcomen hoger tot expressie komt. Ook is het mogelijk dat het aan 
IHH en TGFB gerelateerde WNT deze functie overneemt. 
In hoofdstuk 3 werden deze signaaltransductieroutes in centrale 
chondrosarcomen onderzocht. Het bleek echter dat, in tegenstelling tot in 
de perifere chondrosarcomen, in centrale chondrosarcomen EXT normaal is, 
zowel de DNA-volgorde als de afschrijving op mRNA-niveau. Tevens was IHH 
normaal actief, hoewel er toch afwijkingen in de distributie van de HSPG’s 
in de matrix gevonden werden. Een van de HSPG’s, syndecan-2, werd zelfs 
intracellulair in de kraakbeencellen gevonden in plaats van in de matrix. 
Meer onderzoek is nodig om deze bevinding te kunnen verklaren. 
Door middel van β-catenine kleuring vonden we in graad I centrale 
chondrosarcomen een significant hogere activiteit van WNT dan 
in enchondromen (respectievelijk 48% en 17%) (Figuur 3.3). Deze 
verschillen zijn echter niet groot genoeg om β-catenine een rol te geven als 
immunohistologische marker bij het maken van onderscheid tussen beiden. 
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Markers om de prognose van chondrosarcomen te voorspellen
Veel onderzoeken hebben zich toegespitst op de vraag of er moleculaire 
markers zijn die de prognose van chondrosarcomen kunnen voorspellen. 
In Hoofdstuk 2 werd naast variatie in het onderscheid tussen benigne 
en maligne kraakbeentumoren, ook een grote variatie in het graderen van 
hooggradige chondrosarcomen gevonden. Gradering is momenteel de enige 
basis voor het stellen van prognoses. De grote variatie hierin bevestigt de 
noodzaak van het ontdekken van objectieve moleculaire markers die het 
onderscheid tussen de drie verschillende graden kunnen maken en daarmee 
de keuze voor een bepaalde behandeling en de te verwachte prognose 
kunnen aanwijzen. 
In dit proefschrift werd de vraag naar prognostische markers voor 
chondrosarcomen uitgediept. In hoofdstuk 3 werd een associatie gevonden 
tussen histologische graad (volgens Evans) en de expressie (mate van 
aanwezigheid) van TGFB (Figuur 3.3). TGFB is verantwoordelijk voor velerlei 
signaaltransductie routes die bijvoorbeeld leiden tot proliferatie, overleving 
van cellen, de vorming van matrix (steunweefsel) rond cellen en het vormen 
van bloedvaten. Het is dus goed voor te stellen dat maligne tumoren beter 
in staat zijn deze eigenschappen te verzamelen dan benigne. Bij analyse van 
deze uitkomsten in het kader van de uitgebreide follow-up kon echter geen 
relatie tussen TGFB en een slechte prognose gelegd worden die onafhankelijk 
was van histologische graad.
Datzelfde gold voor CDK4 en MDM2 in hoofdstuk 4. Beide genen zijn 
gelegen op chromosoom 12q13, een locus waarvan uit eerdere studies 
bleek dat deze geamplificeerd is in centrale chondrosarcomen. Tevens 
hebben beide genen een functie in de celcyclus. De celcyclus is een soort 
voorgeprogrammeerd protocol dat de levensverwachting en voortplanting 
van een cel dicteert. Cellen doorlopen achtereenvolgens een M-fase (Mitose) 
waarin de kern wordt gedeeld en de cel wordt gesplitst. De periode tussen 
twee M-fases wordt de interfase genoemd. De interfase bestaat uit de G1-, 
S- en G2-fase (Figuur 4.3). Tijdens de S-fase (Synthese), repliceert de cel 
zijn DNA, wat essentieel is voor celdeling. Voorafgaand aan, én aansluitend 
op de S-fase zijn er twee fases waarin de cel kan groeien: de G1- en G2-fase 
(Gap (ruimte)). Gedurende deze gap-fases wordt er ook gecontroleerd of er 
geen fouten gemaakt zijn bij de replicatie en of alle voorbereidingen getroffen 
zijn om de cel te laten doorgaan met de volgende fase. Deze controle wordt 
onder andere uitgevoerd door CDK4 en MDM2. 
In centrale chondrosarcomen werd een correlatie gevonden tussen zowel 
amplificatie van 12q13 en een verhoogde expressie van CDK4, als tussen de 
expressie van CDK4 en MDM2 en histologische graad (figuur 4.3). Echter, 
een relatie, onafhankelijk van histologische graad, tussen CDK4-expressie 
en prognose kon niet worden vastgesteld. 
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Het onderzoek naar de variatie in gradering van kraakbeentumoren, 
beschreven in hoofdstuk 2, bevestigt tevens dat conclusies uit studies naar 
nieuwe moleculaire markers altijd in het kader van uitgebreide follow-up 
getrokken moeten worden. Onderzoeksresultaten moeten dus gerelateerd 
worden aan objectieve gegevens zoals “metastasevrije periode”. Tevens 
benadrukt het de noodzaak van een goede archivering van studiemateriaal, 
zowel het patiëntenmateriaal als de bijbehorende follow-up data. 
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Nieuwe strategieën voor de behandeling van chondrosarcomen
Chondrosarcomen reageren niet op conventionele radiotherapie 
en chemotherapie. Dat betekent dat chirurgie de enige curatieve 
behandelingsmodaliteit is. Curatief wil zeggen dat als doel van de behandeling 
genezing wordt beoogd, in tegenstelling tot palliatief waarbij pijnbestrijding 
en het behoud van kwaliteit van leven als doel gesteld wordt. 
Dit impliceert dat patiënten bij wie het chondrosarcoom ontstaan is op een 
plaats die niet toegankelijk is voor chirurgie met vrije marges (bijvoorbeeld 
in de bekken- of de schedelbasisbotten), en patiënten met tumoren die 
gemetastaseerd zijn naar organen zoals de longen, per definitie niet curatief 
behandeld kunnen worden waardoor ze een zeer slechte prognose hebben. 
Recent echter lijken er goede resultaten te zijn voor deze tumorlokalisaties 
bij bestraling met protonen, waarbij de stralingsbundel heel precies gericht 
kan worden en er minimale schade aan de omliggende weefsels ontstaat. 
De laatse doelstelling van dit proefschrift was het ontwikkelen van nieuwe 
strategieën voor de medicamenteuze behandeling van chondrosarcomen. 
Deze doelstelling werd op twee manieren aangepakt: volgens op hypotheses 
gebaseerde methodes (hoofdstuk 3, 4 en 6) en volgens een op screening 
gebaseerde methode (hoodstuk 5). Nieuwe strategieën verkregen uit beide 
methodes werden in vitro getest op levende chondrosarcoomcellen. Tevens 
werd één strategie verder bestudeerd in een chondrosarcomen muizenmodel, 
in vivo.
In hoofdstuk 3 werd onderzocht of de activiteit van IHH, die in centrale 
chondrosarcomen aanwezig bleek te zijn, als aangrijpingspunt voor 
therapie kon dienen. Zes chondrosarcoom-cellijnen werden daartoe 
behandeld met cyclopamine. Cyclopamine remt de activiteit van de IHH 
signaaltransductieroute door het blokkeren van intercellulair SMO. Het is 
momenteel in ontwikkeling als behandeling van onder andere glioblastomen 
en medulloblastomen (twee soorten hersentumoren). Echter, in slechts 
een van de zes chondrosarcoom-cellijnen werd de celgroei geremd. Verder 
onderzoek naar de effectiviteit van cyclopamine bij de behandeling van 
kraakbeentumoren lijkt derhalve niet zinvol. 
Een ander aangrijpingspunt voor de behandeling van chondrosarcomen is 
beschreven in hoofdstuk 4, te weten de verhoogde expressie van CDK4-
in hooggradige chondrosarcomen. In vitro werd met behulp van short 
hairpin RNA (shRNA) alle CDK4 activiteit in drie chondrosarcoom-cellijnen 
weggevangen. Deze shRNA-stukjes werden in de cellen gebracht met behulp 
van lentivirussen. Dit leidde in alledrie de cellijnen tot remming van de celgroei. 
Eenzelfde effect werd bewerkstelligd door het herintroduceren van het p16-
gen in deze cellen. Het p16-eiwit heeft een remmende rol in de celcyclus 
waarin ook CDK4 betrokken is. In hooggradige centrale chondrosarcomen is 
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de genetische informatie van het p16 gen vaak verdwenen (gedeleteerd). Door 
het herintroduceren van p16, eveneens met behulp van lentivirussen, werd 
de celgroei geremd in de drie chondrosarcoom cellijnen. Beide strategieën 
zijn echter alleen toepasbaar in het laboratorium en niet op patiënten. Van 
het middel Flavopiridol is bekend dat het CDK’s remt in vivo. Flavopiridol zou 
dus door het remmen van CDK4 een rol kunnen spelen bij de behandeling 
van chondrosarcomen. Meer onderzoek is nodig om dit verder uit te diepen.
Uit de vakliteratuur en de studie beschreven in hoofdstuk 6 blijkt dat 
cyclo-oxygenase-2 (COX-2) ook verhoogd tot expressie komt in hooggradige 
chondrosarcomen, wat een interessant aangrijpingspunt is voor therapie. 
Tevens werd in enchondromatosis gerelateerde tumoren een hogere 
COX-2-expressie gevonden dan in solitaire tumoren. COX-remmers 
zijn geregistreerd als analgetica en ontstekingsremmers en er is veel 
onderzoek gedaan naar hun veiligheid. Celecoxib en NS-398, twee selectieve 
COX-2-remmers, bleken in vitro celgroei te remmen in drie van de vier 
chondrosarcoom cellijnen. Vervolgens werd de behandeling met celecoxib 
in een chondrosarcoom muizenmodel onderzocht. Bij immunoincompetente 
muizen werden menselijke chondrosarcoomcellen onder de huid ingespoten. 
Deze cellen vormen een xenograft en zo kan de groei van de tumor tijdens 
het experiment, vanaf de buitenkant van de muis, gevolgd worden. De 
muizen werden behandeld met ofwel een celecoxib profylaxe, dat wil zeggen 
dat de behandeling één week voordat chondrosarcoomcellen ingespoten 
werden, gestart werd, ofwel de behandeling werd gestart vier weken nadat 
de cellen ingespoten waren. Beide groepen werden nog onderverdeeld in lage 
en hoge dosis celecoxib. De profylaxegroep boekte vooral in de eerste vier 
weken van het experiment goede resultaten en de tumoren bleven kleiner 
dan in de controlegroep. Na week zes begonnen de tumoren die met een 
lage concentratie celecoxib behandeld werden (zowel de profylaxe- als de 
behandelinggroep) harder te groeien dan de controlegroep. De tumoren 
die profylactisch met een hoge dosis celecoxib werden behandeld, bleven 
gedurende het hele experiment kleiner dan die in de controlegroep.
Er lijkt dus een beschermend effect te zijn van een hoge concentratie 
celecoxib profylaxe, wat een optie zou kunnen zijn voor de behandeling 
van enchondromen en osteochondromen bij EC- en MO-patiënten ter 
voorkoming van maligne ontaarding. Echter, meer onderzoek naar de 
plotselinge groeiversnelling bij lage celecoxibconcentraties is nodig voordat 
therapie bij patiënten gerechtvaardigd kan worden. 
In hoofstuk 5 werd op een screenende wijze gezocht naar nieuwe strategieën 
voor de behandeling van chondrosarcomen. Hiertoe werd gebruik gemaakt 
van “kinome profiling” met behulp van de nieuwe Pepchip®-techniek. Het 
kinoom is de verzameling van kinases in het menselijk lichaam. Een kinase 
is een enzym dat een fosfaatgroep kan aanbrengen op een ander eiwit of 
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een ander molecuul (fosforylering). Door fosforylering wordt het doeleiwit 
geactiveerd of geïnactiveerd. Deze schakelfunctie kan zo chemische 
reacties in de cel aansturen en vormt een belangrijke factor in de interne 
signaaltransductie. Dat maakt kinases een uitermate goed aangrijpingspunt 
voor behandeling. De fosfaatgroep die wordt gebruikt door een kinase is vaak 
afkomstig van een molecuul adenosine-tri-fosfaat (ATP) en op dit principe 
berust de Pepchip®, waarbij activiteit van de kinases gemeten wordt door het 
inbouwen van radioactief fosfaat. 
In het onderzoek beschreven in hoofdstuk 5 werd activiteit van kinases 
gemeten in vier chondrosarcoom cellijnen en negen primaire kweken van 
chondrosarcoompatiënten. Activiteit van de Src-familie van kinases en van 
PDGFRβ werd gevonden in alle celkweken. Src is een belangrijke regulator 
in verschillende intracellulaire processen, zoals embryogenese en celgroei. 
Genetische mutaties in het Src-gen leiden tot een verhoogde graad van 
maligniteit van colorectaal carcinomen. In hoofdstuk 5 werden vervolgens 
Src-remmer dasatinib, bekend van de behandeling van leukemieën, en 
PDGFRβ-remmer imatinib, bekend van de behandeling van gastro-intestinale 
stromaceltumoren, getest op hun celgroeiremmende eigenschappen op 
chondrosarcoomcellen. Hoewel chondrosarcomen ongevoelig bleken te zijn 
voor imatinib, werd met dasatinib in zeven van de negen celkweken een 
groeiremmend effect waargenomen. Hiermee is dasatinib geïdentificeerd 
als een potentiële behandelingsoptie voor inoperabele chondrosarcomen en 
deze bemoedigende data verdienen in de toekomst verdere aandacht in in 
vivo modellen voor chondrosarcoomgroei, alsmede in klinische trials. 
Naast de Src-familie werden met behulp van de Pepchip® ook nog AKT, 
Aurorakinase B en CDK2 geïdentificeerd als actief in chondrosarcoom 
celkweken. Elk van deze kinases is interessant voor verdere studies 
naar nieuwe behandelingsstrategieën voor het chondrosarcoom. 
Van AKT is in andere studies aangetoond dat het een rol speelt in de 
overleving van chondrosarcoomcellen. AKT speelt een rol in verschillende 
pathofysiologische processen zoals het ontstaan van diabetes mellitus, 
Alzheimer en carcinogenese. AKT-activiteit kan geremd worden met behulp 
van Enzastaurine. Momenteel worden in vitro experimenten uitgevoerd die 
gebaseerd zijn op deze bevinding.
Aurorakinase B speelt een belangrijke rol bij de celdeling. Het zorgt 
ervoor dat het DNA op de juiste manier uit elkaar getrokken wordt tijden 
de mitose. Overexpressie van Aurorakinase B kan leiden tot aneuploidie: 
een onevenwichtige verspreiding van het genetische materiaal tussen twee 
kernen. Aneuploidie wordt veel gevonden in hooggradige chondrosarcomen. 
Pyrazoloquinazolines als AZD-1152 zijn in staat Aurorakinase B te remmen. 
Flavopiridol, dat in hoofdstuk 4 als potentiële therapie voor chondrosarcomen 
genoemd werd als CDK4-remmer, heeft ook een remmende werking op 
CDK1 en 2. Het feit dat CDK1 en 2-remming en daarmee Flavopiridol in 
Nederlandse samenvatting
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hoofdstuk 5 opnieuw als mogelijke strategie voor behandeling gevonden 
wordt, versterkt het belang van deze bevindingen. 
 
Samenvattend hebben zowel de hypothese-gerelateerde als de screenende 
methode meerdere voorzetten gegeven voor vervolgstudies, welke hopelijk 
zullen leiden tot nieuwe therapeutische strategieën voor de behandeling van 
inoperabele en gemetastaseerde chondrosarcomen. 
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